0001651944-23-000077.txt : 20230803 0001651944-23-000077.hdr.sgml : 20230803 20230803163729 ACCESSION NUMBER: 0001651944-23-000077 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 231140728 BUSINESS ADDRESS: STREET 1: 12340 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 12340 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 10-Q 1 dmtk-20230630.htm 10-Q dmtk-20230630
000165194412-312023Q2false0.50.250.25four00016519442023-01-012023-06-3000016519442023-07-28xbrli:shares00016519442023-06-30iso4217:USD00016519442022-12-31iso4217:USDxbrli:shares0001651944dmtk:TestRevenueMember2023-04-012023-06-300001651944dmtk:TestRevenueMember2022-04-012022-06-300001651944dmtk:TestRevenueMember2023-01-012023-06-300001651944dmtk:TestRevenueMember2022-01-012022-06-300001651944dmtk:ContractualActivitiesMember2023-04-012023-06-300001651944dmtk:ContractualActivitiesMember2022-04-012022-06-300001651944dmtk:ContractualActivitiesMember2023-01-012023-06-300001651944dmtk:ContractualActivitiesMember2022-01-012022-06-3000016519442023-04-012023-06-3000016519442022-04-012022-06-3000016519442022-01-012022-06-300001651944us-gaap:CommonStockMember2022-12-310001651944us-gaap:AdditionalPaidInCapitalMember2022-12-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001651944us-gaap:RetainedEarningsMember2022-12-310001651944us-gaap:CommonStockMember2023-03-310001651944us-gaap:CommonStockMember2023-01-012023-03-310001651944us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016519442023-01-012023-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001651944us-gaap:RetainedEarningsMember2023-01-012023-03-310001651944us-gaap:AdditionalPaidInCapitalMember2023-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001651944us-gaap:RetainedEarningsMember2023-03-3100016519442023-03-310001651944us-gaap:CommonStockMember2023-06-300001651944us-gaap:CommonStockMember2023-04-012023-06-300001651944us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300001651944us-gaap:RetainedEarningsMember2023-04-012023-06-300001651944us-gaap:AdditionalPaidInCapitalMember2023-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001651944us-gaap:RetainedEarningsMember2023-06-300001651944us-gaap:CommonStockMember2021-12-310001651944us-gaap:AdditionalPaidInCapitalMember2021-12-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001651944us-gaap:RetainedEarningsMember2021-12-3100016519442021-12-310001651944us-gaap:CommonStockMember2022-01-012022-03-310001651944us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016519442022-01-012022-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310001651944us-gaap:RetainedEarningsMember2022-01-012022-03-310001651944us-gaap:CommonStockMember2022-03-310001651944us-gaap:AdditionalPaidInCapitalMember2022-03-310001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001651944us-gaap:RetainedEarningsMember2022-03-3100016519442022-03-310001651944us-gaap:CommonStockMember2022-04-012022-06-300001651944us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-04-012022-06-300001651944us-gaap:RetainedEarningsMember2022-04-012022-06-300001651944us-gaap:CommonStockMember2022-06-300001651944us-gaap:AdditionalPaidInCapitalMember2022-06-300001651944us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300001651944us-gaap:RetainedEarningsMember2022-06-3000016519442022-06-30dmtk:revenueStream0001651944dmtk:ContractRevenueAdhesivePatchKitsMember2023-04-012023-06-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2022-04-012022-06-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2023-01-012023-06-300001651944dmtk:ContractRevenueAdhesivePatchKitsMember2022-01-012022-06-300001651944dmtk:ContractRevenueRNAExtractionsMember2023-04-012023-06-300001651944dmtk:ContractRevenueRNAExtractionsMember2022-04-012022-06-300001651944dmtk:ContractRevenueRNAExtractionsMember2023-01-012023-06-300001651944dmtk:ContractRevenueRNAExtractionsMember2022-01-012022-06-300001651944dmtk:ContractRevenueProjectManagementFeesMember2023-04-012023-06-300001651944dmtk:ContractRevenueProjectManagementFeesMember2022-04-012022-06-300001651944dmtk:ContractRevenueProjectManagementFeesMember2023-01-012023-06-300001651944dmtk:ContractRevenueProjectManagementFeesMember2022-01-012022-06-300001651944dmtk:TestMember2023-06-300001651944dmtk:TestMember2022-12-310001651944dmtk:ContractualActivitiesMember2023-06-300001651944dmtk:ContractualActivitiesMember2022-12-310001651944us-gaap:WarrantMember2023-04-012023-06-300001651944us-gaap:WarrantMember2022-04-012022-06-300001651944us-gaap:WarrantMember2023-01-012023-06-300001651944us-gaap:WarrantMember2022-01-012022-06-300001651944us-gaap:StockOptionMember2023-04-012023-06-300001651944us-gaap:StockOptionMember2022-04-012022-06-300001651944us-gaap:StockOptionMember2023-01-012023-06-300001651944us-gaap:StockOptionMember2022-01-012022-06-300001651944us-gaap:RestrictedStockMember2023-04-012023-06-300001651944us-gaap:RestrictedStockMember2022-04-012022-06-300001651944us-gaap:RestrictedStockMember2023-01-012023-06-300001651944us-gaap:RestrictedStockMember2022-01-012022-06-3000016519442019-08-292019-08-29xbrli:pure0001651944us-gaap:CorporateDebtSecuritiesMember2023-06-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2023-06-300001651944us-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:MunicipalNotesMember2022-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2022-12-310001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-06-300001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-06-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944us-gaap:MunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2023-04-012023-06-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2022-04-012022-06-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2023-01-012023-06-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMember2022-01-012022-06-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MinimumMember2023-01-012023-06-300001651944srt:MaximumMemberus-gaap:WarrantyRightsAndObligationsFairValueOptionMember2023-01-012023-06-300001651944us-gaap:WarrantyRightsAndObligationsFairValueOptionMembersrt:MinimumMember2022-01-012022-06-300001651944srt:MaximumMemberus-gaap:WarrantyRightsAndObligationsFairValueOptionMember2022-01-012022-06-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-12-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-03-310001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-04-012023-06-300001651944dmtk:WarrantLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-06-300001651944us-gaap:LetterOfCreditMemberus-gaap:FairValueInputsLevel1Memberdmtk:RestrictedCashMember2023-06-300001651944us-gaap:LetterOfCreditMemberus-gaap:FairValueInputsLevel1Memberdmtk:RestrictedCashMember2022-12-3100016519442023-06-0100016519442023-06-020001651944dmtk:CowenLimitedLiabilityCompanyMemberdmtk:AtTheMarketOfferingMember2020-11-102020-11-100001651944dmtk:CowenLimitedLiabilityCompanyMemberdmtk:AtTheMarketOfferingMember2020-11-102021-12-310001651944dmtk:CowenLimitedLiabilityCompanyMemberdmtk:AtTheMarketOfferingMember2022-01-012022-12-310001651944dmtk:CowenLimitedLiabilityCompanyMemberdmtk:AtTheMarketOfferingMember2023-04-012023-06-300001651944dmtk:CowenLimitedLiabilityCompanyMemberdmtk:AtTheMarketOfferingMember2023-01-012023-06-300001651944dmtk:CowenLimitedLiabilityCompanyMember2022-08-082022-08-080001651944dmtk:CowenLimitedLiabilityCompanyMember2023-04-012023-06-300001651944dmtk:CowenLimitedLiabilityCompanyMember2023-01-012023-06-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2017-06-232017-06-230001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMemberus-gaap:CommonStockMember2023-06-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2021-12-310001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2021-01-012021-12-310001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2023-06-300001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2022-12-310001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2023-06-300001651944dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember2022-12-310001651944dmtk:PlacementAgentWarrantsMember2015-01-012016-12-310001651944dmtk:PlacementAgentWarrantsMember2016-12-310001651944us-gaap:CommonStockMemberdmtk:PlacementAgentWarrantsMember2016-12-310001651944dmtk:PlacementAgentWarrantsMember2016-01-012018-12-310001651944dmtk:PlacementAgentWarrantsMember2018-12-310001651944us-gaap:CommonStockMemberdmtk:PlacementAgentWarrantsMember2018-12-310001651944dmtk:TwoThousandEighteenConvertibleBridgeNotesMemberdmtk:PlacementAgentWarrantsMember2020-01-012020-12-310001651944dmtk:TwoThousandEighteenConvertibleBridgeNotesMemberdmtk:PlacementAgentWarrantsMember2020-12-310001651944dmtk:TwoThousandEighteenConvertibleBridgeNotesMemberus-gaap:CommonStockMemberdmtk:PlacementAgentWarrantsMember2020-12-310001651944dmtk:PlacementAgentWarrantsMember2023-06-300001651944dmtk:PlacementAgentWarrantsMember2022-12-310001651944us-gaap:CostOfSalesMember2023-04-012023-06-300001651944us-gaap:CostOfSalesMember2022-04-012022-06-300001651944us-gaap:CostOfSalesMember2023-01-012023-06-300001651944us-gaap:CostOfSalesMember2022-01-012022-06-300001651944us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001651944us-gaap:SellingAndMarketingExpenseMember2022-04-012022-06-300001651944us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001651944us-gaap:SellingAndMarketingExpenseMember2022-01-012022-06-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001651944us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001651944us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001651944srt:ScenarioForecastMember2024-01-012024-01-010001651944srt:ScenarioForecastMembersrt:MinimumMember2024-01-012024-01-010001651944srt:ScenarioForecastMembersrt:MaximumMember2024-01-012024-01-010001651944dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember2023-01-012023-06-30dmtk:warrant0001651944dmtk:RestructuringPlanMember2023-06-262023-06-260001651944dmtk:RestructuringPlanMember2023-04-012023-06-300001651944dmtk:RestructuringPlanMember2023-01-012023-06-300001651944dmtk:RestructuringPlanMember2023-06-300001651944us-gaap:RelatedPartyMember2023-04-012023-06-300001651944us-gaap:RelatedPartyMember2022-04-012022-06-300001651944us-gaap:RelatedPartyMember2023-01-012023-06-300001651944us-gaap:RelatedPartyMember2022-01-012022-06-300001651944us-gaap:RelatedPartyMember2023-06-300001651944us-gaap:RelatedPartyMember2022-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________________
FORM 10-Q
________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to            
Commission File Number: 001-38118
________________________
DERMTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
________________________
Delaware84-2870849
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
12340 El Camino Real,
San Diego ,CA
92130
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (858) 450-4222
________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per shareDMTK
The Nasdaq Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of July 28, 2023, the registrant had 33,679,086 shares of common stock, $0.0001 par value per share, outstanding.


Table of Contents
Page
i

PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
DERMTECH, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
(Unaudited)
June 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$42,790 $77,757 
Short-term marketable securities43,406 48,411 
Accounts receivable3,865 4,172 
Inventory1,352 1,757 
Prepaid expenses and other current assets2,329 3,940 
Total current assets93,742 136,037 
Property and equipment, net6,074 6,375 
Operating lease right-of-use assets53,791 56,007 
Restricted cash3,467 3,488 
Other assets 168 
Total assets$157,074 $202,075 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable$2,324 $2,419 
Accrued compensation7,387 7,894 
Accrued liabilities3,695 3,464 
Short-term deferred revenue295 109 
Current portion of operating lease liabilities2,246 1,634 
Current portion of finance lease obligations67 116 
Total current liabilities16,014 15,636 
Warrant liability6 5 
Long-term finance lease obligations, less current portion46 53 
Operating lease liabilities, long-term52,931 54,028 
Total liabilities68,997 69,722 
Stockholders’ equity:  
Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 33,408,810 and 30,297,408 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
3 3 
Additional paid-in capital473,855 456,171 
Accumulated other comprehensive loss(101)(774)
Accumulated deficit(385,680)(323,047)
Total stockholders’ equity88,077 132,353 
Total liabilities and stockholders’ equity$157,074 $202,075 
See accompanying notes to unaudited condensed consolidated financial statements.
1

DERMTECH, INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenues:
Test revenue $3,565 $4,147 $6,990 $7,665 
Contract revenue415 86 467 286 
Total revenues3,980 4,233 7,457 7,951 
Cost of revenues:    
Cost of test revenue3,909 3,236 7,700 6,766 
Cost of contract revenue63 37 93 61 
Total cost of revenues3,972 3,273 7,793 6,827 
Gross profit/(loss)8 960 (336)1,124 
Operating expenses:    
Sales and marketing13,033 15,001 28,450 30,444 
Research and development3,887 6,915 8,296 13,253 
General and administrative15,220 8,878 27,095 17,452 
Total operating expenses32,140 30,794 63,841 61,149 
Loss from operations(32,132)(29,834)(64,177)(60,025)
Other income/(expense):    
Interest income, net763 149 1,545 215 
Change in fair value of warrant liability6 105 (1)122 
Total other income769 254 1,544 337 
Net loss$(31,363)$(29,580)$(62,633)$(59,688)
Weighted average shares outstanding used in computing net loss per share, basic and diluted31,791,736 29,964,849 31,177,886 29,904,972 
Net loss per share of common stock outstanding, basic and diluted$(0.99)$(0.99)$(2.01)$(2.00)
See accompanying notes to unaudited condensed consolidated financial statements.
2

DERMTECH, INC.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net loss$(31,363)$(29,580)$(62,633)$(59,688)
Unrealized net gain/(loss) on marketable securities and cash equivalents188 (171)673 (741)
Comprehensive loss$(31,175)$(29,751)$(61,960)$(60,429)
See accompanying notes to unaudited condensed consolidated financial statements.
3

DERMTECH, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share and per share data)
(Unaudited)
Common stockAdditional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Total
stockholders’
equity
SharesAmount
Balance, December 31, 202230,297,408 $3 $456,171 $(774)$(323,047)$132,353 
Issuance of common stock at a weighted average price of $3.68 through at-the-market offering, net of $0.1 million issuance costs
107,451 — 270 — — 270 
Issuance of common stock from option exercises and RSU releases510,027 — 92 — — 92 
Issuance of common stock from Employee Stock Purchase Plan174,025 — 576 — — 576 
Unrealized net gain on available-for-sale marketable securities and cash equivalents— — — 485 — 485 
Stock-based compensation— — 4,736 — — 4,736 
Net loss— — — — (31,270)(31,270)
Balance, March 31, 202331,088,911 $3 $461,845 $(289)$(354,317)$107,242 
Issuance of common stock at a weighted average price of $2.62 through at-the-market offering, net of $0.1 million in issuance costs
1,759,210 — 4,495 — — 4,495 
Issuance of common stock from RSU releases560,689 —  — —  
Unrealized net gain on available-for-sale marketable securities and cash equivalents— — — 188 — 188 
Stock-based compensation— — 7,515 — — 7,515 
Net loss— — — — (31,363)(31,363)
Balance, June 30, 202333,408,810 $3 $473,855 $(101)$(385,680)$88,077 



See accompanying notes to unaudited condensed consolidated financial statements.
4

DERMTECH, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share and per share data)
(Unaudited)
Common stockAdditional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Total
stockholders’
equity
SharesAmount
Balance, December 31, 202129,772,922 $3 $436,183 $(124)$(206,364)$229,698 
Issuance of common stock from option exercises and RSU releases109,275 — 40 — — 40 
Issuance of common stock from warrant exercises11,101 — 12 — — 12 
Issuance of common stock from Employee Stock Purchase Plan47,339 — 515 — — 515 
Unrealized net loss on available-for-sale marketable securities— — — (570)— (570)
Stock-based compensation— — 3,894 — — 3,894 
Net loss— — — — (30,108)(30,108)
Balance, March 31, 202229,940,637 $3 $440,644 $(694)$(236,472)$203,481 
Issuance of common stock from option exercises and RSU releases88,591 —  — —  
Issuance of common stock from warrant exercises9,219 — 10 — — 10 
Unrealized net loss on available-for-sale marketable securities— — — (171)— (171)
Stock-based compensation— — 4,837 — — 4,837 
Net loss— — — — (29,580)(29,580)
Balance, June 30, 202230,038,447 $3 $445,491 $(865)$(266,052)$178,577 
See accompanying notes to unaudited condensed consolidated financial statements.
5

DERMTECH, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Six Months Ended June 30,
20232022
Cash flows from operating activities:  
Net loss$(62,633)$(59,688)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation936 766 
Change in fair value of warrant liability1 (122)
Amortization of operating lease right-of-use assets2,216 1,109 
Stock-based compensation12,251 8,731 
Amortization of premiums, net of accretion of discounts on marketable securities(202)283 
Loss on disposal of equipment13 285 
Changes in operating assets and liabilities:  
Accounts receivable307 (2,115)
Inventory405 (952)
Prepaid expenses and other current assets1,779 483 
Operating lease liabilities(485)(654)
Accounts payable, accrued liabilities and deferred revenue690 (53)
Accrued compensation(507)2,698 
Net cash used in operating activities(45,229)(49,229)
Cash flows from investing activities:  
Purchases of marketable securities(25,568)(20,171)
Sales and maturities of marketable securities31,448 14,139 
Purchases of property and equipment(1,016)(1,360)
Net cash provided by/(used in) investing activities4,864 (7,392)
Cash flows from financing activities:  
Proceeds from issuance of common stock in connection with at-the-market offering, net4,765  
Proceeds from exercise of common stock warrants 22 
Proceeds from exercise of stock options92 40 
Proceeds from contributions to the Employee Stock Purchase Plan576 515 
Principal repayments of finance lease obligations(56)(60)
Net cash provided by financing activities5,377 517 
Net decrease in cash, cash equivalents and restricted cash(34,988)(56,104)
Cash, cash equivalents and restricted cash, beginning of period81,245 179,907 
Cash, cash equivalents and restricted cash, end of period$46,257 $123,803 
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents$42,790 $120,333 
Restricted cash3,467 3,470 
Total cash, cash equivalents and restricted cash$46,257 $123,803 
Supplemental cash flow information:  
Cash paid for interest on finance lease obligations$2 $7 
Supplemental disclosure of noncash investing and financing activities:  
Purchases of property and equipment recorded in accounts payable$78 $11 
Right-of-use assets obtained in exchange for lease obligations$ $17,059 
Property and equipment acquired under finance leases$ $48 
Change in unrealized net gains/(losses) on available-for-sale marketable securities and cash equivalents$673 $(741)
See accompanying notes to unaudited condensed consolidated financial statements.
6

DERMTECH, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
1.    The Company and a Summary of its Significant Accounting Policies
(a)    Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of melanoma and management of skin cancer. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.
The Company has incurred operating losses since inception and has an accumulated deficit of $385.7 million at June 30, 2023. As of June 30, 2023, cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of our business. The Company may be required to further reduce operating expenses, which could have an adverse impact its ability to achieve intended business objectives. The Company's management believes that currently available resources will provide sufficient funds to meet operating plans for at least the next twelve months from the issuance of our unaudited condensed consolidated financial statements. Considering the restructuring activities (Note 5) implemented in June 2023, the Company believes it has enough capital to fund anticipated operating costs for at least the next twelve months. The Company anticipates that it will need to raise additional capital in order to support its planned operations and to continue developing and commercializing genomic tests.
(b)    Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiary. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of June 30, 2023, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
7

(c)    Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
(d)    Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk.
(e)    Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and test revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its test and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for test revenue and then for contract revenue.
Test Revenue
The Company generates revenues from its DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the DMT or (ii) the DMT with TERT test, which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote sample collection of ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT and send a collection kit to the patient. The DermTech Connect app and telemedicine service are currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, test results are provided to the clinician indicating whether the sample collected is indicative of melanoma or not.
8

The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.3 million and $0.7 million in revenue for the three and six months ended June 30, 2023, respectively, and an additional $0.1 million and $8,000 in revenue for the three and six months ended June 30, 2022, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners and RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting. Contract revenue can be highly variable in any period as it is closely linked to the clinical trial progress of the Company’s biopharma customers.
(a) Disaggregation of Revenue
The following table presents the Company’s revenues disaggregated by revenue source during the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Test Revenue
DermTech Melanoma Test$3,565 $4,147 $6,990 $7,665 
Contract Revenue
Adhesive patch kits388 38 424 104 
RNA extractions14  16 110 
Project management fees13 48 27 72 
Total revenues$3,980 $4,233 $7,457 $7,951 
(b) Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of June 30, 2023 and December 31, 2022 was $0.3 million and $0.1 million, respectively. As of December 31, 2022, the Company reclassified $1.0 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of June 30, 2023, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was immaterial.
9

(f)    Accounts Receivable
Test Accounts Receivable
Due to the nature of the Company’s test revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.5 million and $4.1 million of net test accounts receivable as of June 30, 2023 and December 31, 2022, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and, as of June 30, 2023, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.4 million and $0.1 million of contract accounts receivable as of June 30, 2023 and December 31, 2022, respectively.
(g)    Net Loss Per Share
Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the periods presented, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same.
Outstanding anti-dilutive securities not included in diluted net loss per share (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Shares issuable upon exercise of common stock warrants709 714 709 714 
Shares issuable upon exercise of stock options1,921 1,758 1,921 1,758 
Shares issuable upon the release of restricted stock units3,562 2,912 3,562 2,912 
6,192 5,384 6,192 5,384 
(h)    Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
10

2.    Balance Sheet Details
Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of June 30, 2023 were as follows (in thousands):
June 30, 2023
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$10,048 $ $(78)$9,970 
U.S. government debt securities33,524 99 (187)33,436 
Total short-term marketable securities, available-for-sale$43,572 $99 $(265)$43,406 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2022 were as follows (in thousands):
December 31, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$13,535 $2 $(236)$13,301 
Municipal debt securities1,001  (8)993 
U.S. government debt securities34,675 10 (568)34,117 
Total short-term marketable securities, available-for-sale$49,211 $12 $(812)$48,411 
As of June 30, 2023, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.8 million; the remaining debt securities that the Company held at that date had an estimated market value of $2.6 million and contractual maturities of up to 18 months. As of December 31, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $8.2 million and contractual maturities of up to 23 months.
The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of June 30, 2023 or December 31, 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and six months ended June 30, 2023 and 2022 were not significant.
11

The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2023 aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
June 30, 2023
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$9,379 $(73)$591 $(5)$9,970 $(78)
U.S. government debt securities16,974 (168)1,964 (19)18,938 (187)
Total short-term marketable securities, available-for-sale$26,353 $(241)$2,555 $(24)$28,908 $(265)
The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
December 31, 2022
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$6,533 $(105)$5,503 $(131)$12,036 $(236)
Municipal securities  992 (8)992 (8)
U.S. government debt securities10,907 (196)19,026 (372)29,933 (568)
Total short-term marketable securities, available-for-sale$17,440 $(301)$25,521 $(511)$42,961 $(812)
Prepaid Expenses and Property and Equipment, Net
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Prepaid expenses and other current assets:
Prepaid expenses$1,513 $3,207 
Other current assets816 733 
Total prepaid expenses and other current assets$2,329 $3,940 
Property and equipment, gross:
Laboratory equipment$6,305 $6,250 
Computer equipment853 872 
Furniture and fixtures1,247 913 
Leasehold improvements597 1,344 
Total property and equipment, gross9,002 9,379 
Less accumulated depreciation(2,928)(3,004)
Total property and equipment, net$6,074 $6,375 
12

Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Accrued compensation:
Accrued bonus and commissions$3,778 $3,257 
Accrued salaries and wages3,609 4,637 
Total accrued compensation$7,387 $7,894 
Accrued liabilities:
Accrued consulting services$309 $894 
Customer refund liability980 980 
Restructuring liability 1,730  
Other accrued expenses676 1,590 
Total accrued liabilities$3,695 $3,464 

3. Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 (in thousands):
June 30, 2023
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:
Money market$17,577 $ $ $17,577 
U.S. government debt securities 10,227  10,227 
Total cash equivalents17,577 10,227  27,804 
Marketable securities, available for sale:
Corporate debt securities 9,970  9,970 
U.S. government debt securities 33,436  33,436 
Total marketable securities, available for sale 43,406  43,406 
Total assets measured at fair value on a recurring basis$17,577 $53,633 $ $71,210 
Liabilities:
Warrant liability$ $ $6 $6 
Total liabilities measured at fair value on a recurring basis$ $ $6 $6 
13

The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money Market$9,365 $ $ $9,365 
Corporate debt securities 7,374  7,374 
U.S. government debt securities 18,396  18,396 
Total cash equivalents9,365 25,770  35,135 
Marketable securities, available for sale:
Corporate debt 13,301  13,301 
Municipal debt securities 993  993 
U.S. government debt securities 34,117  34,117 
Total marketable securities, available for sale 48,411  48,411 
Total assets measured at fair value on a recurring basis$9,365 $74,181 $ $83,546 
Liabilities:
Warrant liability$ $ $5 $5 
Total liabilities measured at fair value on a recurring basis$ $ $5 $5 

The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date, including the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Assumed risk-free interest rate5.40%2.96%
4.35% - 5.40%
2.37% - 2.96%
Assumed volatility133.99%96.21%
123.28% - 133.99%
92.77% - 96.21%
Expected term1.17 years2.17 years
1.17 - 1.42 years
2.17 - 2.42 years
Expected dividend yield
14

The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2022$5 
Change in fair value of warrant liability7 
Balance as of March 31, 2023$12 
Change in fair value of warrant liability(6)
Balance as of June 30, 2023$6 
As of June 30, 2023 and December 31, 2022, the Company maintains letters of credit of $3.5 million and $3.5 million, respectively, related to its lease arrangements, secured by cash of June 30, 2023 and money market accounts as of December 31, 2022, in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.
The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts.
4.    Stockholders’ Equity
(a)    Common Stock

On June 2, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of Delaware to increase the authorized number of shares of common stock of the Company from 50,000,000 to 100,000,000 shares (the “Amended Certificate”). The Amended Certificate was approved by the Company’s stockholders at the 2023 Annual Meeting.
(b)    At-The-Market Offering
On November 10, 2020, the Company entered into a sales agreement (the “2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. Through December 31, 2021, the Company issued an aggregate of 1,482,343 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $30.05, net of $1.6 million in issuance costs resulting in net proceeds to the Company of approximately $42.9 million. During 2022, the Company did not issue or sell any shares of common stock pursuant to the 2020 Sales Agreement.

During the three months ended June 30, 2023, the Company issued an aggregate of 1,759,210 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.62 resulting in aggregate gross proceeds of approximately $4.6 million, reduced by $0.1 million issuance costs, resulting in net proceeds to the Company of approximately $4.5 million. For the six months ended June 30, 2023, the Company issued an aggregate of 1,866,661 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.68 resulting in aggregate gross proceeds of approximately $5.0 million, reduced by $0.2 million in issuance costs, resulting in net proceeds to the Company of approximately $4.8 million. As of June 30, 2023, $0.5 million is available pursuant to the 2020 Sales Agreement.

On August 8, 2022, the Company entered into a second sales agreement (the “2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the three and six months ended June 30, 2023, the Company did not issue any shares pursuant to the 2022 Sales Agreement.
15

(c)    Warrants
SPAC Warrants
The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings, which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and, as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated, and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.
The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.
In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 as of June 30, 2023 and December 31, 2022. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of June 30, 2023 and December 31, 2022.
Placement Agent Warrants
In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 4,510 as of June 30, 2023 and December 31, 2022.
(d)    Stock-Based Compensation
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the DermTech, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”), and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Cost of revenue$435 $298 $847 $633 
Sales and marketing1,548 1,067 3,056 2,528 
Research and development676 1,330 1,237 1,825 
General and administrative4,856 2,142 7,111 3,745 
Total stock-based compensation$7,515 $4,837 $12,251 $8,731 

The total compensation cost related to non-vested awards not yet recognized as of June 30, 2023 was $31.2 million, which is expected to be recognized over a weighted average term of 2.43 years.

16

Departure of Former Chief Executive Officer
Stock-based compensation expense for the three and six months ended June 30, 2023 includes accelerated expense of $2.9 million and $3.0 million, respectively, in connection with the transition agreement dated March 1, 2023, between the Company and its former Chief Executive Officer, John Dobak, M.D. (the "Transition Agreement"). The accelerated expense is included within general and administrative expenses in the condensed consolidated statement of operations.
Dr. Dobak resigned from his position as Chief Executive Officer and member of the board of directors of the Company (the "Board") effective May 8, 2023 and agreed to serve as a consultant to the Company on an as needed basis until January 1, 2024. The terms of the Transition Agreement allow for continuing vesting of Dr. Dobak's equity awards through the end of the consulting period on January 1, 2024. At the termination of the consulting period, consistent with Dr. Dobak's change of control and severance plan, he will immediately receive an additional 10 months vesting of equity awards and the period to exercise his vested stock options will be increased from 90 days to 12 months.
The Company assessed the consulting services under the Transition Agreement as nonsubstantive pursuant to ASC 718, Compensation – Stock Compensation (ASC 718) and recognized all stock-based compensation expense related to Dr. Dobak's equity awards vesting in connection with the Transition Agreement upon his resignation.
5.    Commitments and Contingencies
Restructuring Plan

On June 26, 2023, the Board approved a restructuring plan (the “Restructuring Plan”) to prioritize growth opportunities for the DMT, streamline operations, suspend pipeline programs, and significantly reduce overall operating expenses. The Restructuring Plan includes a reduction of the Company’s workforce by approximately 15%. The actions associated with the employee restructuring under the Restructuring Plan are expected to be substantially complete in the third quarter of 2023.

The Company incurred approximately $2.1 million in restructuring charges in connection with the Restructuring Plan for the three and six months ended June 30, 2023, which consist of $1.8 million in charges related to severance payments and employee benefits and $0.3 million in charges related to stock-based compensation for the acceleration of share-based awards. Restructuring charges are included in general and administrative expenses in the condensed consolidated statement of operations.

The restructuring liability as of June 30, 2023 is $1.7 million and is included within accrued liabilities in the condensed consolidated balance sheets.
Legal Proceedings
From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.
6.    Related Party Transactions
During 2022 and 2023, the Company engaged EVERSANA Life Science Services, LLC and its subsidiary Intouch Group, LLC (collectively, “EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s former Chief Commercial Officer, is an employee of EVERSANA. Mr. Wood's last day of employment as Chief Commercial Officer of the Company was July 3, 2023. The Company incurred $0.4 million and $0.9 million in costs for the three months ended June 30, 2023 and 2022, respectively, and $0.9 million and $1.6 million in costs for the six months ended June 30, 2023 and 2022, respectively. Amounts due to EVERSANA were $0.2 million and $0.3 million as of June 30, 2023 and December 31, 2022, respectively.
There were no other related party transactions identified during the three and six months ended June 30, 2023 and 2022.
17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) of DermTech, Inc. (together with its subsidiaries, “DermTech,” “we,” “us,” “our” or the “Company”) should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited condensed consolidated financial statements and notes thereto and the MD&A for the fiscal year ended December 31, 2022, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, (the “SEC”) on March 2, 2023.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report, including the following MD&A, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") that are intended to be covered by the “safe harbor” created by those sections. All statements, other than statements of historical facts, contained in this report, including statements regarding DermTech’s or its management’s intentions, beliefs, expectations and strategies for the future and its statements, estimates and expectations regarding the Restructuring Plan, its potential cost savings and any related future effects of the Restructuring Plan, are forward looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” "might," “will,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “potential,” “could,” “would,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this report, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 or in this Quarterly Report on Form 10-Q. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this report or to conform these forward-looking statements to actual results.
Overview
We are a molecular diagnostic company developing and marketing novel non-invasive genomics tests to aid in the diagnosis of melanoma and management of skin cancer. Our technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or to rule out melanoma with a 99% negative predictive value ("NPV") (Gerami et al. J Am Acad Dermatol. 2017; Skelsey et al. SKIN. 2021). Our scalable genomics assays have been designed to work with our adhesive patch, the DermTech Smart StickerTM (the “Smart Sticker”), which is used to non-invasively collect skin tissue samples for analysis.
We are initially commercializing tests that will address unmet needs in the diagnostic pathway of pigmented skin lesions, such as moles or dark colored skin spots. The DermTech Melanoma Test (“DMT”) facilitates the clinical assessment of pigmented skin lesions for melanoma. We initially marketed this test directly to a concentrated group of dermatologists and are currently expanding marketing efforts to a broader group of clinicians and to a small group of primary care providers. The application of our Smart Sticker to collect samples non-invasively may allow us to eventually market the DMT to primary care physicians more broadly, beyond integrated primary care networks. We process our tests in our high complexity molecular laboratory that is Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified, College of American Pathologists accredited and New York licensed. We also provide laboratory services to several pharmaceutical companies that access our technology on a contract basis for their clinical trials or other studies to advance new drugs.
18

Events, Trends and Uncertainties
The DMT without the additional test for the presence of telomerase reverse transcriptase gene driver mutations (“TERT”) (formerly known as PLAplus) became eligible for Medicare reimbursement on February 10, 2020. Each reference to the DMT in this paragraph refers only to the DMT without the add-on test for TERT. In late October 2019, the American Medical Association provided us with a Proprietary Laboratory Analyses Code (“PLA Code”). Pricing of $760 for the PLA Code was published on December 24, 2019 as part of the Clinical Laboratory Fee Schedule for 2020. The final Local Coverage Determination (“LCD”) expanded the coverage proposal in the draft LCD from one to two tests per date of service, and it allows clinicians to order the DMT if they have sufficient skill and experience to decide whether a pigmented lesion should be biopsied. Our local Medicare Administrative Contractor, Noridian, has issued its own LCD (“Noridian’s LCD”) announcing coverage of the DMT. Even though the effective date of Noridian’s LCD was June 7, 2020, Noridian began reimbursing us for the DMT as of February 10, 2020. With Medicare coverage granted, we have the opportunity to approach commercial payors, and, as a result, we believe that the DMT may generate significant revenues in the future. No LCD currently covers the optional add-on test for TERT available to those ordering the DMT.
Despite the grant of Medicare coverage for the DMT (without the add-on test for TERT), uncertainty surrounds commercial payor reimbursement, including governmental and commercial payors, of any test incorporating new technology, including tests developed using our technologies. Because each payor generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse our tests, seeking payor approvals is a time-consuming and costly process. We cannot be certain that coverage for our current tests and our planned tests will be provided in the future by additional commercial payors or that existing policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. If we cannot obtain or maintain coverage and reimbursement from private and governmental payors, such as Medicare and Medicaid, for our current tests, or new tests or test enhancements, our ability to generate revenues could be limited. This may have a material adverse effect on our business, financial condition, results of operation and cash flows.
Restructuring Plan
On June 26, 2023, the board of directors of the Company (the “Board”) approved restructuring actions (the "Restructuring Plan") that are intended to prioritize the significant growth opportunities for the DMT, streamline operations, suspend pipeline programs and significantly reduce overall operating expenses. These restructuring actions primarily related to sales, marketing and general and administrative functions and resulted in a workforce reduction of approximately 15% of the Company’s workforce. The Company currently estimates annualized savings of between $25 million and $30 million upon completion of the Restructuring Plan.

As part of the Restructuring Plan, the Company incurred one-time charges of $2.1 million. The one-time charges consist primarily of severance payments, employee benefits and stock-based compensation for the acceleration of share-based awards. The restructuring liability as of June 30, 2023 is $1.7 million and is included within accrued liabilities in the condensed consolidated balance sheets. The actions associated with the employee restructuring under the Restructuring Plan are expected to be substantially complete in the third quarter of 2023.
Contract Revenue
Contract revenues with pharmaceutical companies relate to ongoing clinical trial contracts and new contracts. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors. Many of our historical contracts with third parties were structured to contain milestone billing payments, which typically are advance payments on work yet to be performed. These advanced payments are structured to help fund operations and are included in deferred revenue as the work has not yet been performed. These advance payments will remain in deferred revenue until we process the laboratory portion of the contracts allowing us to recognize the revenue.
Supply Chain and Inflationary Environment
Global supply chain disruptions and the higher inflationary environment have resulted in higher prices, which could impact our liquidity, business, financial condition and results of operations.


19

Financial Overview
Revenue
We generate revenue through laboratory services that are billed to Medicare, private medical insurance companies and pharmaceutical companies who order our laboratory services, which can include sample collection kits, test development, patient segmentation and stratification, genomic analysis, data analysis and reporting. Our revenue is generated from two revenue streams: test revenue and contract revenue. Test revenue can be highly variable as it is based on payments received by government and private insurance payors that are and are not under contract and can vary based on patient insurance coverage, deductibles and co-pays. As much of our test revenue is driven by the samples that are sent by physicians to our central lab for testing, a key performance measure for us is samples that are received and processed by our central lab successfully, also known as billable samples. We are currently prioritizing volume in geographies where we have payer coverage versus overall volume growth as one factor to potentially increase average selling price and help preserve our cash runway. We recently stopped testing samples from pediatric patients and certain Fitzpatrick skin types based on guidance from our lab accrediting organization. We are working on a plan to reintroduce testing for these cohorts with extremely low prevalence of melanoma. Based on these factors, we expect test volumes in 2023 to be affected.
Our laboratory services are ordered by customers on projects that may span over several years, which makes our contract revenue highly variable. Segments of these contracts may be increased, delayed or eliminated based on the success of our customers’ clinical trials or other factors.
Operating Expenses
Sales and Marketing Expenses
Sales and marketing expenses are primarily related to our specialty field sales force, market research, reimbursement efforts, conference attendance, public relations, advertising and general marketing.
Research and Development Expenses
Our research and development ("R&D") expenses consist primarily of salaries and fringe benefits, clinical trials, consulting costs, facilities costs, laboratory costs, equipment expense and depreciation. We also conduct clinical trials to validate the performance characteristics of our tests and to show medical cost benefit in support of our reimbursement efforts.
General and Administrative Expenses
Our general and administrative expenses consist of senior management compensation, consulting, legal, billing and collections, human resources, information technology, accounting, insurance, and general business expenses.
Financing Activities
2020 At-The-Market Offering
On November 10, 2020, the Company entered into a sales agreement with Cowen and Company, LLC ("Cowen") relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million (the "2020 Sales Agreement"). Through December 31, 2021, the Company issued an aggregate of 1,482,343 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $30.05, net of $1.6 million in issuance costs resulting in net proceeds to the Company of approximately $42.9 million. During 2022, the Company did not issue or sell any shares of common stock pursuant to the 2020 Sales Agreement. During the three months ended June 30, 2023, the Company issued an aggregate of 1,759,210 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.62, net of $0.1 million issuance costs, resulting in net proceeds to the Company of approximately $4.5 million. During the six months ended June 30, 2023, the Company issued an aggregate of 1,866,661 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.68, net of $0.2 million issuance costs, resulting in net proceeds of approximately $4.8 million. As of June 30, 2023, $0.5 million is available pursuant to the 2020 Sales Agreement.
20

2022 At-The-Market Offering
On August 8, 2022, the Company entered into a sales agreement with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million (the "2022 Sales Agreement"). The Company did not issue or sell any shares of common stock pursuant to the 2022 Sales Agreement during 2022 nor the first or second quarter of 2023.
Results of Operations
Three Months Ended June 30, 2023 and June 30, 2022
(In thousands, except per share amounts and billable test revenue samples)Three Months Ended June 30,
20232022$ Change% Change
Revenues:
Test revenue $3,565 $4,147 $(582)(14)%
Contract revenue415 86 329 *
Total revenues3,980 4,233 (253)(6)%
Cost of revenues:
Cost of test revenue3,909 3,236 673 21 %
Cost of contract revenue63 37 26 70 %
Total cost of revenues3,972 3,273 699 21 %
Gross profit960 (952)(99)%
Gross profit as a percent of total revenue— %23 %
Operating expenses:  
Sales and marketing13,033 15,001 (1,968)(13)%
Research and development3,887 6,915 (3,028)(44)%
General and administrative15,220 8,878 6,342 71 %
Total operating expenses32,140 30,794 1,346 %
Loss from operations(32,132)(29,834)(2,298)%
Other income:  
Interest income, net763 149 614 *
Change in fair value of warrant liability105 (99)(94)%
Total other income769 254 515 *
Net loss$(31,363)$(29,580)$(1,783)%
Basic and diluted net loss per share$(0.99)$(0.99)$— — %
Other Operating Data:
Billable test revenue samples17,450 18,320 (870)(5)%
* Absolute value percentage change greater than 100

21

Revenue

Test Revenue
Test revenues decreased $0.6 million, or 14%, to $3.6 million for the three months ended June 30, 2023, compared to $4.1 million for the three months ended June 30, 2022. The decrease in test revenues was primarily driven by a decrease in average selling price from lower collection estimates for certain non-contracted commercial payors and a decrease in billable sample volume. Billable samples decreased to approximately 17,450 for the three months ended June 30, 2023, compared to approximately 18,320 for the three months ended June 30, 2022. Sample volume is dependent on two major factors: the number of clinicians who order a test in any given quarter and the number of tests ordered by each clinician during the period. The number of ordering clinicians and the utilization per clinician can vary based on a number of factors, including the types of skin cancer conditions presented to clinicians, clinician reimbursement, office workflow, market awareness, clinician education and other factors.
Contract Revenue
Contract revenues with pharmaceutical companies increased $0.3 million to $0.4 million for the three months ended June 30, 2023, compared to $0.1 million for the three months ended June 30, 2022. The increase is attributable to significant kit shipments made to several pharmaceutical companies. Contract revenues can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can be difficult to forecast due to variability of patient enrollment, drug safety and efficacy and other factors.
Cost of Revenue
Cost of revenues increased $0.7 million, or 21%, to $4.0 million for the three months ended June 30, 2023, compared to $3.3 million for the three months ended June 30, 2022. The increase was largely attributable to higher overhead costs pertaining to our new facility and higher lab supply expenses. As of June 30, 2023, a large portion of the costs of revenue are fixed, and these costs include the CLIA facility, quality assurance, management and supervision and equipment calibration and depreciation. The variable cost of revenue expenses incurred primarily relate to compensation-related costs for our laboratory scientists and technicians, laboratory supplies, shipping costs and Smart Sticker collection kits. We remain committed to continuing the automation of our laboratory processes in order to become more cost efficient and productive.
Operating Expenses
Sales and Marketing
Sales and marketing expense decreased $2.0 million, or 13%, to $13.0 million for the three months ended June 30, 2023 compared to $15.0 million for the three months ended June 30, 2022. The decrease was due to reduced spend around marketing activities, reduced consulting costs and lower employee-related compensation costs. As part of the Restructuring Plan, we expect sales and marketing expenses to be reduced further in the second half of 2023.
Research and Development
R&D expenses decreased $3.0 million, or 44%, to $3.9 million for the three months ended June 30, 2023 compared to $6.9 million for the three months ended June 30, 2022. The decrease was due to reduced compensation costs from lower headcount, lower clinical study costs and lower lab supply spending.
General and Administrative
General and administrative expenses increased $6.3 million, or 71%, to $15.2 million for the three months ended June 30, 2023, compared to $8.9 million for the three months ended June 30, 2022. The increase was primarily due to $2.1 million in costs related to the Restructuring Plan, separation benefits of $3.4 million related to our former CEO, including $2.9 million of stock-based compensation for the acceleration of share-based awards, and higher overhead from our new facility. As part of the Restructuring Plan, we expect general and administrative expenses to be reduced in the second half of 2023.
22

Interest Income, net
Interest income, net of $0.8 million and $0.1 million for the three months ended June 30, 2023 and 2022, respectively, consists primarily of interest earned on our short-term marketable securities.
Change in Fair Value of Warrant Liability
Change in fair value of warrant liability for the three months ended June 30, 2023 was a gain of $6,000, compared to a gain of $105,000 for the three months ended June 30, 2022. The change in fair value of warrant liability is calculated by adjusting the value of the outstanding Private SPAC Warrants held by original holders to the current market value at each reporting period.

Six Months Ended June 30, 2023 and June 30, 2022
(In thousands, except per share amounts and billable test revenue samples)Six Months Ended June 30,
20232022$ Change% Change
Revenues:
Test revenue $6,990 $7,665 $(675)(9)%
Contract revenue467 286 181 63 %
Total revenues7,457 7,951 (494)(6)%
Cost of revenues:
Cost of test revenue7,700 6,766 934 14 %
Cost of contract revenue93 61 32 52 %
Total cost of revenues7,793 6,827 966 14 %
Gross (loss) profit(336)1,124 (1,460)*
Gross (loss) profit as a percent of total revenue(5)%14 %
Operating expenses:  
Sales and marketing28,450 30,444 (1,994)(7)%
Research and development8,296 13,253 (4,957)(37)%
General and administrative27,095 17,452 9,643 55 %
Total operating expenses63,841 61,149 2,692 %
Loss from operations(64,177)(60,025)(4,152)%
Other income/(expense):  
Interest income, net1,545 215 1,330 *
Change in fair value of warrant liability(1)122 (123)*
Total other income1,544 337 1,207 *
Net loss$(62,633)$(59,688)$(2,945)%
Basic and diluted net loss per share$(2.01)$(2.00)$(0.01)%
Other Operating Data:
Billable test revenue samples35,250 32,690 2,560 %
* Absolute value percentage change greater than 100

23

Test Revenue
Test revenues decreased $0.7 million, or 9%, to $7.0 million for the six months ended June 30, 2023, compared to $7.7 million for the six months ended June 30, 2022. The decrease in test revenues was primarily driven by a decrease in average selling price from lower collection estimates for certain non-contracted commercial payors, including revenue adjustments for tests run in prior periods, partially offset by increased billable sample volume. Billable samples increased to approximately 35,250 for the six months ended June 30, 2023, compared to approximately 32,690 for the six months ended June 30, 2022.
Contract Revenue
Contract revenues with pharmaceutical companies increased $0.2 million, or 63%, to $0.5 million for the six months ended June 30, 2023, compared to $0.3 million for the six months ended June 30, 2022. Contract revenue can be highly variable as it is dependent on the pharmaceutical customers’ clinical trial progress, which can change due to variability of patient enrollment, drug safety and efficacy and other factors.
Cost of Revenue
Cost of revenues increased $1.0 million, or 14%, to $7.8 million for the six months ended June 30, 2023, compared to $6.8 million for the six months ended June 30, 2022. The increase was largely attributable to a higher billable sample volume in 2023 and higher overhead costs pertaining to our new facility. As of June 30, 2023, a large portion of the costs of revenue are fixed, and these costs include the CLIA facility, quality assurance, management and supervision and equipment calibration and depreciation. The variable cost of revenue expenses incurred primarily relate to compensation-related costs for our laboratory scientists and technicians, laboratory supplies, shipping costs, equipment maintenance, and utilities. We remain committed to continuing the automation of our laboratory processes in order to become more cost efficient and productive.
Operating Expenses
Sales and Marketing
Sales and marketing expenses decreased $2.0 million, or 7%, to $28.5 million for the six months ended June 30, 2023, compared to $30.4 million for the six months ended June 30, 2022. The decrease was due to reduced spend around marketing activities, reduced consulting costs and lower employee-related compensation costs. As part of the Restructuring Plan, we expect sales and marketing expenses to be reduced further in the second half of 2023.
Research and Development
R&D expenses decreased $5.0 million, or 37%, to $8.3 million for the six months ended June 30, 2023, compared to $13.3 million for the six months ended June 30, 2022. The decrease was due to reduced compensation costs from lower headcount, lower clinical study costs and lower lab supply spending.
General and Administrative
General and administrative expenses increased $9.6 million, or 55%, to $27.1 million for the six months ended June 30, 2023, compared to $17.5 million for the six months ended June 30, 2022. The increase was primarily due to $2.1 million in costs related to the Restructuring Plan, separation benefits of $3.6 million related to our former CEO, including $3.0 million of stock-based compensation for the acceleration of share-based awards, higher employee-compensation related costs and higher overhead from our new facility. As part of the Restructuring Plan, we expect general and administrative expenses to be reduced in the second half of 2023.
Interest Income, net
Interest income, net of $1.5 million and $0.2 million for the six months ended June 30, 2023 and 2022, respectively, consists primarily of interest earned on our short-term marketable securities.
24

Change in Fair Value of Warrant Liability
Change in fair value of warrant liability for the six months ended June 30, 2023 was a loss of $1,000, compared to a gain of $0.1 million for the six months ended June 30, 2022. The change in fair value of warrant liability is calculated by adjusting the value of the outstanding Private SPAC Warrants held by original holders to the current market value at each reporting period.
Liquidity and Capital Resources
We have never been profitable and have historically incurred substantial net losses, including net losses of $116.7 million for the twelve months ended December 31, 2022 and $62.6 million for the six months ended June 30, 2023. As of June 30, 2023, our accumulated deficit was $385.7 million. At the end of 2020, throughout 2021 and the second quarter of 2023, we raised approximately $49.5 million in gross proceeds facilitated through our at-the-market offering. In addition, we completed an underwritten public offering in January 2021, which raised a total of $143.7 million in gross proceeds. We have historically financed operations through private placement and public equity offerings.
We expect our losses to continue as a result of costs relating to ongoing R&D expenses, general and administrative expenses and sales and marketing costs for existing products. These losses have had, and will continue to have, an adverse effect on our working capital. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.
As of June 30, 2023, our cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. Based on our current business operations and the Restructuring Plan, we believe our current cash, cash equivalents and short-term marketable securities will be sufficient to meet our anticipated cash requirements for at least the next 12 months. While we believe we have enough capital to fund anticipated operating costs for at least the next 12 months, we expect to incur significant additional operating losses over at least the next several years. We anticipate that we will raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements in order to support our planned operations and to continue developing and commercializing genomic tests. We may also consider raising additional capital in the future to expand our business and to pursue strategic investments. Our present and future funding requirements will depend on many factors, including:
our revenue growth rate and ability to generate cash flows from operating activities;
our ability to successfully execute and realize the intended benefits of the Restructuring Plan;
our sales and marketing and R&D activities;
effects of competing technological and market developments;
costs of and potential delays in product development;
changes in regulatory oversight applicable to our tests; and
timing of and costs related to future international expansion.
There can be no assurances as to the availability of additional financing or the terms upon which additional financing may be available to us. If we are unable to obtain sufficient funding at acceptable terms, we may be forced to significantly curtail our operations, and lack of sufficient funding may have a material adverse impact on our ability to continue as a going concern.
25

Cash Flow Analysis
(amounts in thousands)Six Months Ended June 30,
20232022
Net cash used in operating activities$(45,229)$(49,229)
Net cash provided by/(used in) investing activities4,864 (7,392)
Net cash provided by financing activities5,377 517 
Net cash used in operating activities for the six months ended June 30, 2023 totaled $45.2 million, primarily driven by the $62.6 million net loss, offset partially by non-cash related items, including $12.3 million in stock-based compensation, $2.2 million in amortization of operating lease ROU assets and $0.9 million in depreciation. In addition, we had a net cash inflow of $2.2 million through net changes in working capital balances driven primarily by cash inflows of $0.3 million due to decreases in accounts receivable, $0.4 million from the decrease in inventory, $1.8 million through the decrease of prepaid expenses and other current assets and $0.7 million through the increase in accounts payable, accrued liabilities and deferred revenue, partially offset by cash outflows of $0.5 million from the increase in accrued compensation and $0.5 million from the increase in operating lease liabilities.
Net cash provided by investing activities for the six months ended June 30, 2023 totaled $4.9 million, which related to the outflow from the purchase of $25.6 million of marketable securities and $1.0 million from the purchase of equipment offset by the inflow from the sales and maturities of marketable securities of $31.4 million.
Net cash provided by financing activities for the six months ended June 30, 2023 totaled $5.4 million, which was driven primarily by $4.8 million in net proceeds raised from the 2020 Sales Agreement and $0.6 million in proceeds from contributions to the 2020 ESPP.
Off-Balance Sheet Arrangements
As of June 30, 2023, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
Critical Accounting Policies and Significant Judgments and Estimates
Critical accounting policies, significant judgments and estimates are those that we believe are most important for the portrayal of the Company’s financial condition and results and that require management’s most subjective and complex judgments. Judgments and uncertainties regarding the application of these policies may result in materially different amounts being reported under various conditions or using different assumptions. There have been no material changes to the critical accounting estimates previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Recent Accounting Pronouncements
See Item 1 of Part I, Note 1(h) of the condensed consolidated financial statements herein.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures.
Disclosure controls and procedures enable us to record, process, summarize and report information required to be included in our Exchange Act filings within the required time period. Our disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed by us in the periodic reports filed with the SEC is accumulated and communicated to our management, including our principal executive, financial and accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
26

Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q, as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2023, the Company’s disclosure controls and procedures were effective as of such date for this purpose.
Changes in Internal Control over Financial Reporting
There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitation on Effectiveness of Controls
It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
27

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently a party to any material legal proceedings.
Item 1A. Risk Factors.
There have not been any material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, except for the addition of the following risk factor:

We may fail to achieve the expected cost savings and related benefits from our Restructuring Plan.

On June 26, 2023, the Board approved the Restructuring Plan, which is intended to prioritize the significant growth opportunities for the DMT, streamline operations, suspend pipeline programs and significantly reduce overall operating expenses. The Restructuring Plan primarily relates to sales, marketing and G&A functions and resulted in a workforce reduction of approximately 15% of the Company’s workforce. As part of the Restructuring Plan, the Company incurred one-time charges of $2.2 million in the second quarter of 2023. The one-time charges consist primarily of severance payments, employee benefits and stock-based compensation for the acceleration of share-based awards.

The Company currently estimates annualized savings of between $25 million and $30 million upon completion of the Restructuring Plan. There is no guarantee that the Restructuring Plan will achieve its intended benefits. For example, the Company's cost restructuring efforts may not result in the anticipated savings or other economic benefits, or could result in total costs and expenses that are greater than expected. In addition, the Company may not be able to effectively realize all the cost savings anticipated by the Restructuring Plan and may incur termination and other costs not previously contemplated, which could be material. The Restructuring Plan may cause disruption to the Company's business operations. For example, the Restructuring Plan resulted in the loss of a number of long-term employees, which could result in the loss of institutional knowledge and expertise and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect the Company's operations. In addition, the Restructuring Plan could negatively impact the Company's ability to attract, integrate, retain and motivate key employees.
28

Item 6. Exhibits.
The following documents are filed as part of this Form 10-Q.
Exhibit
No.
DescriptionFiled
Herewith
FormIncorporated
by Reference
File No.
Date Filed
3.1X
3.2


10-K001-381183/11/20
10.1*^8-K/A001-381187/13/23
10.2*8-K001-381186/05/23
10.3*^8-K001-381185/09/23
10.4*8-K001-381185/09/23
31.1X
31.2X
32.1**X
101.INSInline XBRL Instance DocumentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104
The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 has been formatted in Inline XBRL.
X
*Management contract or compensatory plan or arrangement
^Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.
** This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing.
29

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DermTech, Inc.
Date: August 3, 2023
By:/s/ Bret Christensen
Bret Christensen
Chief Executive Officer
(Principal Executive Officer)
Date: August 3, 2023
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(Principal Financial and Accounting Officer)
30
EX-3.1 2 dmtkex31amendedandrestated.htm EX-3.1 Document

Exhibit 3.1


AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

CONSTELLATION ALPHA CAPITAL CORP.

(originally incorporated on August 27, 2019 under the name Constellation Alpha Capital Corp.)

FIRST: The name of the Corporation is DermTech, Inc.

SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle 19808. The name of its registered agent at such address is Corporation Service Company.

THIRD: The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

FOURTH: The total number of shares of all classes of stock that the Corporation shall have authority to issue is 55,000,000 shares, consisting of (i) 50,000,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”), and (ii) 5,000,000 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”).

The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.

A. COMMON STOCK.

1.General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series.

2.Voting. The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one vote for each share thereof held by such holder; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation. There shall be no cumulative voting.

The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.

3.Dividends. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend or other rights of any then outstanding Preferred Stock.

4.Liquidation. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any then outstanding Preferred Stock.




B. PREFERRED STOCK.

Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. Any shares of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.

Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General Corporation Law of the State of Delaware, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.

The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.

FIFTH: Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation.

SIXTH: In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of the State of Delaware, and subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the By-laws of the Corporation by the affirmative vote of a majority of the directors present at any regular or special meeting of the Board of Directors at which a quorum is present. The stockholders may not adopt, amend, alter or repeal the By-laws of the Corporation, or adopt any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes that all the stockholders would be entitled to cast in any annual election of directors or class of directors. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article SIXTH.

SEVENTH: Except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal. If the General Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended.

EIGHTH: The Corporation shall provide indemnification as follows:

1.Actions, Suits and Proceedings Other than by or in the Right of the Corporation. The Corporation shall indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed






action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to hereafter as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.

2.Actions or Suits by or in the Right of the Corporation. The Corporation shall indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that no indemnification shall be made under this Section 2 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including attorneys’ fees) which the Court of Chancery of Delaware or such other court shall deem proper.

3.Indemnification for Expenses of Successful Party. Notwithstanding any other provisions of this Article EIGHTH, to the extent that an Indemnitee has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of this Article EIGHTH, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee shall be indemnified against all expenses (including attorneys’ fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith. Without limiting the foregoing, if any action, suit or proceeding is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee, (ii) an adjudication that Indemnitee was liable to the Corporation, (iii) a plea of guilty or nolo contendere by Indemnitee,

(iv)an adjudication that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and (v) with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe his or her conduct was unlawful, Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto.

4.Notification and Defense of Claim. As a condition precedent to an Indemnitee’s right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought unless the Corporation has confirmed to the Indemnitee that it is aware of such action, suit, proceeding or investigation and that indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection with such action, suit, proceeding or investigation, other than as provided below






in this Section 4. Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Corporation, (ii) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (iii) the Corporation shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Article EIGHTH. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (ii) above. The Corporation shall not be required to indemnify Indemnitee under this Article EIGHTH for any amounts paid in settlement of any action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee’s written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.

5.Advance of Expenses. Subject to the provisions of Section 6 of this Article EIGHTH, in the event of any threatened or pending action, suit, proceeding or investigation of which the Corporation receives notice under this Article EIGHTH, any expenses (including attorneys’ fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter; provided, however, that the payment of such expenses incurred by or on behalf of Indemnitee in advance of the final disposition of such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article EIGHTH; and provided further that no such advancement of expenses shall be made under this Article EIGHTH if it is determined (in the manner described in Section 6) that (i) Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (ii) with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment.

6.Procedure for Indemnification and Advancement of Expenses. In order to obtain indemnification or advancement of expenses pursuant to Section 1, 2, 3 or 5 of this Article EIGHTH, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless (i) the Corporation has assumed the defense pursuant to Section 4 of this Article EIGHTH (and none of the circumstances described in Section 4 of this Article EIGHTH that would nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate counsel have occurred) or (ii) the Corporation determines within such 60-day period that Indemnitee did not meet the applicable standard of conduct set forth in Section 1, 2 or 5 of this Article EIGHTH, as the case may be. Any such indemnification, unless ordered by a court, shall be made with respect to requests under Section 1 or 2 only as authorized in the specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because Indemnitee has met the applicable standard of conduct set forth in Section 1 or 2, as the case may be. Such determination shall be made in each instance (a) by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question (“disinterested directors”), whether or not a quorum, (b) by a committee of disinterested directors designated by majority vote of disinterested directors, whether or not a quorum, (c) if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular legal counsel to the Corporation) in a written opinion, or (d) by the stockholders of the Corporation.

7.Remedies. Subject to Article TWELFTH, the right to indemnification or advancement of expenses as granted by this Article EIGHTH shall be enforceable by Indemnitee in any court of competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Corporation pursuant to Section 6 of this Article EIGHTH that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met






the applicable standard of conduct. In any suit brought by Indemnitee to enforce a right to indemnification, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article EIGHTH. Indemnitee’s expenses (including attorneys’ fees) reasonably incurred in connection with successfully establishing Indemnitee’s right to indemnification, in whole or in part, in any such proceeding shall also be indemnified by the Corporation. Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification hereunder, it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the General Corporation Law of the State of Delaware.

8.Limitations. Notwithstanding anything to the contrary in this Article EIGHTH, except as set forth in Section 7 of this Article EIGHTH, the Corporation shall not indemnify an Indemnitee pursuant to this Article EIGHTH in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors of the Corporation. Notwithstanding anything to the contrary in this Article EIGHTH, the Corporation shall not indemnify an Indemnitee to the extent such Indemnitee is reimbursed from the proceeds of insurance, and in the event the Corporation makes any indemnification payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification payments to the Corporation to the extent of such insurance reimbursement.

9.Subsequent Amendment. No amendment, termination or repeal of this Article EIGHTH or of the relevant provisions of the General Corporation Law of the State of Delaware or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to indemnification under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.

10.Other Rights. The indemnification and advancement of expenses provided by this Article EIGHTH shall not be deemed exclusive of any other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee’s official capacity and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained in this Article EIGHTH shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and directors providing indemnification rights and procedures different from those set forth in this Article EIGHTH. In addition, the Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article EIGHTH.

11.Partial Indemnification. If an Indemnitee is entitled under any provision of this Article EIGHTH to indemnification by the Corporation for some or a portion of the expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify Indemnitee for the portion of such expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in settlement to which Indemnitee is entitled.

12.Insurance. The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware.

13.Savings Clause. If this Article EIGHTH or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including attorneys’ fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts paid in settlement in connection with any action,






suit, proceeding or investigation, whether civil, criminal or administrative, including an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article EIGHTH that shall not have been invalidated and to the fullest extent permitted by applicable law.

14.Definitions. Terms used herein and defined in Section 145(h) and Section 145(i) of the General Corporation Law of the State of Delaware shall have the respective meanings assigned to such terms in such Section 145(h) and Section 145(i).

NINTH: This Article NINTH is inserted for the management of the business and for the conduct of the affairs of the Corporation.

1.General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.

2.Number of Directors; Election of Directors. Subject to the rights of holders of any series of Preferred Stock to elect directors, the number of directors of the Corporation shall be established by the Board of Directors. Election of directors need not be by written ballot, except as and to the extent provided in the By-laws of the Corporation.

3.Classes of Directors. Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board of Directors shall be and is divided into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. The Board of Directors is authorized to assign members of the Board of Directors already in office to Class I, Class II or Class III at the time such classification becomes effective.

4.Terms of Office. Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected; provided that each director initially assigned to Class I shall serve for a term expiring at the Corporation’s first annual meeting of stockholders held after the effectiveness of this Restated Certificate of Incorporation; each director initially assigned to Class II shall serve for a term expiring at the Corporation’s second annual meeting of stockholders held after the effectiveness of this Restated Certificate of Incorporation; and each director initially assigned to Class III shall serve for a term expiring at the Corporation’s third annual meeting of stockholders held after the effectiveness of this Restated Certificate of Incorporation; provided further, that the term of each director shall continue until the election and qualification of his or her successor and be subject to his or her earlier death, resignation or removal.

5.Quorum. The greater of (a) a majority of the directors at any time in office and (b) one third of the number of directors fixed pursuant to Section 2 of this Article NINTH shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.

6.Action at Meeting. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation.

7.Removal. Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only for cause and only by the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors.

8.Vacancies. Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly-created directorship in the Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director’s earlier death, resignation or removal.






9.Stockholder Nominations and Introduction of Business, Etc. Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the By-laws of the Corporation.

10.Amendments to Article. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH.

TENTH: Stockholders of the Corporation may not take any action by written consent in lieu of a meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article TENTH.

ELEVENTH: Special meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chairman of the Board or the Chief Executive Officer, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By-laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy-five percent (75%) of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article ELEVENTH.

TWELFTH: Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of the Corporation, to the Corporation or the Corporation’s stockholders, (iii) any action or proceeding asserting a claim against the Corporation or any current or former director, officer or other employee of the Corporation, arising out of or pursuant to any provision of the Delaware General Corporation Law or this Certificate of Incorporation or the By-Laws of the Corporation (in each case, as they may be amended from time to time), (iv) any action or proceeding to interpret, apply, enforce or determine the validity of this Certificate of Incorporation or the Bylaws of the Corporation (including any right, obligation, or remedy thereunder), (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi) any action asserting a claim against the Corporation or any director, officer or other employee of the Corporation, governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to the provisions of this Article TWELFTH. This Article TWELFTH shall not apply to actions brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any claim for which the federal courts have exclusive jurisdiction.






IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation, which restates, integrates and amends the certificate of incorporation of the Corporation, and which has been duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, has been executed by its duly authorized officer on this 29th day of August, 2019.

DERMTECH, INC.


By:    /s/ John Dobak


John Dobak, CEO




CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

DERMTECH, INC.

DermTech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

1.The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 27, 2019. The original Certificate of Incorporation was amended and restated on August 29, 2019 (the “Amended and Restated Certificate of Incorporation”).

2.The following paragraph is hereby inserted after the first paragraph in Paragraph FOURTH of the Amended and Restated Certificate of

Incorporation:

“Upon the close of trading on The Nasdaq Capital Market on August 29, 2019 (the “Effective Time”), each two (2) shares of the Common Stock issued and outstanding or held in treasury at the Effective Time shall be reclassified as and changed into one (1) share of Common Stock, par value $0.0001 per share, without any action by the holders thereof. In lieu of any fractional shares to which a holder of shares of Common Stock would be otherwise entitled, the Corporation shall, at its election, either (i) pay in cash, without interest, an amount equal to such fractional interest (after taking into account and aggregating all shares of Common Stock then held by such holder) multiplied by the closing price of the Common Stock as last reported on the Nasdaq Capital Market on the day of the Effective Time (determined on a post-split basis), or (ii) round up to the next whole share.”

3.This Certificate of Amendment has been duly authorized and adopted by the Corporation’s Board of Directors in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

(Signature page follows)




IN WITNESS WHEREOF, DermTech, Inc. has caused this Certificate of Amendment to be signed by John Dobak, a duly authorized officer of the Corporation, on August 29, 2019.

DERMTECH, INC.,

a Delaware corporation


By:/s/ John Dobak
Name:John Dobak
Title:Chief Executive Officer







[Signature Page to Certificate of Amendment]




DERMTECH, INC.

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES A CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 151 OF THE

DELAWARE GENERAL CORPORATION LAW

The undersigned, John Dobak and Steven Kemper, do hereby certify that:

1.They are the President and Secretary, respectively, of DermTech, Inc., a Delaware corporation (the “Corporation”).

2.The Corporation is authorized to issue 5,000,000 shares of preferred stock, none of which are issued and outstanding.

3.The following resolutions were duly adopted by the board of directors of the Corporation (the “Board of Directors”):

WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 5,000,000 shares, $0.0001 par value per share, issuable from time to time in one or more series;

WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them; and

WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a series of the preferred stock, which shall consist of up to 1,250 shares of the preferred stock which the Corporation has the authority to issue, as follows:

NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows:




TERMS OF PREFERRED STOCK

Section 1.    Definitions. For the purposes hereof, the following terms shall have the following meanings:

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.

Alternate Consideration” shall have the meaning set forth in Section 7(d).

Beneficial Ownership Limitation” shall have the meaning set forth in Section 6(d).

Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

Commission” means the United States Securities and Exchange Commission.

Common Stock” means the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.

Common Stock Equivalents” means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

Conversion Amount” means the sum of the Stated Value at issue.

Conversion Date” shall have the meaning set forth in Section 6(a).

Conversion Price” shall have the meaning set forth in Section 6(b).

Conversion Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance with the terms hereof.

Effective Date” means the date that the Conversion Shares Registration Statement filed by the Corporation pursuant to the Subscription Agreements is first declared effective by the Commission.

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

Fundamental Transaction” shall have the meaning set forth in Section 7(d).

Holder” shall have the meaning given such term in Section 2.

Liquidation” shall have the meaning set forth in Section 5.

Notice of Conversion” shall have the meaning set forth in Section 6(a).

Original Issue Date” means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock. The Preferred Stock may be issued in certificated form or in book-entry form at the election of the Holder. To the extent that any shares of Preferred




Stock are issued in book-entry form, references herein to “certificates” shall instead refer to the book-entry notation relating to such shares.

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

Preferred Stock” shall have the meaning set forth in Section 2.

Registration Statement” means a registration statement that registers the resale of the Conversion Shares of the Holders, who shall be named as “selling stockholders” therein and meets the requirements of the Subscription Agreements.

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Share Delivery Date” shall have the meaning set forth in Section 6(c).

Stated Value” shall have the meaning set forth in Section 2.

Subscription Agreements” means those certain subscription agreements entered into on or about August 1, 2019, each by and between the Corporation and the purchaser thereto, and each as amended, modified or supplemented from time to time in accordance with its terms.

Subsidiary” means any direct or indirect subsidiary of the Corporation formed or acquired before or after the date of the Subscription Agreements.

Successor Entity” shall have the meaning set forth in Section 7(d).

Trading Day” means a day on which the principal Trading Market is open for business.

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, an OTC market place or the OTC Bulletin Board (or any successors to any of the foregoing).

Transaction Documents” means the Subscription Agreements, this Certificate of Designation and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder

Transfer Agent” means Continental Stock Transfer & Trust Company, the current transfer agent for the Common Stock, and any successor transfer agent of the Corporation.

Underlying Shares” means the shares of Common Stock issued and issuable upon conversion of the Preferred Stock.

Section 2. Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 1,250 (which shall not be subject to increase without the written consent of a majority of the holders of the Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $3,250 (the “Stated Value”).






Section 3.    Dividends.

a)Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Preferred Stock; and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.

Section 4. Voting Rights. Except as otherwise provided herein or as otherwise required by the Delaware General Corporation Law, the Preferred Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of Preferred Stock, (a) (i) alter or change adversely the powers, preferences or rights given to the Preferred Stock, (ii) alter or amend this Certificate of Designation, subject to the restriction on amending the Beneficial Ownership Limitation set forth in Section 6(d), or (iii) amend or repeal any provision of, or add any provision to, the certificate of incorporation or bylaws of the Corporation, or file any articles of amendment or certificate of designations of preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the powers, preferences or rights of the Preferred Stock in a manner materially different than the effect of such actions on the Common Stock (regardless, in the case of clause (i), (ii) or (iii), of whether any of the foregoing actions shall be by means of amendment to the certificate of incorporation of the Corporation or by merger, consolidation or otherwise), (b) issue further shares of Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Preferred Stock or (c) enter into any agreement with respect to any of the foregoing.


Section 5. Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Corporation and the payment of any liquidation preference owed to the holders of shares of capital stock of the Corporation ranking senior to the Preferred Stock upon liquidation, the Holders of the Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock) in the net assets of the Corporation. The Corporation shall mail written notice of any such Liquidation to each Holder.

Section 6.    Conversion.

a)Conversions at Option of Holder. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A (a “Notice of Conversion”). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by facsimile such Notice of Conversion to the Corporation (such date, the “Conversion Date”). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. Provided the Transfer Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder’s election, whether the applicable conversion shares shall be credited to the account of the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC Delivery”). To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing the shares of Preferred Stock to the Corporation unless all of the shares of




Preferred Stock represented thereby are so converted, in which case such Holder shall deliver the certificate representing such shares of Preferred Stock promptly following the Conversion Date at issue. Shares of Preferred Stock converted into Common Stock in accordance with the terms hereof shall be canceled and shall not be reissued.

b)Conversion Price. The conversion price for the Preferred Stock shall equal $3.25, subject to adjustment herein (the

Conversion Price”).

c)Mechanics of Conversion

i.Delivery of Certificate Upon Conversion. Not later than three (3) Trading Days after each Conversion Date (the “Share Delivery Date”), the Corporation shall (A) deliver, or cause to be delivered, to the converting Holder a certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Preferred Stock or (B) in the case of a DWAC Delivery, electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with DTC through its DWAC system which, on or after the earlier of (i) the six month anniversary of the Original Issue Date or (ii) the Effective Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Subscription Agreements or applicable law). If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Preferred Stock unsuccessfully tendered for conversion to the Corporation.

ii.Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock and payment of dividends on the Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions set forth in the Subscription Agreements) be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Conversion Shares Registration Statement is then effective under the Securities Act, shall be registered for public resale in accordance with such Conversion Shares Registration Statement (subject to such Holder’s compliance with its obligations under the Registration Rights Agreement) to the extent required by the Subscription Agreements.

iii.Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share.

iv.Transfer Taxes and Expenses. The issuance of certificates for shares of the Common Stock on conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery




of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion.

d)Beneficial Ownership Limitation. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder’s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Preferred Stock) beneficially owned by such Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates) and of how many shares of Preferred Stock are convertible shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder’s determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation’s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or

(iii)a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Corporation shall within two Trading Days confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall initially be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Stock held by the applicable Holder. Notwithstanding the foregoing, by written notice to the Corporation, which will not be effective until the sixty-first (61st) day after such notice is delivered to the Corporation, the Holder may reset the Beneficial Ownership Limitation percentage to a higher or lower percentage; provided that such notice shall not be required in the event of a Fundamental Transaction (as defined below). Upon such a change by a Holder to the Beneficial Ownership Limitation, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum 61-day notice required by this Section 6(d) (except in the event of a Fundamental Transaction). The provisions of this paragraph shall be construed and implemented




in a manner otherwise than in strict conformity with the terms of this Section 6(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock. The determination of whether the conversion of shares of Preferred Stock into Common Stock is permitted under this Section 6(d) shall be made by the record holder of such shares of Preferred Stock in such record holder’s sole discretion, and the submission of a Notice of Conversion shall be conclusively deemed to constitute such record holder’s determination that the conversion of the shares of Preferred Stock identified in such Notice of Conversion is permitted under this Section 6(d).

Section 7.    Certain Adjustments.

a)Stock Dividends and Stock Splits. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b)Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder of will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder’s Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c)Pro Rata Distributions. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete Conversion of this Preferred Stock (without regard to any limitations on Conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such






Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d)Fundamental Transaction. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’ right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the holder of this Preferred Stock, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a






conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction Documents referring to the “Corporation” shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein.

e)Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.

Section 8.    Miscellaneous.

a)Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 11099 N. Torrey Pines Road #100, La Jolla, CA 92037 Attention: John Dobak, or such other address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the books of the Corporation, or if no such facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Subscription Agreements. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.

b)Lost or Mutilated Preferred Stock Certificate. If a Holder’s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.

c)Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in Court of Chancery of the State of Delaware. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject




to the jurisdiction of such Delaware Chancery Courts, or such Delaware Chancery Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

d)Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.

e)Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.

f)Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.

g)Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.

h)Status of Converted or Redeemed Preferred Stock. Shares of Preferred Stock may only be issued pursuant to the Subscription Agreements. If any shares of Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Convertible Preferred Stock.

i)Redemption. The Preferred Stock is not redeemable.

Section 9. Fractional Shares. Preferred Stock may be issued in fractions of a share that shall entitle the holder, in proportion to such holder’s fractional shares, to receive dividends, participate in distributions and to have the benefit of all other rights of holders of Preferred Stock.

*********************




RESOLVED, FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of Delaware law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate this 29th day of August, 2019.

/s/ John Dobak/s/ Steven Kemper
Name: John DobakName: Steven Kemper
Title: Chief Executive OfficerTitle: Secretary




ANNEX A

NOTICE OF CONVERSION

(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED STOCK)

The undersigned hereby elects to convert the number of shares of Series A Convertible Preferred Stock indicated below into shares of common stock, par value $0.0001 per share (the “Common Stock”), of DermTech, Inc., a Delaware corporation (the “Corporation”), according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in accordance with the Subscription Agreements. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.

Conversion calculations:

Date to Effect Conversion: _____________________________________________

Number of shares of Preferred Stock owned prior to Conversion: _______________

Number of shares of Preferred Stock to be Converted: ________________________

Stated Value of shares of Preferred Stock to be Converted: ____________________

Number of shares of Common Stock to be Issued: ___________________________

Applicable Conversion Price:____________________________________________

Number of shares of Preferred Stock subsequent to Conversion: ________________

Address for Delivery: ______________________

or

DWAC Instructions:

Broker no: _________

Account no: ___________

[HOLDER]

By:___________________________________

Name:

Title:






DERMTECH, INC.

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES B-1 CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 151 OF THE

DELAWARE GENERAL CORPORATION LAW

The undersigned, John Dobak and Kevin Sun, do hereby certify that:

1.They are the President and Secretary, respectively, of DermTech, Inc., a Delaware corporation (the “Corporation”).

2.The Corporation is authorized to issue 5,000,000 shares of preferred stock, 1,230.77 of which are issued and outstanding.

3.The following resolutions were duly adopted by the board of directors of the Corporation (the “Board of Directors”):

WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 5,000,000 shares, $0.0001 par value per share, issuable from time to time in one or more series;

WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them; and

WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a new series of the preferred stock, which shall consist of up to 3,200 shares of the preferred stock which the Corporation has the authority to issue, as follows:

NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a new series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows:






TERMS OF PREFERRED STOCK

Section 1.    Definitions. For the purposes hereof, the following terms shall have the following meanings:

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.

Alternate Consideration” shall have the meaning set forth in Section 7(d).

Automatic Conversion” shall have the meaning set forth in Section 6(c).

Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

Commission” means the United States Securities and Exchange Commission.

Common Stock” means the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.

Common Stock Equivalents” means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

Conversion Price” shall have the meaning set forth in Section 6(b).

Conversion Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance with the terms hereof.

Effective Date” means the date that the Registration Statement filed by the Corporation pursuant to the Registration Rights Agreement is first declared effective by the Commission.

Fundamental Transaction” shall have the meaning set forth in Section 7(d).

Holder” shall have the meaning given such term in Section 2.

Liquidation” shall have the meaning set forth in Section 5.

Original Issuance Date” means the date of the “Closing” as defined in the Securities Purchase Agreement.

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

Preferred Stock” shall have the meaning set forth in Section 2.

Registration Rights Agreement” means that certain Registration Rights Agreement entered into on or about March 4, 2020, by and among the Corporation and the signatories thereto, as amended, modified or supplemented from time to time in accordance with its terms.




Registration Statement” means a registration statement that registers the resale of the Conversion Shares of the Holders, who shall be named as “selling stockholders” therein and meets the requirements of the Registration Rights Agreement.

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Securities Purchase Agreement” means that certain Securities Purchase Agreement entered into on or about February 28, 2020, by and among the Corporation and the purchasers thereto, as amended, modified or supplemented from time to time in accordance with its terms.

Stated Value” shall have the meaning set forth in Section 2.

Stockholder Approval” means such approval as is required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity), including Nasdaq Listing Standard Rule 5635(d), from the stockholders of the Corporation with respect to the transactions contemplated by the Transaction Documents, including the approval of the issuance of all of the Conversion Shares in excess of 19.99% of the issued and outstanding Common Stock on the execution date of the Securities Purchase Agreement.

Subsidiary” means any direct or indirect subsidiary of the Corporation formed or acquired before or after the date of the Securities

Purchase Agreement.

Successor Entity” shall have the meaning set forth in Section 7(d).

Trading Day” means a day on which the principal Trading Market is open for business.

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, an OTC market place or the OTCMarkets (or any successors to any of the foregoing).

Transaction Documents” means the Securities Purchase Agreement, the Registration Rights Agreement, this Certificate of Designation and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

Transfer Agent” means Continental Stock Transfer & Trust Company, the current transfer agent for the Common Stock, and any successor transfer agent of the Corporation.

Section 2. Designation, Amount and Par Value. The series of preferred stock of the Corporation shall be designated as the Series B-1 Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 3,200 (which shall not be subject to increase without the written consent of the holders (each, a “Holder” and collectively, the “Holders”) of a majority of the then outstanding shares of Preferred Stock). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10,500.00 (the “Stated Value”).

Section 3. Dividends. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Preferred Stock; and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.

Section 4. Voting Rights. Except as otherwise provided herein or as otherwise required by the Delaware General Corporation Law, the Preferred Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a






majority of the then outstanding shares of Preferred Stock, (a) (i) alter or change adversely the powers, preferences or rights given to the Preferred Stock,

(ii)alter or amend this Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, the certificate of incorporation or bylaws of the Corporation, or file any certificate of amendment or certificate of designations of preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the powers, preferences or rights of the Preferred Stock in a manner materially different than the effect of such actions on the Common Stock (regardless, in the case of clause (i), (ii) or (iii), of whether any of the foregoing actions shall be by means of amendment to the certificate of incorporation of the Corporation or by merger, consolidation or otherwise), (b) issue further shares of Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Preferred Stock or (c) enter into any agreement with respect to any of the foregoing.

Section 5. Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Corporation and the payment of any liquidation preference owed to the holders of shares of capital stock of the Corporation ranking senior to the Preferred Stock upon liquidation, the Holders of the Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis without regard to any limitation in Section 6 on the conversion of this Preferred Stock) in the net assets of the Corporation. The Corporation shall mail written notice of any such Liquidation to each Holder.

Section 6.    Conversion.

a)No Optional Conversion. The Preferred Stock shall only be convertible upon receipt of Stockholder Approval and pursuant to an Automatic Conversion (as defined below). The Preferred Stock shall not be convertible at the option of the Holder. Shares of Preferred Stock converted into Common Stock in accordance with the terms hereof shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B1 Convertible Preferred Stock.

b)Conversion Price. The conversion price for the Preferred Stock shall equal $10.50, subject to adjustment herein (the

Conversion Price”).

c)Automatic Conversion. Notwithstanding anything herein to the contrary, on the first Trading Day after the Corporation obtains Stockholder Approval, all outstanding shares of Preferred Stock shall automatically be converted into such number of shares of Common Stock as determined by dividing the Stated Value by the Conversion Price then in effect (the “Automatic Conversion”). Upon the occurrence of such Automatic Conversion, the Holder shall promptly surrender any certificates representing such shares at the office of the Corporation or the Transfer Agent. On the date such Automatic Conversion takes place, the outstanding shares of Preferred Stock shall be converted automatically without any further action by the Holder and whether or not any certificates representing such shares are surrendered to the Corporation or the Transfer Agent; provided, however, that in the case of converting shares of Preferred Stock then held in certificated form, the Corporation shall not be obligated to issue certificates evidencing the applicable Conversion Shares unless either (i) the certificates evidencing such shares of Preferred Stock are delivered to the Corporation or the Transfer Agent or (ii) the Holder notifies the Corporation or the Transfer Agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates. On the date of such Automatic Conversion, each Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, notwithstanding that any certificates representing such shares of Preferred Stock shall not have been surrendered at the office of the Corporation or that any such certificates evidencing such Conversion Shares shall not then be actually delivered to such Holder. Provided the Transfer Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program (and subject to Section 6(e)(i)), the Holder may provide written notice to the Corporation that the applicable Conversion Shares be credited to the account of the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC Delivery”).

d)Conversion and Issuance Limitations. Until the Corporation has obtained Stockholder Approval, (i) the Preferred Stock shall not be convertible and (ii) the Corporation may not issue any Conversion Shares.




e)Mechanics of Automatic Conversion

i.Delivery of Book-Entry Statement Upon Automatic Conversion. Not later than three (3) Trading Days after the date of the Automatic Conversion, the Corporation shall (A) deliver, or cause to be delivered, to the converting Holder a book-entry statement evidencing the number of Conversion Shares being acquired upon the Automatic Conversion (or, subject to Section 6(c), a stock certificate representing such Conversion Shares upon request of the Holder), which, on or after the earlier of (i) the Effective Date or (ii) the twelve-month anniversary of the Original Issuance Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Securities Purchase Agreement or applicable law) or (B) in the case of an election for DWAC Delivery (which shall be available if, and only if, on the date of the Automatic Conversion neither restrictive legends nor trading restrictions are then required by the Securities Purchase Agreement or applicable law), electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with DTC through its DWAC system.

ii.Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock and payment of dividends on the Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions set forth in the Securities Purchase Agreement) be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Registration Statement is then effective under the Securities Act, shall be registered for public resale in accordance with such Registration Statement (subject to such Holder’s compliance with its obligations under the Registration Rights Agreement).

iii.Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share.

iv.Transfer Taxes and Expenses. The issuance of certificates for shares of the Common Stock on conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.

Section 7.    Certain Adjustments.

a)Stock Dividends and Stock Splits. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record




date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b)Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder’s Preferred Stock (without regard to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.

c)Pro Rata Distributions. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution.

d)Fundamental Transaction. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 6 on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6 on the conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in






such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’ right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the holder of this Preferred Stock, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction Documents referring to the “Corporation” shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein.

e)Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.

Section 8.    Miscellaneous.

a)Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder shall be in writing and delivered personally or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 11099 N. Torrey Pines Road #100, La Jolla, CA 92037 Attention: John Dobak, or such other address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by email, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address, facsimile number or address of such Holder appearing on the books of the Corporation, or if no such email address, facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Securities Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email to the email address set forth in this Section, (ii) the date of transmission, if such notice or communication is delivered via facsimile to the facsimile number set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (iii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile to the facsimile number set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iv) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (v) upon actual receipt by the party to whom such notice is required to be given.

b)Book-Entry; Certificates. The Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder’s shares of Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder’s shares of Preferred Stock. To the extent that any shares of Preferred Stock are issued in book-entry form, references herein to “certificates” shall instead refer to the book-entry notation relating to such shares.




c)Lost or Mutilated Preferred Stock Certificate. If a Holder’s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.

d)Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in Court of Chancery of the State of Delaware. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such Delaware Chancery Courts, or such Delaware Chancery Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

e)Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.

f)Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.

g)Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.

h)Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.

i)Status of Converted or Redeemed Preferred Stock. Shares of Preferred Stock may only be issued pursuant to the Securities Purchase Agreement. If any shares of Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B-1 Convertible Preferred Stock.




j)Redemption. The Preferred Stock is not redeemable.

Section 9. Fractional Shares. Preferred Stock may be issued in fractions of a share that shall entitle the holder, in proportion to such holder’s fractional shares, to receive dividends, participate in distributions and to have the benefit of all other rights of holders of Preferred Stock.

*********************




RESOLVED, FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock in accordance with the foregoing resolution and the provisions of Delaware law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate of Designation this 2nd day of March, 2020.

/s/ John Dobak/s/ Kevin Sun
Name: John DobakName: Kevin Sun
Title: PresidentTitle: Secretary




DERMTECH, INC.

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES B-2 CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 151 OF THE

DELAWARE GENERAL CORPORATION LAW

The undersigned, John Dobak and Kevin Sun, do hereby certify that:

1.They are the President and Secretary, respectively, of DermTech, Inc., a Delaware corporation (the “Corporation”).

2.The Corporation is authorized to issue 5,000,000 shares of preferred stock, 1,230.77 of which are issued and outstanding.

3.The following resolutions were duly adopted by the board of directors of the Corporation (the “Board of Directors”):

WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 5,000,000 shares, $0.0001 par value per share, issuable from time to time in one or more series;

WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them; and

WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to a new series of the preferred stock, which shall consist of up to 525 shares of the preferred stock which the Corporation has the authority to issue, as follows:

NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a new series of preferred stock for cash or exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows:






TERMS OF PREFERRED STOCK

Section 1.    Definitions. For the purposes hereof, the following terms shall have the following meanings:

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.

Alternate Consideration” shall have the meaning set forth in Section 7(d).

Beneficial Ownership Limitation” shall have the meaning set forth in Section 6(e).

Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

Commission” means the United States Securities and Exchange Commission.

Common Stock” means the Corporation’s common stock, par value $0.0001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.

Common Stock Equivalents” means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

Conversion Date” shall have the meaning set forth in Section 6(a).

Conversion Price” shall have the meaning set forth in Section 6(b).

Conversion Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance with the terms hereof.

Effective Date” means the date that the Registration Statement filed by the Corporation pursuant to the Registration Rights Agreement is first declared effective by the Commission.

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

Fundamental Transaction” shall have the meaning set forth in Section 7(d).

Holder” shall have the meaning given such term in Section 2.

Liquidation” shall have the meaning set forth in Section 5.

Notice of Conversion” shall have the meaning set forth in Section 6(a).

Original Issuance Date” means the date of the “Closing” as defined in the Securities Purchase Agreement.

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

Preferred Stock” shall have the meaning set forth in Section 2.




Registration Rights Agreement” means that certain Registration Rights Agreement entered into on or about March 4, 2020, by and among the Corporation and the signatories thereto, as amended, modified or supplemented from time to time in accordance with its terms.

Registration Statement” means a registration statement that registers the resale of the Conversion Shares of the Holders, who shall be named as “selling stockholders” therein and meets the requirements of the Registration Rights Agreement.

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Securities Purchase Agreement” means that certain Securities Purchase Agreement entered into on or about February 28, 2020, by and among the Corporation and the purchasers thereto, as amended, modified or supplemented from time to time in accordance with its terms.

Share Delivery Date” shall have the meaning set forth in Section 6(d).

Stated Value” shall have the meaning set forth in Section 2.

Stockholder Approval” means such approval as is required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity), including Nasdaq Listing Standard Rule 5635(d), from the stockholders of the Corporation with respect to the transactions contemplated by the Transaction Documents, including the approval of the issuance of all of the Conversion Shares in excess of 19.99% of the issued and outstanding Common Stock on the execution date of the Securities Purchase Agreement.

Subsidiary” means any direct or indirect subsidiary of the Corporation formed or acquired before or after the date of the Securities

Purchase Agreement.

Successor Entity” shall have the meaning set forth in Section 7(d).

Trading Day” means a day on which the principal Trading Market is open for business.

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, an OTC market place or the OTCMarkets (or any successors to any of the foregoing).

Transaction Documents” means the Securities Purchase Agreement, the Registration Rights Agreement, this Certificate of Designation and all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

Transfer Agent” means Continental Stock Transfer & Trust Company, the current transfer agent for the Common Stock, and any successor transfer agent of the Corporation.

Section 2. Designation, Amount and Par Value. The series of preferred stock of the Corporation shall be designated as the Series B-2 Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 525 (which shall not be subject to increase without the written consent of the holders (each, a “Holder” and collectively, the “Holders”) of a majority of the then outstanding shares of Preferred Stock). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10,500.00 (the “Stated Value”).


Section 3.    Dividends.

Subject to the limitations set forth in Section 7(c), Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock basis)




to and in the same form as dividends (other than dividends in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Preferred Stock; and the Corporation shall pay no dividends (other than dividends in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.

Section 4. Voting Rights. Except as otherwise provided herein or as otherwise required by the Delaware General Corporation Law, the Preferred Stock shall have no voting rights. However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of Preferred Stock, (a) (i) alter or change adversely the powers, preferences or rights given to the Preferred Stock, (ii) alter or amend this Certificate of Designation, subject to the restriction on amending the Beneficial Ownership Limitation set forth in Section 6(e), or (iii) amend or repeal any provision of, or add any provision to, the certificate of incorporation or bylaws of the Corporation, or file any certificate of amendment or certificate of designations of preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the powers, preferences or rights of the Preferred Stock in a manner materially different than the effect of such actions on the Common Stock (regardless, in the case of clause (i), (ii) or (iii), of whether any of the foregoing actions shall be by means of amendment to the certificate of incorporation of the Corporation or by merger, consolidation or otherwise), (b) issue further shares of Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Preferred Stock or (c) enter into any agreement with respect to any of the foregoing.

Section 5. Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Corporation and the payment of any liquidation preference owed to the holders of shares of capital stock of the Corporation ranking senior to the Preferred Stock upon liquidation, the Holders of the Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis without regard to any limitation in Section 6 on the conversion of this Preferred Stock) in the net assets of the Corporation. The Corporation shall mail written notice of any such Liquidation to each Holder.

Section 6.    Conversion.

a)Conversions at Option of Holder. The Preferred Stock shall only be convertible on or following the first Trading Day after the Corporation obtains Stockholder Approval. On or following the first Trading Day after the Corporation obtains Stockholder Approval, the Preferred Stock shall be convertible at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(e)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A (a “Notice of Conversion”). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by electronic mail (with receipt confirmed) or by facsimile such Notice of Conversion to the Corporation (such date, the “Conversion Date”). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. Provided the Transfer Agent is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program (and subject to Section 6(d)(i)), the Notice of Conversion may specify, at the Holder’s election, whether the applicable Conversion Shares shall be credited to the account of the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC Delivery”). To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender any certificates representing the shares of Preferred Stock to the Corporation unless all of the shares of Preferred Stock represented thereby are so converted (a “Full Conversion”), in which case such Holder shall deliver to the Corporation any such certificates representing such shares of Preferred Stock promptly following the Conversion Date at issue. In the event of a Full Conversion, if the converting shares of Preferred Stock are then held in certificated form, the Corporation shall not be obligated to issue certificates evidencing the applicable Conversion Shares unless either (i) the certificates evidencing such shares of






Preferred Stock are delivered to the Corporation or the Transfer Agent or (ii) the Holder notifies the Corporation or the Transfer Agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates. Shares of Preferred Stock converted into Common Stock in accordance with the terms hereof shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B2 Convertible Preferred Stock.

b)    Conversion Price. The conversion price for the Preferred Stock shall equal $10.50, subject to adjustment herein (the

Conversion Price”).

c)Conversion and Issuance Limitations. Notwithstanding any other terms set forth herein, until the Corporation has obtained Stockholder Approval, (i) the Preferred Stock shall not be convertible and (ii) the Corporation may not issue any Conversion Shares.

d)Mechanics of Conversion

i.Delivery of Book-Entry Statement Upon Conversion. Not later than three (3) Trading Days after each Conversion Date (the “Share Delivery Date”), the Corporation shall (A) deliver, or cause to be delivered, to the converting Holder a book-entry statement evidencing the number of Conversion Shares being acquired upon the conversion of shares of Preferred Stock (or, subject to Section 6(a), a stock certificate representing such Conversion Shares upon request of the Holder), which, on or after the earlier of (i) the Effective Date or (ii) the twelve-month anniversary of the Original Issuance Date, shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Securities Purchase Agreement or applicable law) or (B) in the case of an election for DWAC Delivery (which shall be available if, and only if, on the applicable Conversion Date neither restrictive legends nor trading restrictions are then required by the Securities Purchase Agreement or applicable law), electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such book-entry statement (or stock certificate, if applicable) is not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its electronic receipt of such book-entry statement (or stock certificate, if applicable) for Conversion Shares, in which event the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Preferred Stock unsuccessfully tendered for conversion to the Corporation.

ii.Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock and payment of dividends on the Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder (and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions set forth in the Securities Purchase Agreement) be issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding shares of Preferred Stock and payment of dividends hereunder. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and nonassessable and, if the Registration Statement is then effective under the Securities Act, shall be registered for public resale in accordance with such Registration Statement (subject to such Holder’s compliance with its obligations under the Registration Rights Agreement).

iii.Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the next whole share.




iv.Transfer Taxes and Expenses. The issuance of certificates for shares of the Common Stock on conversion of this Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion.

e)Beneficial Ownership Limitation. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice of Conversion, such Holder (together with such Holder’s Affiliates, and any Persons acting as a group together with such Holder or any of such Holder’s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of the Preferred Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein (including, without limitation, the Preferred Stock) beneficially owned by such Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 6(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(e) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates) and of how many shares of Preferred Stock are convertible shall be in the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder’s determination of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 6(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation’s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Corporation shall within two Trading Days confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall initially be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Stock held by the applicable Holder. Notwithstanding the foregoing, by written notice to the Corporation, which will not be effective until the sixty-first (61st) day after such notice is delivered to the Corporation, the Holder may reset the Beneficial Ownership Limitation percentage to a higher or lower percentage; provided that such notice shall not be required in the event of a Fundamental Transaction (as defined below). Upon such a change by a Holder to the Beneficial Ownership Limitation, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum 61-day notice required by this Section 6(e) (except in the event of a Fundamental Transaction). The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this




paragraph shall apply to a successor holder of Preferred Stock. The determination of whether the conversion of shares of Preferred Stock into Common Stock is permitted under this Section 6(e) shall be made by the record holder of such shares of Preferred Stock in such record holder’s sole discretion, and the submission of a Notice of Conversion shall be conclusively deemed to constitute such record holder’s determination that the conversion of the shares of Preferred Stock identified in such Notice of Conversion is permitted under this Section 6(e).

Section 7.    Certain Adjustments.

a)Stock Dividends and Stock Splits. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b)Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder’s Preferred Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c)Pro Rata Distributions. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).




d)Fundamental Transaction. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 6 on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6 on the conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’ right to convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents in accordance with the provisions of this Section 7(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the holder of this Preferred Stock, deliver to the Holder in exchange for this Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation and the other Transaction Documents referring to the “Corporation” shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Corporation herein.






e)Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.

Section 8.    Miscellaneous.

a)Notices. Any and all notices or other communications or deliveries to be provided by the Holders hereunder, including, without limitation, any Notice of Conversion, shall be in writing and delivered personally or sent by a nationally recognized overnight courier service, addressed to the Corporation, at 11099 N. Torrey Pines Road #100, La Jolla, CA 92037 Attention: John Dobak, or such other address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 8. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by email, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the email address, facsimile number or address of such Holder appearing on the books of the Corporation, or if no such email address, facsimile number or address appears on the books of the Corporation, at the principal place of business of such Holder, as set forth in the Securities Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via email to the email address set forth in this Section, (ii) the date of transmission, if such notice or communication is delivered via facsimile to the facsimile number set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (iii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile to the facsimile number set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iv) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (v) upon actual receipt by the party to whom such notice is required to be given.

b)Book-Entry; Certificates. The Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder’s shares of Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder’s shares of Preferred Stock. To the extent that any shares of Preferred Stock are issued in book-entry form, references herein to “certificates” shall instead refer to the book-entry notation relating to such shares.

c)Lost or Mutilated Preferred Stock Certificate. If a Holder’s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.

d)Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in Court of Chancery of the State of Delaware. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such Delaware Chancery Courts, or such Delaware Chancery Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably waives, to the fullest




extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

e)Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.

f)Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.

g)Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.

h)Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.

i)Status of Converted or Redeemed Preferred Stock. Shares of Preferred Stock may only be issued pursuant to the Securities Purchase Agreement. If any shares of Preferred Stock shall be converted or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B-2 Convertible Preferred Stock.

j)Redemption. The Preferred Stock is not redeemable.

Section 9. Fractional Shares. Preferred Stock may be issued in fractions of a share that shall entitle the holder, in proportion to such holder’s fractional shares, to receive dividends, participate in distributions and to have the benefit of all other rights of holders of Preferred Stock.

*********************




RESOLVED, FURTHER, that the Chairman, the president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock in accordance with the foregoing resolution and the provisions of Delaware law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate of Designation this 2nd day of March, 2020.

/s/ John Dobak/s/ Kevin Sun
Name: John DobakName: Kevin Sun
Title: PresidentTitle: Secretary




ANNEX A

NOTICE OF CONVERSION

(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED STOCK)

The undersigned hereby elects to convert the number of shares of Series B-2 Convertible Preferred Stock indicated below into shares of common stock, par value $0.0001 per share (the “Common Stock”), of DermTech, Inc., a Delaware corporation (the “Corporation”), according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in accordance with the Securities Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.

Conversion calculations:

Date to Effect Conversion: _____________________________________________

Number of shares of Preferred Stock owned prior to Conversion: _______________

Number of shares of Preferred Stock to be Converted: ________________________

Stated Value of shares of Preferred Stock to be Converted: ____________________

Number of shares of Common Stock to be Issued: ___________________________

Applicable Conversion Price:____________________________________________

Number of shares of Preferred Stock subsequent to Conversion: ________________

Address for Delivery: ______________________

or

DWAC Instructions:

Broker no: _________

Account no: ___________

[HOLDER]

By:___________________________________

Name:

Title:






SECOND CERTIFICATE OF AMENDMENT

OF THE

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

DERMTECH, INC.

DermTech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

1.The name of the Corporation is DermTech, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 27, 2019. The original Certificate of Incorporation was amended and restated and filed with the Secretary of State of the State of Delaware on August 29, 2019 (the “Amended and Restated Certificate of Incorporation”). A Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock was filed with the Secretary of State of the State of Delaware on August 29, 2019. A Certificate of Amendment to the Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 29, 2019. A Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock was filed with the Secretary of State of the State of Delaware on March 2, 2020. A Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock was filed with the Secretary of State of the State of Delaware on March 2, 2020.

2.The Amended and Restated Certificate of Incorporation, as amended, is hereby further amended by deleting in its entirety Article TWELFTH thereof and replacing therewith the following new Article TWELFTH:

“TWELFTH:

A.Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of the Corporation, to the Corporation or the Corporation’s stockholders, (iii) any action or proceeding asserting a claim against the Corporation or any current or former director, officer or other employee of the Corporation, arising out of or pursuant to any provision of the Delaware General Corporation Law or this Certificate of Incorporation or the By-Laws of the Corporation (in each case, as they may be amended from time to time), (iv) any action or proceeding to interpret, apply, enforce or determine the validity of this Certificate of Incorporation or the Bylaws of the Corporation (including any right, obligation, or remedy thereunder), (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi) any action asserting a claim governed by the internal affairs doctrine against the Corporation or any director, officer or other employee of the Corporation, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article TWELFTH shall not apply to actions brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any claim for which the federal courts have exclusive jurisdiction.

B.Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.




Any person or entity holding, owning or otherwise acquiring any interest in any security of the Corporation shall be deemed to have notice of and consented to the provisions of this Article TWELFTH.”

3.The Board of Directors of the Corporation has duly adopted resolutions (i) declaring this Second Certificate of Amendment to be advisable, (ii) adopting and approving this Second Certificate of Amendment, (iii) directing that this Second Certificate of Amendment be submitted to the stockholders of the Corporation for their approval at the 2020 Annual Meeting of the stockholders of the Corporation and (iv) recommending to the stockholders of the Corporation that this Second Certificate of Amendment be approved.

4.This Second Certificate of Amendment was submitted to and duly adopted and approved by the stockholders of the Corporation at the 2020 Annual Meeting of the stockholders of the Corporation in accordance with the provisions of Sections 222 and 242 of the Delaware General Corporation Law.

5.This Second Certificate of Amendment has been duly authorized, adopted and approved by the Corporation’s Board of Directors in accordance with the provisions of Sections 141 and 242 of the Delaware General Corporation Law.

(Signature page follows)






IN WITNESS WHEREOF, DermTech, Inc. has caused this Second Certificate of Amendment to be signed by John Dobak, a duly authorized officer of the Corporation, on May 27, 2020.

DERMTECH, INC.,

a Delaware corporation


By:/s/ John Dobak
Name:John Dobak
Title:Chief Executive Officer






















[Signature Page to Certificate of Amendment]




CERTIFICATE OF ELIMINATION

OF

SERIES A CONVERTIBLE PREFERRED STOCK

OF

DERMTECH, INC.

Pursuant to Section 151(g) of the

General Corporation Law of the State of Delaware

DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows:

1.That, pursuant to Section 151 of the General Corporation Law of the State of Delaware and authority granted in the Amended and Restated Certificate of Incorporation of the Corporation, as theretofore amended (the “Certificate of Incorporation”), the Board of Directors of the Corporation, by resolution duly adopted, authorized the issuance of a series of up to 1,250 shares of Series A Convertible Preferred Stock, par value $0.0001 per share, of the Corporation (the “Series A Convertible Preferred Stock”), and established the voting powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof, and, on August 29, 2019, filed a Certificate of Designation (the “Certificate of Designation”) with respect to such Series A Convertible Preferred Stock in the office of the Secretary of State of the State of Delaware.

2.That no shares of the Series A Convertible Preferred Stock are outstanding and no shares thereof will be issued subject to the Certificate of

Designation.

3.That the Board of Directors of the Corporation has adopted the following resolutions:

RESOLVED: That no shares of the Corporation’s authorized Series A Convertible Preferred Stock, par value $0.0001 per share (the Series A Convertible Preferred Stock”) are outstanding and that no shares of the Series A Convertible Preferred Stock will be issued subject to the Certificate of Designation previously filed on August 29, 2019 with respect to the Series A Convertible Preferred Stock.

RESOLVED: That the proper officers of the Corporation be and hereby are authorized and directed to file a certificate setting forth these resolutions with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware for the purpose of eliminating from the Corporation’s certificate of incorporation all matters set forth in the Certificate of Designation with respect to the Series A Convertible Preferred Stock; and further that upon such filing all authorized shares of Series A Convertible Preferred Stock shall be eliminated and restored to the status of authorized but unissued shares of undesignated preferred stock under the Corporation’s certificate of incorporation.

4.That, accordingly, all matters set forth in the Certificate of Designation with respect to the Series A Convertible Preferred Stock be, and hereby are, eliminated from the Certificate of Incorporation, as heretofore amended, of the Corporation.

[Signature page follows]




IN WITNESS WHEREOF, the undersigned authorized officer of the Corporation has executed this Certificate of Elimination as of September

9, 2020.

DERMTECH, INC.


By:/s/ John Dobak
Name:John Dobak
Title:President




CERTIFICATE OF ELIMINATION

OF

SERIES B-1 CONVERTIBLE PREFERRED STOCK

OF

DERMTECH, INC.

Pursuant to Section 151(g) of the

General Corporation Law of the State of Delaware

DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows:

1.That, pursuant to Section 151 of the General Corporation Law of the State of Delaware and authority granted in the Amended and Restated Certificate of Incorporation of the Corporation, as theretofore amended (the “Certificate of Incorporation”), the Board of Directors of the Corporation, by resolution duly adopted, authorized the issuance of a series of up to 3,200 shares of Series B-1 Convertible Preferred Stock, par value $0.0001 per share, of the Corporation (the “Series B-1 Convertible Preferred Stock”), and established the voting powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof, and, on March 2, 2020, filed a Certificate of Designation (the “Certificate of Designation”) with respect to such Series B-1 Convertible Preferred Stock in the office of the Secretary of State of the State of Delaware.

2.That no shares of the Series B-1 Convertible Preferred Stock are outstanding and no shares thereof will be issued subject to the Certificate of

Designation.

3.That the Board of Directors of the Corporation has adopted the following resolutions:

RESOLVED: That no shares of the Corporation’s authorized Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the Series B-1 Convertible Preferred Stock”) are outstanding and that no shares of the Series B-1 Convertible Preferred Stock will be issued subject to the Certificate of Designation previously filed on March 2, 2020 with respect to the Series B-1 Convertible Preferred Stock.

RESOLVED: That the proper officers of the Corporation be and hereby are authorized and directed to file a certificate setting forth these resolutions with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware for the purpose of eliminating from the Corporation’s certificate of incorporation all matters set forth in the Certificate of Designation with respect to the Series B-1 Convertible Preferred Stock; and further that upon such filing all authorized shares of Series B-1 Convertible Preferred Stock shall be eliminated and restored to the status of authorized but unissued shares of undesignated preferred stock under the Corporation’s certificate of incorporation.

4.That, accordingly, all matters set forth in the Certificate of Designation with respect to the Series B-1 Convertible Preferred Stock be, and hereby are, eliminated from the Certificate of Incorporation, as heretofore amended, of the Corporation.

[Signature page follows]




IN WITNESS WHEREOF, the undersigned authorized officer of the Corporation has executed this Certificate of Elimination as of September

9, 2020.

DERMTECH, INC.


By:/s/ John Dobak
Name:John Dobak
Title:President




CERTIFICATE OF ELIMINATION

OF

SERIES B2 CONVERTIBLE PREFERRED STOCK

OF

DERMTECH, INC.

Pursuant to Section 151(g) of the

General Corporation Law of the State of Delaware

DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows:

1.That, pursuant to Section 151 of the General Corporation Law of the State of Delaware and authority granted in the Amended and Restated Certificate of Incorporation of the Corporation, as theretofore amended (the “Certificate of Incorporation”), the Board of Directors of the Corporation, by resolution duly adopted, authorized the issuance of a series of up to 525 shares of Series B2 Convertible Preferred Stock, par value $0.0001 per share, of the Corporation (the “Series B2 Convertible Preferred Stock”), and established the voting powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof, and, on March 2, 2020, filed a Certificate of Designation (the “Certificate of Designation”) with respect to such Series B2 Convertible Preferred Stock in the office of the Secretary of State of the State of Delaware.

2.That no shares of the Series B2 Convertible Preferred Stock are outstanding and no shares thereof will be issued subject to the Certificate of

Designation.

3.That the Board of Directors of the Corporation has adopted the following resolutions:

RESOLVED: That no shares of the Corporation’s authorized Series B2 Convertible Preferred Stock, par value $0.0001 per share (the Series B2 Convertible Preferred Stock”) are outstanding and that no shares of the Series B2 Convertible Preferred Stock will be issued subject to the Certificate of Designation previously filed on March 2, 2020 with respect to the Series B2 Convertible Preferred Stock.

RESOLVED: That the proper officers of the Corporation be and hereby are authorized and directed to file a certificate setting forth these resolutions with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware for the purpose of eliminating from the Corporation’s certificate of incorporation all matters set forth in the Certificate of Designation with respect to the Series B2 Convertible Preferred Stock; and further that upon such filing all authorized shares of Series B2 Convertible Preferred Stock shall be eliminated and restored to the status of authorized but unissued shares of undesignated preferred stock under the Corporation’s certificate of incorporation.

4.That, accordingly, all matters set forth in the Certificate of Designation with respect to the Series B2 Convertible Preferred Stock be, and hereby are, eliminated from the Certificate of Incorporation, as heretofore amended, of the Corporation.

[Signature page follows]




IN WITNESS WHEREOF, the undersigned authorized officer of the Corporation has executed this Certificate of Elimination as of September

9, 2020.

DERMTECH, INC.


By:/s/ John Dobak
Name:John Dobak
Title:President





THIRD CERTIFICATE OF AMENDMENT
OF THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
DERMTECH, INC.

DermTech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

1.The Amended and Restated Certificate of Incorporation of the Corporation, as amended, is hereby further amended by deleting the first paragraph of Article FOURTH thereof and replacing therewith the following:

“FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 105,000,000 shares, consisting of 100,000,000 shares of Common Stock, $0.0001 par value per share (the “Common Stock”) and 5,000,000 shares of Preferred Stock, $0.0001 par value per share (the “Preferred Stock”).”

2.The Board of Directors of the Corporation has duly adopted resolutions (i) declaring this Third Certificate of Amendment to be advisable, (ii) adopting and approving this Third Certificate of Amendment, (iii) directing that this Third Certificate of Amendment be submitted to the stockholders of the Corporation for their approval at the 2023 Annual Meeting of the stockholders of the Corporation and (iv) recommending to the stockholders of the Corporation that this Third Certificate of Amendment be approved.

3.This Third Certificate of Amendment was submitted to and duly adopted and approved by the stockholders of the Corporation at the 2023 Annual Meeting of the stockholders of the Corporation in accordance with the provisions of Sections 222 and 242 of the Delaware General Corporation Law.

4.This Third Certificate of Amendment has been duly authorized, adopted and approved by the Corporation’s Board of Directors in accordance with the provisions of Sections 141 and 242 of the Delaware General Corporation Law.

IN WITNESS WHEREOF, DermTech, Inc. has caused this Third Certificate of Amendment to be signed by its duly authorized officer of the Corporation, on June 1, 2023.


DERMTECH, INC.
By:/s/ Bret Christensen
Name:Bret Christensen
Title:Chief Executive Officer


EX-31.1 3 dmtk-20230630xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Bret Christensen, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 of DermTech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 3, 2023
By:/s/ Bret Christensen
Bret Christensen
Chief Executive Officer
(principal executive officer)

EX-31.2 4 dmtk-20230630xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kevin Sun, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 of DermTech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 3, 2023
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(principal financial and accounting officer)

EX-32.1 5 dmtk-20230630xex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 of DermTech, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies in his capacity as the specified officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: August 3, 2023
By:/s/ Bret Christensen
Bret Christensen
Chief Executive Officer
(principal executive officer)
Date: August 3, 2023
By:/s/ Kevin Sun
Kevin Sun
Chief Financial Officer
(principal financial and accounting officer)
This certification accompanies the Quarterly Report on Form 10-Q to which it relates and shall not be deemed filed with the Securities and Exchange Commission or incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 6 dmtk-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Balance Sheet Details - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Balance Sheet Details - Continuous Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dmtk-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dmtk-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dmtk-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Change in fair value of warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Statistical Measurement Statistical Measurement [Domain] Estimated market value of remaining debt securities with contractual maturities of up to 23 months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 23 Months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 23 Months Total current assets Assets, Current Restricted Cash Restricted Cash [Member] Restricted Cash. Letters of credit maintained Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Restricted cash Restricted Cash Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Entity Filer Category Entity Filer Category Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Computer equipment Computer Equipment Gross Computer equipment gross. Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Accounts payable Accounts Payable, Current Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Assumed volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Corporate debt securities Corporate Debt Securities [Member] Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Total other income Nonoperating Income (Expense) Accrued consulting services Accrued Consulting Services Current Accrued consulting services, current. Issuance price per share (in usd per share) Shares Issued, Price Per Share Prepaid expenses Prepaid Insurance Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Stockholders' Equity Equity [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Proceeds from issuance of common stock in connection with at-the-market offering, net Proceeds from Issuance of Common Stock Accrued liabilities: Accrued Liabilities, Current [Abstract] Proceeds from contributions to the Employee Stock Purchase Plan Proceeds from Stock Plans Warrant liability Warrant Liability Fair Value Disclosure Warrant liability fair value disclosure. Other accrued expenses Other Accrued Liabilities, Current Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Change in fair value of warrant liability Change in fair value of warrant liability Fair Value Adjustment of Warrants Revenue Recognition Revenue [Policy Text Block] Current liabilities: Liabilities, Current [Abstract] Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Proceeds from exercise of common stock warrants Total proceeds from exercise of public warrants Proceeds from Warrant Exercises Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Net loss per share of common stock outstanding, diluted (in usd per share) Earnings Per Share, Diluted Restricted Stock Restricted Stock [Member] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Customer refund liability Customer Refund Liability, Current Prepaid expenses and other current assets: Prepaid Expense and Other Assets, Current [Abstract] Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Private SPAC Warrants Private Special Purpose Acquisition Companies Warrants [Member] Private special purpose acquisition companies warrants. Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Level 3 Fair Value, Inputs, Level 3 [Member] Accelerated expense Share-Based Payment Arrangement, Accelerated Cost Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Cost of revenues: Cost of Revenue [Abstract] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Document Fiscal Period Focus Document Fiscal Period Focus Accounts Receivable Receivable [Policy Text Block] Antidilutive Securities Antidilutive Securities [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] The Company and Summary of its Significant Accounting Policies [Line Items] The Company And Summary Of Its Significant Accounting Policies [Line Items] The company and summary of its significant accounting policies. Warrants issued to purchase common stock (in shares) Class Of Warrant Or Right, Warrants Or Rights Issued To Purchase Common Stock Class of warrant or rights issued to purchase common stock. Accrued compensation: Employee-related Liabilities, Current [Abstract] Common stock Common stock Common Stock [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Short-term marketable securities Marketable Securities, Current City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Income Statement Location Income Statement Location [Domain] Issuance of common stock from warrant exercises Adjustments to Additional Paid in Capital, Warrant Issued Equity Components Equity Components [Axis] Exercise price of warrant (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments Financial Instruments [Domain] Summary of Changes in Fair Value of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Entity Small Business Entity Small Business Accrued bonus and commissions Accrued Vacation, Current Minimum Minimum [Member] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Forecast Forecast [Member] Letter of Credit Letter of Credit [Member] Unrealized net gain/(loss) on marketable securities and cash equivalents OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Issuance of common stock from option exercises and RSU releases Stock Issued During Period, Value, Stock Options Exercised And RSU Release Stock issued during period value stock options exercised and RSU release. Measurement Frequency Measurement Frequency [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Common Stock Warrants Warrant [Member] Assets Assets [Abstract] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent The Company and a Summary of its Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Total liabilities measured at fair value on a recurring basis Liabilities, Fair Value Disclosure Credit losses Credit Losses Credit Losses Operating lease liabilities Increase (Decrease) in Operating Lease Liability Placement Agent Warrants Placement Agent Warrants [Member] Placement agent warrants. Issuance costs Payments of Stock Issuance Costs Principal repayments of finance lease obligations Repayments of Debt and Lease Obligation Debt Instrument, Name Debt Instrument, Name [Domain] Depreciation Depreciation Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. 2018 Convertible Bridge Notes Two Thousand Eighteen Convertible Bridge Notes [Member] Two thousand eighteen convertible bridge notes. Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Income Statement Location Income Statement Location [Axis] Accumulated deficit Retained Earnings [Member] Additional exercise period of stock options (in months) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Additional Exercise Period Amortization of premiums, net of accretion of discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Other assets Other Assets, Noncurrent Assumed risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net loss per share of common stock outstanding, basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Decrease in issuance costs Increase (Decrease) In Stock Issuance Costs Increase decrease in stock issuance costs. Issuance of common stock from Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Stock option Equity Option [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Percent of workforce being reduced Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Sale of Stock Sale of Stock [Domain] Loss on disposal of equipment Gain (Loss) on Disposition of Assets Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Assumed risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Assumed volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Warrants expiration period Warrants and Rights Outstanding, Term Fair Value by Liability Class Fair Value by Liability Class [Domain] Total number exercised of public warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Schedule of Accrued Compensation and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service Product and Service [Domain] Public SPAC Warrants Public Special Purpose Acquisition Companies Warrants [Member] Public special purpose acquisition companies warrants. Reconciliation of cash, cash equivalents and restricted cash, end of period: Restricted Cash and Cash Equivalents [Abstract] Inventory Increase (Decrease) in Inventories Entity Address, City or Town Entity Address, City or Town Related Party Related Party [Member] Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Restructuring liability Restructuring Reserve Anti-dilutive equity instruments excluded from diluted net loss per share of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Supplemental disclosure of noncash investing and financing activities: Noncash Investing and Financing Items [Abstract] Restructuring charges Restructuring Charges Purchases of property and equipment recorded in accounts payable Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Document Transition Report Document Transition Report General and administrative General and Administrative Expense [Member] Total property and equipment, gross Property, Plant and Equipment, Gross Test revenue DermTech Melanoma Test Test Revenue [Member] Test Revenue Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Adhesive patch kits Contract Revenue Adhesive Patch Kits [Member] Contract revenue, adhesive patch kits. Related Party Transactions Related Party Transactions Disclosure [Text Block] Furniture and fixtures Furniture and Fixtures, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Market Value Total marketable securities, available for sale Debt Securities, Available-for-Sale Property and equipment acquired under finance leases Noncash or Part Noncash Acquisition, Fixed Assets Acquired Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Operating Lease, Liability, Current Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accumulated other comprehensive loss AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Warranty liability Warranty, Rights and Obligations, Fair Value Option [Member] Issuance of common stock from Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Entity Shell Company Entity Shell Company Change in unrealized net gains/(losses) on available-for-sale marketable securities and cash equivalents Change In Unrealized Gain (Loss) On Available For Sale Marketable Securities Change in unrealized gain loss on available-for-sale marketable securities. Assumed risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class Liability Class [Axis] Accounting Pronouncements Issued But Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Schedule of Prepaid Expenses and PP&E Schedule Of Prepaid Expenses And Property And Equipment Table [Table Text Block] Schedule of prepaid expenses and PP&E. Counterparty Name Counterparty Name [Domain] Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Conversion ratio of reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Warrant Liability Warrant Liability [Member] Warrant liability. AFS, Greater than 12 months, Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Gross profit/(loss) Gross Profit Severance costs Severance Costs Additional award verting period (in months) Share-Based Compensation Arrangement by Share-Based Payment Award, Additional Award Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Additional Award Vesting Period Short-term deferred revenue Short term deferred revenue Contract with Customer, Liability, Current Common shares issued upon exercise of warrants (in shares) Common Shares Issued Upon Exercise Of Warrants Common shares issued upon exercise of warrants. Security Exchange Name Security Exchange Name Restructuring Plan [Axis] Restructuring Plan [Axis] Total assets measured at fair value on a recurring basis Assets, Fair Value Disclosure AFS, Total, Gross Unrealized Loss Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Municipal debt securities Municipal Notes [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Weighted average term expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Property and equipment, gross: Property, Plant and Equipment, Gross [Abstract] Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Compensation cost related to non-vested awards not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cash equivalents: Cash Equivalents, at Carrying Value Document Type Document Type Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Related Party, Type [Axis] Related Party, Type [Axis] Entity Address, Address Line One Entity Address, Address Line One Laboratory equipment Machinery and Equipment, Gross Entity Registrant Name Entity Registrant Name Warrant liability Warrants and Rights Outstanding Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Cost of revenue Cost of Sales [Member] Increase (decrease) in revenue Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Document Period End Date Document Period End Date Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Long-term finance lease obligations, less current portion Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Liabilities: Liabilities, Fair Value Disclosure [Abstract] Class of Warrant or Right Class of Warrant or Right [Axis] Project management fees Contract Revenue Project Management Fees [Member] Contract revenue project management fees. Restricted cash Restricted Cash, Noncurrent Total stock-based compensation Share-Based Payment Arrangement, Expense Accounts payable, accrued liabilities and deferred revenue Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Total revenues Revenue from Contract with Customer, Including Assessed Tax Issuance of common stock, net of issuance costs shares (in shares) Stock Issued During Period, Shares, New Issues Leasehold improvements Leasehold Improvements, Gross Title of 12(b) Security Title of 12(b) Security Accrued compensation Total accrued compensation Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Related Party, Type [Domain] Related Party, Type [Domain] Contract revenue Contractual Activities [Member] Contract activities. Number of shares issued for each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Schedule of Revenues Disaggregated by Revenue Source Disaggregation of Revenue [Table Text Block] AFS, Greater than 12 months, Gross Unrealized Loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Issuance of common stock, net of issuance costs shares Issuance of preferred stock, total offering amount Stock Issued During Period, Value, New Issues Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Other current assets Other Assets, Current Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Class of Stock [Line Items] Class of Stock [Line Items] Amendment Flag Amendment Flag Money market Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Tax Identification Number Entity Tax Identification Number Inventory Inventory, Net SPAC Warrants Special Purpose Acquisition Companies Warrants [Member] Special purpose acquisition companies warrants. AFS, Less than 12 months, Gross Unrealized Loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value U.S. government debt securities US Government Agencies Short-Term Debt Securities [Member] Cash paid for interest on finance lease obligations Interest Paid, Excluding Capitalized Interest, Operating Activities Purchases of marketable securities Payments to Acquire Marketable Securities Statistical Measurement Statistical Measurement [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Credit Facility Credit Facility [Domain] Balance Sheet Location Balance Sheet Location [Domain] Financial Instrument Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Accrued salaries and wages Accrued Bonus And Deferred Compensation Current Accrued bonus and deferred compensation, current. Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Sales and marketing Selling and Marketing Expense [Member] Weighted average shares outstanding used in computing net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Accrued liabilities Accrued Liabilities Restructuring Plan Restructuring Plan [Member] Restructuring Plan Accumulated deficit Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income, net Interest Income (Expense), Nonoperating, Net Operating expenses: Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital, Common Stock Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional paid-in capital Additional Paid-in Capital [Member] Current assets: Assets, Current [Abstract] Accounts receivable gross Accounts Receivable, before Allowance for Credit Loss, Current Weighted average purchase price per share (in usd per share) Weighted Average Purchase Price Per Share In Offering Weighted average purchase price per share in offering. Balance Sheet Location Balance Sheet Location [Axis] Commitments and Contingencies Commitments Disclosure [Text Block] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total assets Assets Entity Address, State or Province Entity Address, State or Province Counterparty Name Counterparty Name [Axis] Issuance of common stock from option exercises and RSU releases (in shares) Stock Issued During Period, Shares, Stock Options Exercised And RSU Release Stock issued during period shares stock options exercised and RSU release. Cover [Abstract] Cover [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right Class of Warrant or Right [Domain] Number of revenue streams (in number of streams) Number Of Revenue Streams Number of revenue streams. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Recurring Fair Value, Recurring [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Remaining performance obligation, estimated revenue expected to be recognized Revenue, Remaining Performance Obligation, Amount Accounting Policies The Company And Summary Of Its Significant Accounting Policies [Table] The company and summary of its significant accounting policies. Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Estimated market value of remaining debt securities with contractual maturities of up to 21 months Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 21 Months Estimated market value of remaining debt securities with contractual maturities of up to 21 months. Nature of Operations Nature Of Operations Policy [Policy Text Block] Nature Of Operations Policy Total operating expenses Operating Expenses Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock Sale of Stock [Axis] Equity Component Equity Component [Domain] Marketable securities, available for sale: Investments, Fair Value Disclosure [Abstract] Current portion of finance lease obligations Finance Lease, Liability, Current Net cash provided by/(used in) investing activities Net Cash Provided by (Used in) Investing Activities Debt Instrument Debt Instrument [Axis] Scenario [Axis] Scenario [Axis] Weighted average shares outstanding used in computing net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Estimated market value of debt securities with contractual maturities of less than 12 months Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months Estimated market value of debt securities with contractual maturities of less than 12 months. Loss from operations Operating Income (Loss) Credit Facility Credit Facility [Axis] Total liabilities Liabilities Assumed volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Issuance of common stock from warrant exercises (in shares) Adjustments to Additional Paid in Capital, Warrant Issued, Shares Adjustments to Additional Paid in Capital, Warrant Issued, Shares Test Test [Member] Test Revenues: Revenues [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Total cost of revenues Cost of Revenue AFS, Total, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Number of warrants entitle holder to purchase one share Number Of Warrants Entitle Holder To Purchase One Share Number of warrants entitle holder to purchase one share. Measurement Frequency Measurement Frequency [Domain] RNA extractions Contract Revenue R N A Extractions [Member] Contract revenue, RNA extractions. Statement [Line Items] Statement [Line Items] Cowen and Company LLC Cowen Limited Liability Company [Member] Cowen Limited Liability Company. At-The Market Offering At The Market Offering [Member] At the market offering. Scenario [Domain] Scenario [Domain] Schedule of Short-Term Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Sales and marketing Selling and Marketing Expense Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 33,408,810 and 30,297,408 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued U.S. government debt securities US Government Debt Securities [Member] AFS, Less than 12 months, Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 10 dmtk-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jun. 30, 2023
Jul. 28, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-38118  
Entity Registrant Name DERMTECH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-2870849  
Entity Address, Address Line One 12340 El Camino Real  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92130  
City Area Code 858  
Local Phone Number 450-4222  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol DMTK  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   33,679,086
Entity Central Index Key 0001651944  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 42,790 $ 77,757
Short-term marketable securities 43,406 48,411
Accounts receivable 3,865 4,172
Inventory 1,352 1,757
Prepaid expenses and other current assets 2,329 3,940
Total current assets 93,742 136,037
Property and equipment, net 6,074 6,375
Operating lease right-of-use assets 53,791 56,007
Restricted cash 3,467 3,488
Other assets 0 168
Total assets 157,074 202,075
Current liabilities:    
Accounts payable 2,324 2,419
Accrued compensation 7,387 7,894
Accrued liabilities 3,695 3,464
Short-term deferred revenue 295 109
Current portion of operating lease liabilities 2,246 1,634
Current portion of finance lease obligations 67 116
Total current liabilities 16,014 15,636
Warrant liability 6 5
Long-term finance lease obligations, less current portion 46 53
Operating lease liabilities, long-term 52,931 54,028
Total liabilities 68,997 69,722
Stockholders’ equity:    
Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively; 33,408,810 and 30,297,408 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 3 3
Additional paid-in capital 473,855 456,171
Accumulated other comprehensive loss (101) (774)
Accumulated deficit (385,680) (323,047)
Total stockholders’ equity 88,077 132,353
Total liabilities and stockholders’ equity $ 157,074 $ 202,075
Common stock, shares authorized (in shares) 100,000,000 50,000,000
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value per share (in usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 100,000,000 50,000,000
Common stock, shares issued (in shares) 33,408,810 30,297,408
Common stock, shares outstanding (in shares) 33,408,810 30,297,408
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Total revenues $ 3,980 $ 4,233 $ 7,457 $ 7,951
Cost of revenues:        
Total cost of revenues 3,972 3,273 7,793 6,827
Gross profit/(loss) 8 960 (336) 1,124
Operating expenses:        
Sales and marketing 13,033 15,001 28,450 30,444
Research and development 3,887 6,915 8,296 13,253
General and administrative 15,220 8,878 27,095 17,452
Total operating expenses 32,140 30,794 63,841 61,149
Loss from operations (32,132) (29,834) (64,177) (60,025)
Nonoperating Income (Expense) [Abstract]        
Interest income, net 763 149 1,545 215
Change in fair value of warrant liability 6 105 (1) 122
Total other income 769 254 1,544 337
Net loss $ (31,363) $ (29,580) $ (62,633) $ (59,688)
Weighted average shares outstanding used in computing net loss per share, basic (in shares) 31,791,736 29,964,849 31,177,886 29,904,972
Weighted average shares outstanding used in computing net loss per share, diluted (in shares) 31,791,736 29,964,849 31,177,886 29,904,972
Net loss per share of common stock outstanding, basic (in usd per share) $ (0.99) $ (0.99) $ (2.01) $ (2.00)
Net loss per share of common stock outstanding, diluted (in usd per share) $ (0.99) $ (0.99) $ (2.01) $ (2.00)
Test revenue        
Revenues:        
Total revenues $ 3,565 $ 4,147 $ 6,990 $ 7,665
Cost of revenues:        
Total cost of revenues 3,909 3,236 7,700 6,766
Contract revenue        
Revenues:        
Total revenues 415 86 467 286
Cost of revenues:        
Total cost of revenues $ 63 $ 37 $ 93 $ 61
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (31,363) $ (29,580) $ (62,633) $ (59,688)
Unrealized net gain/(loss) on marketable securities and cash equivalents 188 (171) 673 (741)
Comprehensive loss $ (31,175) $ (29,751) $ (61,960) $ (60,429)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2021   29,772,922      
Beginning balance at Dec. 31, 2021 $ 229,698 $ 3 $ 436,183 $ (124) $ (206,364)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock from option exercises and RSU releases (in shares)   109,275      
Issuance of common stock from option exercises and RSU releases 40   40    
Issuance of common stock from warrant exercises (in shares)   11,101      
Issuance of common stock from warrant exercises 12   12    
Issuance of common stock from Employee Stock Purchase Plan (in shares)   47,339      
Issuance of common stock from Employee Stock Purchase Plan 515   515    
Unrealized net gain/(loss) on marketable securities and cash equivalents (570)     (570)  
Stock-based compensation 3,894   3,894    
Net loss (30,108)       (30,108)
Ending balance (in shares) at Mar. 31, 2022   29,940,637      
Ending balance at Mar. 31, 2022 203,481 $ 3 440,644 (694) (236,472)
Beginning balance (in shares) at Dec. 31, 2021   29,772,922      
Beginning balance at Dec. 31, 2021 229,698 $ 3 436,183 (124) (206,364)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized net gain/(loss) on marketable securities and cash equivalents (741)        
Net loss (59,688)        
Ending balance (in shares) at Jun. 30, 2022   30,038,447      
Ending balance at Jun. 30, 2022 178,577 $ 3 445,491 (865) (266,052)
Beginning balance (in shares) at Dec. 31, 2021   29,772,922      
Beginning balance at Dec. 31, 2021 229,698 $ 3 436,183 (124) (206,364)
Ending balance (in shares) at Dec. 31, 2022   30,297,408      
Ending balance at Dec. 31, 2022 132,353 $ 3 456,171 (774) (323,047)
Beginning balance (in shares) at Mar. 31, 2022   29,940,637      
Beginning balance at Mar. 31, 2022 203,481 $ 3 440,644 (694) (236,472)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock from option exercises and RSU releases (in shares)   88,591      
Issuance of common stock from option exercises and RSU releases 0   0    
Issuance of common stock from warrant exercises (in shares)   9,219      
Issuance of common stock from warrant exercises 10   10    
Unrealized net gain/(loss) on marketable securities and cash equivalents (171)     (171)  
Stock-based compensation 4,837   4,837    
Net loss (29,580)       (29,580)
Ending balance (in shares) at Jun. 30, 2022   30,038,447      
Ending balance at Jun. 30, 2022 178,577 $ 3 445,491 (865) (266,052)
Beginning balance (in shares) at Dec. 31, 2022   30,297,408      
Beginning balance at Dec. 31, 2022 132,353 $ 3 456,171 (774) (323,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs shares (in shares)   107,451      
Issuance of common stock, net of issuance costs shares 270   270    
Issuance of common stock from option exercises and RSU releases (in shares)   510,027      
Issuance of common stock from option exercises and RSU releases 92   92    
Issuance of common stock from Employee Stock Purchase Plan (in shares)   174,025      
Issuance of common stock from Employee Stock Purchase Plan 576   576    
Unrealized net gain/(loss) on marketable securities and cash equivalents 485     485  
Stock-based compensation 4,736   4,736    
Net loss (31,270)       (31,270)
Ending balance (in shares) at Mar. 31, 2023   31,088,911      
Ending balance at Mar. 31, 2023 107,242 $ 3 461,845 (289) (354,317)
Beginning balance (in shares) at Dec. 31, 2022   30,297,408      
Beginning balance at Dec. 31, 2022 132,353 $ 3 456,171 (774) (323,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized net gain/(loss) on marketable securities and cash equivalents 673        
Net loss (62,633)        
Ending balance (in shares) at Jun. 30, 2023   33,408,810      
Ending balance at Jun. 30, 2023 88,077 $ 3 473,855 (101) (385,680)
Beginning balance (in shares) at Mar. 31, 2023   31,088,911      
Beginning balance at Mar. 31, 2023 107,242 $ 3 461,845 (289) (354,317)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs shares (in shares)   1,759,210      
Issuance of common stock, net of issuance costs shares 4,495   4,495    
Issuance of common stock from option exercises and RSU releases (in shares)   560,689      
Issuance of common stock from option exercises and RSU releases 0   0    
Unrealized net gain/(loss) on marketable securities and cash equivalents 188     188  
Stock-based compensation 7,515   7,515    
Net loss (31,363)       (31,363)
Ending balance (in shares) at Jun. 30, 2023   33,408,810      
Ending balance at Jun. 30, 2023 $ 88,077 $ 3 $ 473,855 $ (101) $ (385,680)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Stockholders’ Equity (Parenthetical) - Common stock - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Issuance price per share (in usd per share) $ 2.62 $ 3.68
Issuance costs $ 0.1 $ 0.1
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (62,633) $ (59,688)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 936 766
Change in fair value of warrant liability 1 (122)
Amortization of operating lease right-of-use assets 2,216 1,109
Stock-based compensation 12,251 8,731
Amortization of premiums, net of accretion of discounts on marketable securities (202) 283
Loss on disposal of equipment 13 285
Changes in operating assets and liabilities:    
Accounts receivable 307 (2,115)
Inventory 405 (952)
Prepaid expenses and other current assets 1,779 483
Operating lease liabilities (485) (654)
Accounts payable, accrued liabilities and deferred revenue 690 (53)
Accrued compensation (507) 2,698
Net cash used in operating activities (45,229) (49,229)
Cash flows from investing activities:    
Purchases of marketable securities (25,568) (20,171)
Sales and maturities of marketable securities 31,448 14,139
Purchases of property and equipment (1,016) (1,360)
Net cash provided by/(used in) investing activities 4,864 (7,392)
Cash flows from financing activities:    
Proceeds from issuance of common stock in connection with at-the-market offering, net 4,765 0
Proceeds from exercise of common stock warrants 0 22
Proceeds from exercise of stock options 92 40
Proceeds from contributions to the Employee Stock Purchase Plan 576 515
Principal repayments of finance lease obligations (56) (60)
Net cash provided by financing activities 5,377 517
Net decrease in cash, cash equivalents and restricted cash (34,988) (56,104)
Cash, cash equivalents and restricted cash, beginning of period 81,245 179,907
Cash, cash equivalents and restricted cash, end of period 46,257 123,803
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 42,790 120,333
Restricted cash 3,467 3,470
Total cash, cash equivalents and restricted cash 46,257 123,803
Supplemental cash flow information:    
Cash paid for interest on finance lease obligations 2 7
Supplemental disclosure of noncash investing and financing activities:    
Purchases of property and equipment recorded in accounts payable 78 11
Right-of-use assets obtained in exchange for lease obligations 0 17,059
Property and equipment acquired under finance leases 0 48
Change in unrealized net gains/(losses) on available-for-sale marketable securities and cash equivalents $ 673 $ (741)
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
The Company and a Summary of its Significant Accounting Policies The Company and a Summary of its Significant Accounting Policies
(a)    Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of melanoma and management of skin cancer. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.
The Company has incurred operating losses since inception and has an accumulated deficit of $385.7 million at June 30, 2023. As of June 30, 2023, cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of our business. The Company may be required to further reduce operating expenses, which could have an adverse impact its ability to achieve intended business objectives. The Company's management believes that currently available resources will provide sufficient funds to meet operating plans for at least the next twelve months from the issuance of our unaudited condensed consolidated financial statements. Considering the restructuring activities (Note 5) implemented in June 2023, the Company believes it has enough capital to fund anticipated operating costs for at least the next twelve months. The Company anticipates that it will need to raise additional capital in order to support its planned operations and to continue developing and commercializing genomic tests.
(b)    Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiary. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of June 30, 2023, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
(c)    Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
(d)    Concentration of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk.
(e)    Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and test revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its test and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for test revenue and then for contract revenue.
Test Revenue
The Company generates revenues from its DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the DMT or (ii) the DMT with TERT test, which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote sample collection of ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT and send a collection kit to the patient. The DermTech Connect app and telemedicine service are currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, test results are provided to the clinician indicating whether the sample collected is indicative of melanoma or not.
The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.3 million and $0.7 million in revenue for the three and six months ended June 30, 2023, respectively, and an additional $0.1 million and $8,000 in revenue for the three and six months ended June 30, 2022, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners and RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting. Contract revenue can be highly variable in any period as it is closely linked to the clinical trial progress of the Company’s biopharma customers.
(a) Disaggregation of Revenue
The following table presents the Company’s revenues disaggregated by revenue source during the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Test Revenue
DermTech Melanoma Test$3,565 $4,147 $6,990 $7,665 
Contract Revenue
Adhesive patch kits388 38 424 104 
RNA extractions14 — 16 110 
Project management fees13 48 27 72 
Total revenues$3,980 $4,233 $7,457 $7,951 
(b) Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of June 30, 2023 and December 31, 2022 was $0.3 million and $0.1 million, respectively. As of December 31, 2022, the Company reclassified $1.0 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of June 30, 2023, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was immaterial.
(f)    Accounts Receivable
Test Accounts Receivable
Due to the nature of the Company’s test revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.5 million and $4.1 million of net test accounts receivable as of June 30, 2023 and December 31, 2022, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and, as of June 30, 2023, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.4 million and $0.1 million of contract accounts receivable as of June 30, 2023 and December 31, 2022, respectively.
(g)    Net Loss Per Share
Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the periods presented, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same.
Outstanding anti-dilutive securities not included in diluted net loss per share (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Shares issuable upon exercise of common stock warrants709 714 709 714 
Shares issuable upon exercise of stock options1,921 1,758 1,921 1,758 
Shares issuable upon the release of restricted stock units3,562 2,912 3,562 2,912 
6,192 5,384 6,192 5,384 
(h)    Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Details Balance Sheet Details
Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of June 30, 2023 were as follows (in thousands):
June 30, 2023
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$10,048 $— $(78)$9,970 
U.S. government debt securities33,524 99 (187)33,436 
Total short-term marketable securities, available-for-sale$43,572 $99 $(265)$43,406 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2022 were as follows (in thousands):
December 31, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$13,535 $$(236)$13,301 
Municipal debt securities1,001 — (8)993 
U.S. government debt securities34,675 10 (568)34,117 
Total short-term marketable securities, available-for-sale$49,211 $12 $(812)$48,411 
As of June 30, 2023, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.8 million; the remaining debt securities that the Company held at that date had an estimated market value of $2.6 million and contractual maturities of up to 18 months. As of December 31, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $8.2 million and contractual maturities of up to 23 months.
The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of June 30, 2023 or December 31, 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and six months ended June 30, 2023 and 2022 were not significant.
The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2023 aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
June 30, 2023
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$9,379 $(73)$591 $(5)$9,970 $(78)
U.S. government debt securities16,974 (168)1,964 (19)18,938 (187)
Total short-term marketable securities, available-for-sale$26,353 $(241)$2,555 $(24)$28,908 $(265)
The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
December 31, 2022
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$6,533 $(105)$5,503 $(131)$12,036 $(236)
Municipal securities— — 992 (8)992 (8)
U.S. government debt securities10,907 (196)19,026 (372)29,933 (568)
Total short-term marketable securities, available-for-sale$17,440 $(301)$25,521 $(511)$42,961 $(812)
Prepaid Expenses and Property and Equipment, Net
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Prepaid expenses and other current assets:
Prepaid expenses$1,513 $3,207 
Other current assets816 733 
Total prepaid expenses and other current assets$2,329 $3,940 
Property and equipment, gross:
Laboratory equipment$6,305 $6,250 
Computer equipment853 872 
Furniture and fixtures1,247 913 
Leasehold improvements597 1,344 
Total property and equipment, gross9,002 9,379 
Less accumulated depreciation(2,928)(3,004)
Total property and equipment, net$6,074 $6,375 
Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Accrued compensation:
Accrued bonus and commissions$3,778 $3,257 
Accrued salaries and wages3,609 4,637 
Total accrued compensation$7,387 $7,894 
Accrued liabilities:
Accrued consulting services$309 $894 
Customer refund liability980 980 
Restructuring liability 1,730 — 
Other accrued expenses676 1,590 
Total accrued liabilities$3,695 $3,464 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 (in thousands):
June 30, 2023
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:
Money market$17,577 $— $— $17,577 
U.S. government debt securities— 10,227 — 10,227 
Total cash equivalents17,577 10,227 — 27,804 
Marketable securities, available for sale:
Corporate debt securities— 9,970 — 9,970 
U.S. government debt securities— 33,436 — 33,436 
Total marketable securities, available for sale— 43,406 — 43,406 
Total assets measured at fair value on a recurring basis$17,577 $53,633 $— $71,210 
Liabilities:
Warrant liability$— $— $$
Total liabilities measured at fair value on a recurring basis$— $— $$
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money Market$9,365 $— $— $9,365 
Corporate debt securities— 7,374 — 7,374 
U.S. government debt securities— 18,396 — 18,396 
Total cash equivalents9,365 25,770 — 35,135 
Marketable securities, available for sale:
Corporate debt— 13,301 — 13,301 
Municipal debt securities— 993 — 993 
U.S. government debt securities— 34,117 — 34,117 
Total marketable securities, available for sale— 48,411 — 48,411 
Total assets measured at fair value on a recurring basis$9,365 $74,181 $— $83,546 
Liabilities:
Warrant liability$— $— $$
Total liabilities measured at fair value on a recurring basis$— $— $$

The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date, including the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Assumed risk-free interest rate5.40%2.96%
4.35% - 5.40%
2.37% - 2.96%
Assumed volatility133.99%96.21%
123.28% - 133.99%
92.77% - 96.21%
Expected term1.17 years2.17 years
1.17 - 1.42 years
2.17 - 2.42 years
Expected dividend yield
The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2022$
Change in fair value of warrant liability
Balance as of March 31, 2023$12 
Change in fair value of warrant liability(6)
Balance as of June 30, 2023$
As of June 30, 2023 and December 31, 2022, the Company maintains letters of credit of $3.5 million and $3.5 million, respectively, related to its lease arrangements, secured by cash of June 30, 2023 and money market accounts as of December 31, 2022, in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.
The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
(a)    Common Stock

On June 2, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of Delaware to increase the authorized number of shares of common stock of the Company from 50,000,000 to 100,000,000 shares (the “Amended Certificate”). The Amended Certificate was approved by the Company’s stockholders at the 2023 Annual Meeting.
(b)    At-The-Market Offering
On November 10, 2020, the Company entered into a sales agreement (the “2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. Through December 31, 2021, the Company issued an aggregate of 1,482,343 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $30.05, net of $1.6 million in issuance costs resulting in net proceeds to the Company of approximately $42.9 million. During 2022, the Company did not issue or sell any shares of common stock pursuant to the 2020 Sales Agreement.

During the three months ended June 30, 2023, the Company issued an aggregate of 1,759,210 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.62 resulting in aggregate gross proceeds of approximately $4.6 million, reduced by $0.1 million issuance costs, resulting in net proceeds to the Company of approximately $4.5 million. For the six months ended June 30, 2023, the Company issued an aggregate of 1,866,661 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.68 resulting in aggregate gross proceeds of approximately $5.0 million, reduced by $0.2 million in issuance costs, resulting in net proceeds to the Company of approximately $4.8 million. As of June 30, 2023, $0.5 million is available pursuant to the 2020 Sales Agreement.

On August 8, 2022, the Company entered into a second sales agreement (the “2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the three and six months ended June 30, 2023, the Company did not issue any shares pursuant to the 2022 Sales Agreement.
(c)    Warrants
SPAC Warrants
The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings, which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and, as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated, and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.
The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.
In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 as of June 30, 2023 and December 31, 2022. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of June 30, 2023 and December 31, 2022.
Placement Agent Warrants
In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 4,510 as of June 30, 2023 and December 31, 2022.
(d)    Stock-Based Compensation
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the DermTech, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”), and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Cost of revenue$435 $298 $847 $633 
Sales and marketing1,548 1,067 3,056 2,528 
Research and development676 1,330 1,237 1,825 
General and administrative4,856 2,142 7,111 3,745 
Total stock-based compensation$7,515 $4,837 $12,251 $8,731 

The total compensation cost related to non-vested awards not yet recognized as of June 30, 2023 was $31.2 million, which is expected to be recognized over a weighted average term of 2.43 years.
Departure of Former Chief Executive Officer
Stock-based compensation expense for the three and six months ended June 30, 2023 includes accelerated expense of $2.9 million and $3.0 million, respectively, in connection with the transition agreement dated March 1, 2023, between the Company and its former Chief Executive Officer, John Dobak, M.D. (the "Transition Agreement"). The accelerated expense is included within general and administrative expenses in the condensed consolidated statement of operations.
Dr. Dobak resigned from his position as Chief Executive Officer and member of the board of directors of the Company (the "Board") effective May 8, 2023 and agreed to serve as a consultant to the Company on an as needed basis until January 1, 2024. The terms of the Transition Agreement allow for continuing vesting of Dr. Dobak's equity awards through the end of the consulting period on January 1, 2024. At the termination of the consulting period, consistent with Dr. Dobak's change of control and severance plan, he will immediately receive an additional 10 months vesting of equity awards and the period to exercise his vested stock options will be increased from 90 days to 12 months.
The Company assessed the consulting services under the Transition Agreement as nonsubstantive pursuant to ASC 718, Compensation – Stock Compensation (ASC 718) and recognized all stock-based compensation expense related to Dr. Dobak's equity awards vesting in connection with the Transition Agreement upon his resignation.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Restructuring Plan

On June 26, 2023, the Board approved a restructuring plan (the “Restructuring Plan”) to prioritize growth opportunities for the DMT, streamline operations, suspend pipeline programs, and significantly reduce overall operating expenses. The Restructuring Plan includes a reduction of the Company’s workforce by approximately 15%. The actions associated with the employee restructuring under the Restructuring Plan are expected to be substantially complete in the third quarter of 2023.

The Company incurred approximately $2.1 million in restructuring charges in connection with the Restructuring Plan for the three and six months ended June 30, 2023, which consist of $1.8 million in charges related to severance payments and employee benefits and $0.3 million in charges related to stock-based compensation for the acceleration of share-based awards. Restructuring charges are included in general and administrative expenses in the condensed consolidated statement of operations.

The restructuring liability as of June 30, 2023 is $1.7 million and is included within accrued liabilities in the condensed consolidated balance sheets.
Legal Proceedings
From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
During 2022 and 2023, the Company engaged EVERSANA Life Science Services, LLC and its subsidiary Intouch Group, LLC (collectively, “EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s former Chief Commercial Officer, is an employee of EVERSANA. Mr. Wood's last day of employment as Chief Commercial Officer of the Company was July 3, 2023. The Company incurred $0.4 million and $0.9 million in costs for the three months ended June 30, 2023 and 2022, respectively, and $0.9 million and $1.6 million in costs for the six months ended June 30, 2023 and 2022, respectively. Amounts due to EVERSANA were $0.2 million and $0.3 million as of June 30, 2023 and December 31, 2022, respectively.
There were no other related party transactions identified during the three and six months ended June 30, 2023 and 2022.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Nature of Operations Nature of Operations
On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock.
The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of melanoma and management of skin cancer. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.
The Company has incurred operating losses since inception and has an accumulated deficit of $385.7 million at June 30, 2023. As of June 30, 2023, cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of our business. The Company may be required to further reduce operating expenses, which could have an adverse impact its ability to achieve intended business objectives. The Company's management believes that currently available resources will provide sufficient funds to meet operating plans for at least the next twelve months from the issuance of our unaudited condensed consolidated financial statements. Considering the restructuring activities (Note 5) implemented in June 2023, the Company believes it has enough capital to fund anticipated operating costs for at least the next twelve months. The Company anticipates that it will need to raise additional capital in order to support its planned operations and to continue developing and commercializing genomic tests.
Basis of Presentation Basis of Presentation
The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiary. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included.
The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of June 30, 2023, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.
Concentration of Credit Risk Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk.
Revenue Recognition Revenue Recognition
The Company’s revenue is generated from two revenue streams: contract revenue and test revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company recognizes revenue from its test and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for test revenue and then for contract revenue.
Test Revenue
The Company generates revenues from its DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the DMT or (ii) the DMT with TERT test, which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote sample collection of ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT and send a collection kit to the patient. The DermTech Connect app and telemedicine service are currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, test results are provided to the clinician indicating whether the sample collected is indicative of melanoma or not.
The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.3 million and $0.7 million in revenue for the three and six months ended June 30, 2023, respectively, and an additional $0.1 million and $8,000 in revenue for the three and six months ended June 30, 2022, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.
Contract Revenue
Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners and RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting. Contract revenue can be highly variable in any period as it is closely linked to the clinical trial progress of the Company’s biopharma customers.
Deferred Revenue and Remaining Performance Obligations
The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.
In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.
The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of June 30, 2023 and December 31, 2022 was $0.3 million and $0.1 million, respectively. As of December 31, 2022, the Company reclassified $1.0 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services.
Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year or less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period.
Accounts Receivable Accounts Receivable
Test Accounts Receivable
Due to the nature of the Company’s test revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.5 million and $4.1 million of net test accounts receivable as of June 30, 2023 and December 31, 2022, respectively.
Contract Accounts Receivable
Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and, as of June 30, 2023, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.
Net Loss Per Share Net Loss Per Share Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the periods presented, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same.
Accounting Pronouncements Issued But Not Yet Effective Accounting Pronouncements Issued But Not Yet Effective
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.
The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.
Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations.
The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date, including the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of Revenues Disaggregated by Revenue Source The following table presents the Company’s revenues disaggregated by revenue source during the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Test Revenue
DermTech Melanoma Test$3,565 $4,147 $6,990 $7,665 
Contract Revenue
Adhesive patch kits388 38 424 104 
RNA extractions14 — 16 110 
Project management fees13 48 27 72 
Total revenues$3,980 $4,233 $7,457 $7,951 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Outstanding anti-dilutive securities not included in diluted net loss per share (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Shares issuable upon exercise of common stock warrants709 714 709 714 
Shares issuable upon exercise of stock options1,921 1,758 1,921 1,758 
Shares issuable upon the release of restricted stock units3,562 2,912 3,562 2,912 
6,192 5,384 6,192 5,384 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details (Tables)
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Short-Term Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of June 30, 2023 were as follows (in thousands):
June 30, 2023
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$10,048 $— $(78)$9,970 
U.S. government debt securities33,524 99 (187)33,436 
Total short-term marketable securities, available-for-sale$43,572 $99 $(265)$43,406 
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2022 were as follows (in thousands):
December 31, 2022
Amortized CostGross Unrealized
Gains
Gross Unrealized
Losses
Estimated
Market
Value
Short-term marketable securities, available-for-sale:
Corporate debt securities$13,535 $$(236)$13,301 
Municipal debt securities1,001 — (8)993 
U.S. government debt securities34,675 10 (568)34,117 
Total short-term marketable securities, available-for-sale$49,211 $12 $(812)$48,411 
The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2023 aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
June 30, 2023
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$9,379 $(73)$591 $(5)$9,970 $(78)
U.S. government debt securities16,974 (168)1,964 (19)18,938 (187)
Total short-term marketable securities, available-for-sale$26,353 $(241)$2,555 $(24)$28,908 $(265)
The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):
December 31, 2022
Less Than 12 Months12 Months or GreaterTotal
Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair ValueGross Unrealized Loss
Short-term marketable securities, available-for-sale:
Corporate debt securities$6,533 $(105)$5,503 $(131)$12,036 $(236)
Municipal securities— — 992 (8)992 (8)
U.S. government debt securities10,907 (196)19,026 (372)29,933 (568)
Total short-term marketable securities, available-for-sale$17,440 $(301)$25,521 $(511)$42,961 $(812)
Schedule of Prepaid Expenses and PP&E
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Prepaid expenses and other current assets:
Prepaid expenses$1,513 $3,207 
Other current assets816 733 
Total prepaid expenses and other current assets$2,329 $3,940 
Property and equipment, gross:
Laboratory equipment$6,305 $6,250 
Computer equipment853 872 
Furniture and fixtures1,247 913 
Leasehold improvements597 1,344 
Total property and equipment, gross9,002 9,379 
Less accumulated depreciation(2,928)(3,004)
Total property and equipment, net$6,074 $6,375 
Schedule of Accrued Compensation and Accrued Liabilities
Condensed consolidated balance sheet details are as follows (in thousands):
June 30,
2023
December 31,
2022
Accrued compensation:
Accrued bonus and commissions$3,778 $3,257 
Accrued salaries and wages3,609 4,637 
Total accrued compensation$7,387 $7,894 
Accrued liabilities:
Accrued consulting services$309 $894 
Customer refund liability980 980 
Restructuring liability 1,730 — 
Other accrued expenses676 1,590 
Total accrued liabilities$3,695 $3,464 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 (in thousands):
June 30, 2023
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:
Money market$17,577 $— $— $17,577 
U.S. government debt securities— 10,227 — 10,227 
Total cash equivalents17,577 10,227 — 27,804 
Marketable securities, available for sale:
Corporate debt securities— 9,970 — 9,970 
U.S. government debt securities— 33,436 — 33,436 
Total marketable securities, available for sale— 43,406 — 43,406 
Total assets measured at fair value on a recurring basis$17,577 $53,633 $— $71,210 
Liabilities:
Warrant liability$— $— $$
Total liabilities measured at fair value on a recurring basis$— $— $$
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money Market$9,365 $— $— $9,365 
Corporate debt securities— 7,374 — 7,374 
U.S. government debt securities— 18,396 — 18,396 
Total cash equivalents9,365 25,770 — 35,135 
Marketable securities, available for sale:
Corporate debt— 13,301 — 13,301 
Municipal debt securities— 993 — 993 
U.S. government debt securities— 34,117 — 34,117 
Total marketable securities, available for sale— 48,411 — 48,411 
Total assets measured at fair value on a recurring basis$9,365 $74,181 $— $83,546 
Liabilities:
Warrant liability$— $— $$
Total liabilities measured at fair value on a recurring basis$— $— $$
Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model
The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Assumed risk-free interest rate5.40%2.96%
4.35% - 5.40%
2.37% - 2.96%
Assumed volatility133.99%96.21%
123.28% - 133.99%
92.77% - 96.21%
Expected term1.17 years2.17 years
1.17 - 1.42 years
2.17 - 2.42 years
Expected dividend yield
Summary of Changes in Fair Value of Level 3 Liabilities
The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):
Balance as of December 31, 2022$
Change in fair value of warrant liability
Balance as of March 31, 2023$12 
Change in fair value of warrant liability(6)
Balance as of June 30, 2023$
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award
Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the DermTech, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”), and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Cost of revenue$435 $298 $847 $633 
Sales and marketing1,548 1,067 3,056 2,528 
Research and development676 1,330 1,237 1,825 
General and administrative4,856 2,142 7,111 3,745 
Total stock-based compensation$7,515 $4,837 $12,251 $8,731 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)
3 Months Ended 6 Months Ended
Aug. 29, 2019
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
revenueStream
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
The Company and Summary of its Significant Accounting Policies [Line Items]            
Retained earnings (accumulated deficit)   $ (385,680,000)   $ (385,680,000)   $ (323,047,000)
Cash and cash equivalents   42,790,000 $ 120,333,000 42,790,000 $ 120,333,000 77,757,000
Short-term marketable securities   43,406,000   $ 43,406,000   48,411,000
Conversion ratio of reverse stock split 0.5          
Number of revenue streams (in number of streams) | revenueStream       2    
Increase (decrease) in revenue   (300,000) $ 100,000 $ (700,000) $ 8,000  
Short term deferred revenue   295,000   295,000   109,000
Accrued liabilities           1,000,000
Remaining performance obligation, estimated revenue expected to be recognized   0   0    
Accounts receivable   3,865,000   3,865,000   4,172,000
Contract revenue            
The Company and Summary of its Significant Accounting Policies [Line Items]            
Accounts receivable   400,000   400,000   100,000
Test            
The Company and Summary of its Significant Accounting Policies [Line Items]            
Accounts receivable gross   $ 3,500,000   $ 3,500,000   $ 4,100,000
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation Of Revenue [Line Items]        
Total revenues $ 3,980 $ 4,233 $ 7,457 $ 7,951
DermTech Melanoma Test        
Disaggregation Of Revenue [Line Items]        
Total revenues 3,565 4,147 6,990 7,665
Adhesive patch kits        
Disaggregation Of Revenue [Line Items]        
Total revenues 388 38 424 104
RNA extractions        
Disaggregation Of Revenue [Line Items]        
Total revenues 14 0 16 110
Project management fees        
Disaggregation Of Revenue [Line Items]        
Total revenues $ 13 $ 48 $ 27 $ 72
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock 6,192 5,384 6,192 5,384
Common Stock Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock 709 714 709 714
Stock option        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock 1,921 1,758 1,921 1,758
Restricted Stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive equity instruments excluded from diluted net loss per share of common stock 3,562 2,912 3,562 2,912
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 43,572 $ 49,211
Gross Unrealized Gains 99 12
Gross Unrealized Losses (265) (812)
Estimated Market Value 43,406 48,411
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 10,048 13,535
Gross Unrealized Gains 0 2
Gross Unrealized Losses (78) (236)
Estimated Market Value 9,970 13,301
Municipal debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost   1,001
Gross Unrealized Gains   0
Gross Unrealized Losses   (8)
Estimated Market Value   993
U.S. government debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 33,524 34,675
Gross Unrealized Gains 99 10
Gross Unrealized Losses (187) (568)
Estimated Market Value $ 33,436 $ 34,117
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details - Additional Information (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Estimated market value of debt securities with contractual maturities of less than 12 months $ 40,800,000 $ 40,200,000
Estimated market value of remaining debt securities with contractual maturities of up to 21 months 2,600,000  
Estimated market value of remaining debt securities with contractual maturities of up to 23 months   8,200,000
Credit losses $ 0 $ 0
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details - Continuous Loss Position (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]    
AFS, Less than 12 months, Fair Value $ 26,353 $ 17,440
AFS, Less than 12 months, Gross Unrealized Loss (241) (301)
AFS, Greater than 12 months, Fair Value 2,555 25,521
AFS, Greater than 12 months, Gross Unrealized Loss (24) (511)
AFS, Total, Fair Value 28,908 42,961
AFS, Total, Gross Unrealized Loss (265) (812)
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
AFS, Less than 12 months, Fair Value 9,379 6,533
AFS, Less than 12 months, Gross Unrealized Loss (73) (105)
AFS, Greater than 12 months, Fair Value 591 5,503
AFS, Greater than 12 months, Gross Unrealized Loss (5) (131)
AFS, Total, Fair Value 9,970 12,036
AFS, Total, Gross Unrealized Loss (78) (236)
Municipal debt securities    
Debt Securities, Available-for-Sale [Line Items]    
AFS, Less than 12 months, Fair Value   0
AFS, Less than 12 months, Gross Unrealized Loss   0
AFS, Greater than 12 months, Fair Value   992
AFS, Greater than 12 months, Gross Unrealized Loss   (8)
AFS, Total, Fair Value   992
AFS, Total, Gross Unrealized Loss   (8)
U.S. government debt securities    
Debt Securities, Available-for-Sale [Line Items]    
AFS, Less than 12 months, Fair Value 16,974 10,907
AFS, Less than 12 months, Gross Unrealized Loss (168) (196)
AFS, Greater than 12 months, Fair Value 1,964 19,026
AFS, Greater than 12 months, Gross Unrealized Loss (19) (372)
AFS, Total, Fair Value 18,938 29,933
AFS, Total, Gross Unrealized Loss $ (187) $ (568)
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Prepaid expenses and other current assets:    
Prepaid expenses $ 1,513 $ 3,207
Other current assets 816 733
Total prepaid expenses and other current assets 2,329 3,940
Property and equipment, gross:    
Laboratory equipment 6,305 6,250
Computer equipment 853 872
Furniture and fixtures 1,247 913
Leasehold improvements 597 1,344
Total property and equipment, gross 9,002 9,379
Less accumulated depreciation (2,928) (3,004)
Total property and equipment, net $ 6,074 $ 6,375
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accrued compensation:    
Accrued bonus and commissions $ 3,778 $ 3,257
Accrued salaries and wages 3,609 4,637
Total accrued compensation 7,387 7,894
Accrued liabilities:    
Accrued consulting services 309 894
Customer refund liability 980 980
Restructuring liability 1,730 0
Other accrued expenses 676 1,590
Total accrued liabilities $ 3,695 $ 3,464
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Marketable securities, available for sale:    
Total marketable securities, available for sale $ 43,406 $ 48,411
Fair Value, Recurring    
Assets:    
Cash equivalents: 27,804 35,135
Marketable securities, available for sale:    
Total marketable securities, available for sale 43,406 48,411
Total assets measured at fair value on a recurring basis 71,210 83,546
Liabilities:    
Warrant liability 6 5
Total liabilities measured at fair value on a recurring basis 6 5
Fair Value, Recurring | Money market    
Assets:    
Cash equivalents: 17,577 9,365
Fair Value, Recurring | Corporate debt securities    
Assets:    
Cash equivalents:   7,374
Fair Value, Recurring | U.S. government debt securities    
Assets:    
Cash equivalents: 10,227 18,396
Fair Value, Recurring | Level 1    
Assets:    
Cash equivalents: 17,577 9,365
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Total assets measured at fair value on a recurring basis 17,577 9,365
Liabilities:    
Warrant liability 0 0
Total liabilities measured at fair value on a recurring basis 0 0
Fair Value, Recurring | Level 1 | Money market    
Assets:    
Cash equivalents: 17,577 9,365
Fair Value, Recurring | Level 1 | Corporate debt securities    
Assets:    
Cash equivalents:   0
Fair Value, Recurring | Level 1 | U.S. government debt securities    
Assets:    
Cash equivalents: 0 0
Fair Value, Recurring | Level 2    
Assets:    
Cash equivalents: 10,227 25,770
Marketable securities, available for sale:    
Total marketable securities, available for sale 43,406 48,411
Total assets measured at fair value on a recurring basis 53,633 74,181
Liabilities:    
Warrant liability 0 0
Total liabilities measured at fair value on a recurring basis 0 0
Fair Value, Recurring | Level 2 | Money market    
Assets:    
Cash equivalents: 0 0
Fair Value, Recurring | Level 2 | Corporate debt securities    
Assets:    
Cash equivalents:   7,374
Fair Value, Recurring | Level 2 | U.S. government debt securities    
Assets:    
Cash equivalents: 10,227 18,396
Fair Value, Recurring | Level 3    
Assets:    
Cash equivalents: 0 0
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Total assets measured at fair value on a recurring basis 0 0
Liabilities:    
Warrant liability 6 5
Total liabilities measured at fair value on a recurring basis 6 5
Fair Value, Recurring | Level 3 | Money market    
Assets:    
Cash equivalents: 0 0
Fair Value, Recurring | Level 3 | Corporate debt securities    
Assets:    
Cash equivalents:   0
Fair Value, Recurring | Level 3 | U.S. government debt securities    
Assets:    
Cash equivalents: 0 0
Corporate debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale 9,970 13,301
Corporate debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale 9,970 13,301
Corporate debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Corporate debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale 9,970 13,301
Corporate debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
Municipal debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale   993
Municipal debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale   993
Municipal debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale   0
Municipal debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale   993
Municipal debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale   0
U.S. government debt securities    
Marketable securities, available for sale:    
Total marketable securities, available for sale 33,436 34,117
U.S. government debt securities | Fair Value, Recurring    
Marketable securities, available for sale:    
Total marketable securities, available for sale 33,436 34,117
U.S. government debt securities | Fair Value, Recurring | Level 1    
Marketable securities, available for sale:    
Total marketable securities, available for sale 0 0
U.S. government debt securities | Fair Value, Recurring | Level 2    
Marketable securities, available for sale:    
Total marketable securities, available for sale 33,436 34,117
U.S. government debt securities | Fair Value, Recurring | Level 3    
Marketable securities, available for sale:    
Total marketable securities, available for sale $ 0 $ 0
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details) - Warranty liability
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Assumed risk-free interest rate 5.40% 2.96%    
Assumed risk-free interest rate, minimum     4.35% 2.37%
Assumed risk-free interest rate, maximum     5.40% 2.96%
Assumed volatility 133.99% 96.21%    
Assumed volatility, minimum     123.28% 92.77%
Assumed volatility, maximum     133.99% 96.21%
Expected term 1 year 2 months 1 day 2 years 2 months 1 day    
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Minimum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term     1 year 2 months 1 day 2 years 2 months 1 day
Maximum        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term     1 year 5 months 1 day 2 years 5 months 1 day
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details) - Level 3 - Warrant Liability - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 12 $ 5
Change in fair value of warrant liability (6) 7
Ending balance $ 6 $ 12
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Restricted Cash | Level 1 | Letter of Credit    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Letters of credit maintained $ 3.5 $ 3.5
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity - Additional Information (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended 14 Months Ended 24 Months Ended 36 Months Ended
Jan. 01, 2024
Aug. 08, 2022
USD ($)
Nov. 10, 2020
USD ($)
Jun. 23, 2017
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
shares
Jun. 30, 2023
USD ($)
warrant
$ / shares
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2022
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2016
$ / shares
shares
Dec. 31, 2018
$ / shares
shares
Jun. 02, 2023
shares
Jun. 01, 2023
shares
Class of Stock [Line Items]                                
Common stock, shares authorized (in shares)         100,000,000   100,000,000   50,000,000           100,000,000 50,000,000
Issuance of preferred stock, total offering amount | $         $ 4,495 $ 270                    
Proceeds from issuance of common stock in connection with at-the-market offering, net | $             $ 4,765 $ 0                
Warrants expiration period         5 years   5 years                  
Total proceeds from exercise of public warrants | $             $ 0 $ 22                
Compensation cost related to non-vested awards not yet recognized | $         $ 31,200   $ 31,200                  
Weighted average term expected to be recognized             2 years 5 months 4 days                  
Accelerated expense | $         $ 2,900   $ 3,000                  
Cowen and Company LLC                                
Class of Stock [Line Items]                                
Issuance of preferred stock, total offering amount | $   $ 75,000                            
Issuance of common stock, net of issuance costs shares (in shares)         0   0                  
Forecast                                
Class of Stock [Line Items]                                
Additional award verting period (in months) 10 months                              
Forecast | Minimum                                
Class of Stock [Line Items]                                
Additional exercise period of stock options (in months) 90 days                              
Forecast | Maximum                                
Class of Stock [Line Items]                                
Additional exercise period of stock options (in months) 12 months                              
At-The Market Offering | Cowen and Company LLC                                
Class of Stock [Line Items]                                
Issuance of preferred stock, total offering amount | $     $ 50,000       $ 500                  
Issuance of common stock, net of issuance costs shares (in shares)         1,759,210   1,866,661   0     1,482,343        
Weighted average purchase price per share (in usd per share) | $ / shares         $ 2.62   $ 2.68         $ 30.05        
Issuance costs | $                       $ 1,600        
Gross proceeds from issuance of common stock | $         $ 4,600   $ 5,000         $ 42,900        
Decrease in issuance costs | $         100   200                  
Proceeds from issuance of common stock in connection with at-the-market offering, net | $         $ 4,500   $ 4,800                  
SPAC Warrants                                
Class of Stock [Line Items]                                
Warrants issued to purchase common stock (in shares)       14,936,250                        
Number of warrants entitle holder to purchase one share | warrant             4                  
Total number exercised of public warrants (in shares)                   12,120,397   12,120,397        
Common shares issued upon exercise of warrants (in shares)                   3,030,092            
Total proceeds from exercise of public warrants | $                   $ 69,700            
Warrants outstanding (in shares)         2,815,853   2,815,853   2,815,853              
Public SPAC Warrants                                
Class of Stock [Line Items]                                
Warrants issued to purchase common stock (in shares)       14,375,000                        
Private SPAC Warrants                                
Class of Stock [Line Items]                                
Warrants issued to purchase common stock (in shares)       561,250                        
Warrants outstanding (in shares)         80,350   80,350   80,350              
Placement Agent Warrants                                
Class of Stock [Line Items]                                
Warrants issued to purchase common stock (in shares)                         168,522 72,658    
Warrants expiration period                         7 years 7 years    
Warrants outstanding (in shares)         4,510   4,510   4,510              
Placement Agent Warrants | 2018 Convertible Bridge Notes                                
Class of Stock [Line Items]                                
Warrants issued to purchase common stock (in shares)                     15,724          
Warrants expiration period                     7 years          
Common stock                                
Class of Stock [Line Items]                                
Issuance of common stock, net of issuance costs shares (in shares)         1,759,210 107,451                    
Number of shares issued for each warrant (in shares)         0.25   0.25                  
Common stock | SPAC Warrants                                
Class of Stock [Line Items]                                
Exercise price of warrant (in usd per share) | $ / shares         $ 23.00   $ 23.00                  
Number of shares issued for each warrant (in shares)         0.25   0.25                  
Common stock | Placement Agent Warrants                                
Class of Stock [Line Items]                                
Exercise price of warrant (in usd per share) | $ / shares                         $ 8.68 $ 9.54    
Number of shares issued for each warrant (in shares)                         1 1    
Common stock | Placement Agent Warrants | 2018 Convertible Bridge Notes                                
Class of Stock [Line Items]                                
Exercise price of warrant (in usd per share) | $ / shares                     $ 9.54          
Number of shares issued for each warrant (in shares)                     1          
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity - Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation $ 7,515 $ 4,837 $ 12,251 $ 8,731
Cost of revenue        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 435 298 847 633
Sales and marketing        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 1,548 1,067 3,056 2,528
Research and development        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation 676 1,330 1,237 1,825
General and administrative        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation $ 4,856 $ 2,142 $ 7,111 $ 3,745
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 26, 2023
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Commitments And Contingencies [Line Items]        
Restructuring liability   $ 1,730 $ 1,730 $ 0
Restructuring Plan        
Commitments And Contingencies [Line Items]        
Percent of workforce being reduced 15.00%      
Restructuring charges   2,100 2,100  
Severance costs   1,800 1,800  
Accelerated depreciation   300 300  
Restructuring liability   $ 1,700 $ 1,700  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]          
Sales and marketing $ 13,033 $ 15,001 $ 28,450 $ 30,444  
Accounts payable 2,324   2,324   $ 2,419
Related Party          
Related Party Transaction [Line Items]          
Sales and marketing 400 $ 900 900 $ 1,600  
Accounts payable $ 200   $ 200   $ 300
XML 46 dmtk-20230630_htm.xml IDEA: XBRL DOCUMENT 0001651944 2023-01-01 2023-06-30 0001651944 2023-07-28 0001651944 2023-06-30 0001651944 2022-12-31 0001651944 dmtk:TestRevenueMember 2023-04-01 2023-06-30 0001651944 dmtk:TestRevenueMember 2022-04-01 2022-06-30 0001651944 dmtk:TestRevenueMember 2023-01-01 2023-06-30 0001651944 dmtk:TestRevenueMember 2022-01-01 2022-06-30 0001651944 dmtk:ContractualActivitiesMember 2023-04-01 2023-06-30 0001651944 dmtk:ContractualActivitiesMember 2022-04-01 2022-06-30 0001651944 dmtk:ContractualActivitiesMember 2023-01-01 2023-06-30 0001651944 dmtk:ContractualActivitiesMember 2022-01-01 2022-06-30 0001651944 2023-04-01 2023-06-30 0001651944 2022-04-01 2022-06-30 0001651944 2022-01-01 2022-06-30 0001651944 us-gaap:CommonStockMember 2022-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001651944 us-gaap:RetainedEarningsMember 2022-12-31 0001651944 us-gaap:CommonStockMember 2023-03-31 0001651944 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001651944 2023-01-01 2023-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001651944 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001651944 us-gaap:RetainedEarningsMember 2023-03-31 0001651944 2023-03-31 0001651944 us-gaap:CommonStockMember 2023-06-30 0001651944 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0001651944 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001651944 us-gaap:RetainedEarningsMember 2023-06-30 0001651944 us-gaap:CommonStockMember 2021-12-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001651944 us-gaap:RetainedEarningsMember 2021-12-31 0001651944 2021-12-31 0001651944 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001651944 2022-01-01 2022-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0001651944 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001651944 us-gaap:CommonStockMember 2022-03-31 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0001651944 us-gaap:RetainedEarningsMember 2022-03-31 0001651944 2022-03-31 0001651944 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-04-01 2022-06-30 0001651944 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001651944 us-gaap:CommonStockMember 2022-06-30 0001651944 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001651944 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-06-30 0001651944 us-gaap:RetainedEarningsMember 2022-06-30 0001651944 2022-06-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2023-04-01 2023-06-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2022-04-01 2022-06-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2023-01-01 2023-06-30 0001651944 dmtk:ContractRevenueAdhesivePatchKitsMember 2022-01-01 2022-06-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2023-04-01 2023-06-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2022-04-01 2022-06-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2023-01-01 2023-06-30 0001651944 dmtk:ContractRevenueRNAExtractionsMember 2022-01-01 2022-06-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2023-04-01 2023-06-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2022-04-01 2022-06-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2023-01-01 2023-06-30 0001651944 dmtk:ContractRevenueProjectManagementFeesMember 2022-01-01 2022-06-30 0001651944 dmtk:TestMember 2023-06-30 0001651944 dmtk:TestMember 2022-12-31 0001651944 dmtk:ContractualActivitiesMember 2023-06-30 0001651944 dmtk:ContractualActivitiesMember 2022-12-31 0001651944 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001651944 us-gaap:WarrantMember 2022-04-01 2022-06-30 0001651944 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001651944 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001651944 us-gaap:StockOptionMember 2023-04-01 2023-06-30 0001651944 us-gaap:StockOptionMember 2022-04-01 2022-06-30 0001651944 us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001651944 us-gaap:StockOptionMember 2022-01-01 2022-06-30 0001651944 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0001651944 us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0001651944 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001651944 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001651944 2019-08-29 2019-08-29 0001651944 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:MunicipalNotesMember 2022-12-31 0001651944 us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-06-30 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalNotesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2022-12-31 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2023-04-01 2023-06-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-04-01 2022-06-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2023-01-01 2023-06-30 0001651944 us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-06-30 0001651944 srt:MinimumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2023-01-01 2023-06-30 0001651944 srt:MaximumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2023-01-01 2023-06-30 0001651944 srt:MinimumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-06-30 0001651944 srt:MaximumMember us-gaap:WarrantyRightsAndObligationsFairValueOptionMember 2022-01-01 2022-06-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2022-12-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2023-01-01 2023-03-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2023-03-31 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2023-04-01 2023-06-30 0001651944 us-gaap:FairValueInputsLevel3Member dmtk:WarrantLiabilityMember 2023-06-30 0001651944 dmtk:RestrictedCashMember us-gaap:LetterOfCreditMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001651944 dmtk:RestrictedCashMember us-gaap:LetterOfCreditMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001651944 2023-06-01 0001651944 2023-06-02 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2020-11-10 2020-11-10 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2020-11-10 2021-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2022-01-01 2022-12-31 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2023-04-01 2023-06-30 0001651944 dmtk:CowenLimitedLiabilityCompanyMember dmtk:AtTheMarketOfferingMember 2023-01-01 2023-06-30 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2022-08-08 2022-08-08 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2023-04-01 2023-06-30 0001651944 dmtk:CowenLimitedLiabilityCompanyMember 2023-01-01 2023-06-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PublicSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2017-06-23 2017-06-23 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember us-gaap:CommonStockMember 2023-06-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2021-01-01 2021-12-31 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2023-06-30 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2022-12-31 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2023-06-30 0001651944 dmtk:PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember 2022-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2015-01-01 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2016-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2016-01-01 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember us-gaap:CommonStockMember 2018-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-01-01 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember dmtk:TwoThousandEighteenConvertibleBridgeNotesMember us-gaap:CommonStockMember 2020-12-31 0001651944 dmtk:PlacementAgentWarrantsMember 2023-06-30 0001651944 dmtk:PlacementAgentWarrantsMember 2022-12-31 0001651944 us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0001651944 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001651944 us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0001651944 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001651944 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001651944 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001651944 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001651944 srt:ScenarioForecastMember 2024-01-01 2024-01-01 0001651944 srt:MinimumMember srt:ScenarioForecastMember 2024-01-01 2024-01-01 0001651944 srt:MaximumMember srt:ScenarioForecastMember 2024-01-01 2024-01-01 0001651944 dmtk:SpecialPurposeAcquisitionCompaniesWarrantsMember 2023-01-01 2023-06-30 0001651944 dmtk:RestructuringPlanMember 2023-06-26 2023-06-26 0001651944 dmtk:RestructuringPlanMember 2023-04-01 2023-06-30 0001651944 dmtk:RestructuringPlanMember 2023-01-01 2023-06-30 0001651944 dmtk:RestructuringPlanMember 2023-06-30 0001651944 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001651944 us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001651944 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001651944 us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001651944 us-gaap:RelatedPartyMember 2023-06-30 0001651944 us-gaap:RelatedPartyMember 2022-12-31 shares iso4217:USD iso4217:USD shares dmtk:revenueStream pure dmtk:warrant 0001651944 --12-31 2023 Q2 false 0.5 0.25 0.25 4 10-Q true 2023-06-30 false 001-38118 DERMTECH, INC. DE 84-2870849 12340 El Camino Real San Diego CA 92130 858 450-4222 Common Stock, par value $0.0001 per share DMTK NASDAQ Yes Yes Non-accelerated Filer true false false 33679086 42790000 77757000 43406000 48411000 3865000 4172000 1352000 1757000 2329000 3940000 93742000 136037000 6074000 6375000 53791000 56007000 3467000 3488000 0 168000 157074000 202075000 2324000 2419000 7387000 7894000 3695000 3464000 295000 109000 2246000 1634000 67000 116000 16014000 15636000 6000 5000 46000 53000 52931000 54028000 68997000 69722000 0.0001 0.0001 100000000 50000000 33408810 33408810 30297408 30297408 3000 3000 473855000 456171000 -101000 -774000 -385680000 -323047000 88077000 132353000 157074000 202075000 3565000 4147000 6990000 7665000 415000 86000 467000 286000 3980000 4233000 7457000 7951000 3909000 3236000 7700000 6766000 63000 37000 93000 61000 3972000 3273000 7793000 6827000 8000 960000 -336000 1124000 13033000 15001000 28450000 30444000 3887000 6915000 8296000 13253000 15220000 8878000 27095000 17452000 32140000 30794000 63841000 61149000 -32132000 -29834000 -64177000 -60025000 763000 149000 1545000 215000 -6000 -105000 1000 -122000 769000 254000 1544000 337000 -31363000 -29580000 -62633000 -59688000 31791736 31791736 29964849 29964849 31177886 31177886 29904972 29904972 -0.99 -0.99 -0.99 -0.99 -2.01 -2.01 -2.00 -2.00 -31363000 -29580000 -62633000 -59688000 188000 -171000 673000 -741000 -31175000 -29751000 -61960000 -60429000 30297408 3000 456171000 -774000 -323047000 132353000 3.68 100000 107451 270000 270000 510027 92000 92000 174025 576000 576000 485000 485000 4736000 4736000 -31270000 -31270000 31088911 3000 461845000 -289000 -354317000 107242000 2.62 100000 1759210 4495000 4495000 560689 0 0 188000 188000 7515000 7515000 -31363000 -31363000 33408810 3000 473855000 -101000 -385680000 88077000 29772922 3000 436183000 -124000 -206364000 229698000 109275 40000 40000 11101 12000 12000 47339 515000 515000 -570000 -570000 3894000 3894000 -30108000 -30108000 29940637 3000 440644000 -694000 -236472000 203481000 88591 0 0 9219 10000 10000 -171000 -171000 4837000 4837000 -29580000 -29580000 30038447 3000 445491000 -865000 -266052000 178577000 -62633000 -59688000 936000 766000 1000 -122000 2216000 1109000 12251000 8731000 202000 -283000 -13000 -285000 -307000 2115000 -405000 952000 -1779000 -483000 -485000 -654000 690000 -53000 -507000 2698000 -45229000 -49229000 25568000 20171000 31448000 14139000 1016000 1360000 4864000 -7392000 4765000 0 0 22000 92000 40000 576000 515000 56000 60000 5377000 517000 -34988000 -56104000 81245000 179907000 46257000 123803000 42790000 120333000 3467000 3470000 46257000 123803000 2000 7000 78000 11000 0 17059000 0 48000 673000 -741000 The Company and a Summary of its Significant Accounting Policies<div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)    Nature of Operations </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> melanoma and management of skin cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and has an accumulated deficit of $385.7 million at June 30, 2023. As of June 30, 2023, cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of our business. The Company may be required to further reduce operating expenses, which could have an adverse impact its ability to achieve intended business objectives. The Company's management believes that currently available resources will provide sufficient funds to meet operating plans for at least the next twelve months from the issuance of our unaudited condensed consolidated financial statements. Considering the restructuring activities (Note 5) implemented in June 2023, the Company believes it has enough capital to fund anticipated operating costs for at least the next twelve months. The Company anticipates that it will need to raise additional capital in order to support its planned operations and to continue developing and commercializing genomic tests. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)    Basis of Presentation </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiary. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of June 30, 2023, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)    Use of Estimates </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)    Concentration of Credit Risk </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)    Revenue Recognition </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is generated from two revenue streams: contract revenue and test revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from its test and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for test revenue and then for contract revenue.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Test Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from its DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the DMT or (ii) the DMT with TERT test, which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote sample collection of ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT and send a collection kit to the patient. The DermTech Connect app and telemedicine service are currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, test results are provided to the clinician indicating whether the sample collected is indicative of melanoma or not. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.3 million and $0.7 million in revenue for the three and six months ended June 30, 2023, respectively, and an additional $0.1 million and $8,000 in revenue for the three and six months ended June 30, 2022, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners and RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting. Contract revenue can be highly variable in any period as it is closely linked to the clinical trial progress of the Company’s biopharma customers.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a) Disaggregation of Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source during the three and six months ended June 30, 2023 and 2022 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Test Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DermTech Melanoma Test</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adhesive patch kits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA extractions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Project management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(b) Deferred Revenue and Remaining Performance Obligations</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of June 30, 2023 and December 31, 2022 was $0.3 million and $0.1 million, respectively. As of December 31, 2022, the Company reclassified $1.0 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. As of June 30, 2023, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed agreements with an original duration of one year or more was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immaterial</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)    Accounts Receivable </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Test Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Company’s test revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.5 million and $4.1 million of net test accounts receivable as of June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and, as of June 30, 2023, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company recorded $0.4 million and $0.1 million of contract accounts receivable as of June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)    Net Loss Per Share </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the periods presented, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding anti-dilutive securities not included in diluted net loss per share (in thousands):</span></div><div style="margin-top:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h)    Accounting Pronouncements Issued But Not Yet Effective </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.</span></div> Nature of Operations <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, DermTech, Inc., formerly known as Constellation Alpha Capital Corp, (the “Company”), and DermTech Operations, Inc., formerly known as DermTech, Inc., (“DermTech Operations”), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of May 29, 2019, by and among the Company, DT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and DermTech Operations. The Company refers to this agreement, as amended by that certain First Amendment to Agreement and Plan of Merger dated as of August 1, 2019, as the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into DermTech Operations, with DermTech Operations surviving as a wholly-owned subsidiary of the Company. The Company refers to this transaction as the Business Combination. In connection with and two days prior to the completion of the Business Combination, the Company domesticated from the British Virgin Islands to Delaware. DermTech Operations changed its name from DermTech, Inc. to DermTech Operations, Inc. shortly before the completion of the Business Combination. On August 29, 2019, immediately following the completion of the Business Combination, the Company changed its name from Constellation Alpha Capital Corp. to DermTech, Inc., and then effected a one-for-two reverse stock split of its common stock. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) laboratory services including molecular pathology tests to facilitate the diagnosis of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> melanoma and management of skin cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch called the DermTech Smart Sticker™ (the “Smart Sticker”) in order to collect individual biological information for commercial applications in the medical diagnostic field.</span></div>The Company has incurred operating losses since inception and has an accumulated deficit of $385.7 million at June 30, 2023. As of June 30, 2023, cash and cash equivalents totaled approximately $42.8 million and short-term marketable securities totaled approximately $43.4 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of our business. The Company may be required to further reduce operating expenses, which could have an adverse impact its ability to achieve intended business objectives. The Company's management believes that currently available resources will provide sufficient funds to meet operating plans for at least the next twelve months from the issuance of our unaudited condensed consolidated financial statements. Considering the restructuring activities (Note 5) implemented in June 2023, the Company believes it has enough capital to fund anticipated operating costs for at least the next twelve months. The Company anticipates that it will need to raise additional capital in order to support its planned operations and to continue developing and commercializing genomic tests. -385700000 42800000 43400000 Basis of Presentation <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of DermTech, Inc. and its subsidiary. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements and accompanying notes do not include all the information and disclosures required by U.S. GAAP for complete financial statements and should be read together with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. In the opinion of management, all adjustments, which include only normal recurring adjustments considered necessary for a fair presentation, have been included. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes to the unaudited condensed consolidated financial statements. As of June 30, 2023, there have been no material changes in the Company's significant accounting policies from those that were disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</span></div> Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk. Revenue Recognition <div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is generated from two revenue streams: contract revenue and test revenue. The Company accounts for revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from its test and contract services in accordance with the core principles and key aspects considered by the Company. These considerations are described in detail below, first for test revenue and then for contract revenue.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Test Revenue </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenues from its DermTech Melanoma Test or “DMT” which may consist at the option of the ordering clinician of either (i) the DMT or (ii) the DMT with TERT test, which assists a clinician’s diagnosis of melanoma in patients. The Company provides prescribing clinicians with its Smart Sticker to perform non-invasive skin biopsies of clinically ambiguous pigmented skin lesions on patients. The Company also offers clinicians a telemedicine solution where they can request the Smart Sticker collection kit be sent to the patient’s home for a clinician-guided remote sample collection of ambiguous pigmented skin lesions. A patient can also initiate the process by downloading the Company’s telemedicine app, DermTech Connect, which uses store-and-forward technology to allow the patient to take a picture of a suspicious lesion with their phone and have the picture reviewed by an independent clinician who is subscribing to the DermTech Connect platform to assess the suspicious lesion, and if medically necessary, order a DMT and send a collection kit to the patient. The DermTech Connect app and telemedicine service are currently available in most states where permitted by law and applicable standards of practice guidelines. Once the sample is collected by the patient via the telemedicine solution or by a healthcare clinician in person, it is returned to the Company’s CLIA laboratory for analysis. The patient’s ribonucleic acid (“RNA”) and deoxyribonucleic acid (“DNA”) are extracted from the Smart Sticker and analyzed using gene expression and sequencing technology to determine if the pigmented skin lesion contains certain genomic features indicative of melanoma. Upon completion of the gene expression analysis, test results are provided to the clinician indicating whether the sample collected is indicative of melanoma or not. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically updates its estimate of the variable consideration recognized for previously delivered performance obligations. These updates resulted in a decrease of $0.3 million and $0.7 million in revenue for the three and six months ended June 30, 2023, respectively, and an additional $0.1 million and $8,000 in revenue for the three and six months ended June 30, 2022, respectively. These amounts included (i) adjustments for actual collections versus estimated variable consideration as of the beginning of the reporting period and (ii) cash collections and the related recognition of revenue in the current period for tests delivered in prior periods due to the release of the constraint on variable consideration, offset by (iii) reductions in revenue for the accrual for reimbursement claims and settlements.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract revenue is generated from the sale of laboratory services and Smart Stickers to third-party companies through contract research agreements. Revenues are generated from providing gene expression services to facilitate the development of drugs designed to treat dermatologic conditions. The provision of gene expression services may include sample collection using the Company’s Smart Sticker, assay development for research partners and RNA extraction, isolation, expression, amplification and detection, including data analysis and reporting. Contract revenue can be highly variable in any period as it is closely linked to the clinical trial progress of the Company’s biopharma customers.</span></div>Deferred Revenue and Remaining Performance Obligations<div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a majority of historical agreements that produced contract revenue, the Company received a substantial up-front payment and additional payments upon the achievement of various milestones over the life of the agreement. This results in deferred revenue and is relieved upon delivery of the applicable Smart Stickers or RNA extraction results. Changes in accounts receivable and deferred revenue were not materially impacted by any other factors.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue primarily represents upfront milestone payments, for which consideration is received prior to when goods/services are completed or delivered. Upfront fees that are estimated to be recognized as revenue more than one year from the date of collection are classified as long-term deferred revenue. Short-term deferred revenue as of June 30, 2023 and December 31, 2022 was $0.3 million and $0.1 million, respectively. As of December 31, 2022, the Company reclassified $1.0 million of short-term deferred revenue to accrued liabilities for a customer refund obligation in connection with cancellation of future services. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing agreements. For agreements that have an original duration of one year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span> less, the Company has elected the practical expedient applicable to such agreements and does not disclose the remaining performance obligations at the end of each reporting period. 2 -300000 -700000 100000 8000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source during the three and six months ended June 30, 2023 and 2022 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Test Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DermTech Melanoma Test</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adhesive patch kits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA extractions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Project management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,980 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,457 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,951 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3565000 4147000 6990000 7665000 388000 38000 424000 104000 14000 0 16000 110000 13000 48000 27000 72000 3980000 4233000 7457000 7951000 300000 100000 1000000 0 Accounts Receivable <div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Test Accounts Receivable </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Company’s test revenue, it can take a significant amount of time to collect upon billed tests. The Company prepares an analysis on reimbursement collections and data obtained for each financial reporting period to determine the amount of receivables to be recorded relating to tests performed in the applicable period. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. Accounts receivable are written off when all efforts to collect the balance have been exhausted. Adjustments for implicit price concessions attributable to variable consideration are incorporated into the measurement of the accounts receivable balances. The Company recorded $3.5 million and $4.1 million of net test accounts receivable as of June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Accounts Receivable </span></div>Contract accounts receivable are recorded at the net invoice value and are not interest bearing. The Company reserves specific receivables if collectability is no longer reasonably assured, and, as of June 30, 2023, the Company did not maintain any reserves over contract receivables as they relate to large established credit worthy customers. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. 3500000 4100000 400000 100000 Net Loss Per Share Basic and diluted net loss per share of common stock is determined by dividing net loss applicable to holders of common stock by the weighted average number of shares of common stock outstanding during the period. Because there is a net loss attributable to holders of common stock during the periods presented, the outstanding common stock warrants, stock options and restricted stock units (“RSUs”) have been excluded from the calculation of diluted loss per share of common stock because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share are the same. <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding anti-dilutive securities not included in diluted net loss per share (in thousands):</span></div><div style="margin-top:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon the release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 709000 714000 709000 714000 1921000 1758000 1921000 1758000 3562000 2912000 3562000 2912000 6192000 5384000 6192000 5384000 Accounting Pronouncements Issued But Not Yet Effective <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2022-03“). Under the guidance of ASU 2022-03, a contractual restriction on the sale of an equity security is not considered in measuring the security’s fair value. ASU 2022-03 also requires certain disclosures for equity securities that are subject to contractual restrictions. For public business entities, the provisions of ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024 and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is still evaluating the impact of this pronouncement on the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on its condensed consolidated financial statements or disclosures.</span></div> Balance Sheet Details<div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Marketable Securities</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of June 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.8 million; the remaining debt securities that the Company held at that date had an estimated market value of $2.6 million and contractual maturities of up to 18 months. As of December 31, 2022, the estimated market value of debt securities with contractual maturities of less than twelve months was $40.2 million; the remaining debt securities that the Company held at that date had an estimated market value of $8.2 million and contractual maturities of up to 23 months.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. It was determined that no credit losses existed as of June 30, 2023 or December 31, 2022 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. Gross realized gains and losses on the Company’s debt securities for the three and six months ended June 30, 2023 and 2022 were not significant.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2023 aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:34.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(241)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,555 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,908 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:34.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(511)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(812)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Expenses and Property and Equipment, Net </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,002 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Compensation and Accrued Liabilities </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus and commissions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued salaries and wages</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued consulting services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer refund liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring liability </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of June 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,048 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value of debt securities classified as available-for-sale securities by major security type and class of security as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,211 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of June 30, 2023 aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:34.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(241)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,555 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,908 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(265)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2022, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands):</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:34.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Less Than 12 Months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term marketable securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">29,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total short-term marketable securities, available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,440 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,521 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(511)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(812)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10048000 0 78000 9970000 33524000 99000 187000 33436000 43572000 99000 265000 43406000 13535000 2000 236000 13301000 1001000 0 8000 993000 34675000 10000 568000 34117000 49211000 12000 812000 48411000 40800000 2600000 40200000 8200000 0 0 9379000 73000 591000 5000 9970000 78000 16974000 168000 1964000 19000 18938000 187000 26353000 241000 2555000 24000 28908000 265000 6533000 105000 5503000 131000 12036000 236000 0 0 992000 8000 992000 8000 10907000 196000 19026000 372000 29933000 568000 17440000 301000 25521000 511000 42961000 812000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,002 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1513000 3207000 816000 733000 2329000 3940000 6305000 6250000 853000 872000 1247000 913000 597000 1344000 9002000 9379000 2928000 3004000 6074000 6375000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed consolidated balance sheet details are as follows (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus and commissions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued salaries and wages</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued compensation</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,387 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued consulting services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Customer refund liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restructuring liability </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3778000 3257000 3609000 4637000 7387000 7894000 309000 894000 980000 980000 1730000 0 676000 1590000 3695000 3464000 Fair Value Measurements<div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 (in thousands): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,210 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,135 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date, including the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"></td><td style="width:27.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35% - 5.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.21%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.28% - 133.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.77% - 96.21%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 - 1.42 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 - 2.42 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:82.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, the Company maintains letters of credit of $3.5 million and $3.5 million, respectively, related to its lease arrangements, secured by cash of June 30, 2023 and money market accounts as of December 31, 2022, in accordance with certain of its lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in the condensed consolidated balance sheets.</span></div>The Company believes the carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximate their estimated fair values due to the short-term nature of these accounts The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. <div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s marketable debt securities are classified as available-for-sale securities based on management's intentions and are at Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active. The Company has classified marketable securities with original maturities of greater than one year as short-term investments based upon the Company’s ability to use all of those marketable securities to satisfy the liquidity needs of the Company’s current operations. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Private SPAC Warrants (as defined below) was determined using the Black-Scholes-Merton valuation model and included an unobservable input: expected volatility. Expected volatility is considered by the Company to be an unobservable input and is calculated using a weighted average of historical volatilities of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. The model also incorporated several observable assumptions at each valuation date, including the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk-free interest rate over the remaining term.</span></div> <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2023 (in thousands): </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,633 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,210 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money Market</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,770 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,135 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available for sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,181 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,546 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 17577000 0 0 17577000 0 10227000 0 10227000 17577000 10227000 0 27804000 0 9970000 0 9970000 0 33436000 0 33436000 0 43406000 0 43406000 17577000 53633000 0 71210000 0 0 6000 6000 0 0 6000 6000 9365000 0 0 9365000 0 7374000 0 7374000 0 18396000 0 18396000 9365000 25770000 0 35135000 0 13301000 0 13301000 0 993000 0 993000 0 34117000 0 34117000 0 48411000 0 48411000 9365000 74181000 0 83546000 0 0 5000 5000 0 0 5000 5000 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the fair value of the Company’s warrant liability using the Black-Scholes-Merton valuation model:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"></td><td style="width:27.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35% - 5.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37% - 2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.21%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.28% - 133.99%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.77% - 96.21%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 - 1.42 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 - 2.42 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0.0540 0.0296 0.0435 0.0540 0.0237 0.0296 1.3399 0.9621 1.2328 1.3399 0.9277 0.9621 P1Y2M1D P2Y2M1D P1Y2M1D P1Y5M1D P2Y2M1D P2Y5M1D 0 0 0 0 <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.212%"><tr><td style="width:1.0%"></td><td style="width:82.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5000 7000 12000 -6000 6000 3500000 3500000 Stockholders’ Equity<div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)    Common Stock</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of Delaware to increase the authorized number of shares of common stock of the Company from 50,000,000 to 100,000,000 shares (the “Amended Certificate”). The Amended Certificate was approved by the Company’s stockholders at the 2023 Annual Meeting.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)    At-The-Market Offering</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company entered into a sales agreement (the “2020 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $50.0 million. Through December 31, 2021, the Company issued an aggregate of 1,482,343 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $30.05, net of $1.6 million in issuance costs resulting in net proceeds to the Company of approximately $42.9 million. During 2022, the Company did not issue or sell any shares of common stock pursuant to the 2020 Sales Agreement. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended June 30, 2023, the Company issued an aggregate of 1,759,210 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.62 resulting in aggregate gross proceeds of approximately $4.6 million, reduced by $0.1 million issuance costs, resulting in net proceeds to the Company of approximately $4.5 million. For the six months ended June 30, 2023, the Company issued an aggregate of 1,866,661 shares of common stock pursuant to the 2020 Sales Agreement at a weighted average purchase price of $2.68 resulting in aggregate gross proceeds of approximately $5.0 million, reduced by $0.2 million in issuance costs, resulting in net proceeds to the Company of approximately $4.8 million. As of June 30, 2023, $0.5 million is available pursuant to the 2020 Sales Agreement.</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 8, 2022, the Company entered into a second sales agreement (the “2022 Sales Agreement”) with Cowen relating to the sale of shares of the Company’s common stock from time to time with an aggregate offering price of up to $75.0 million under a second at-the-market offering program. For the three and six months ended June 30, 2023, the Company did not issue any shares pursuant to the 2022 Sales Agreement. </span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)    Warrants </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPAC Warrants </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously issued a total of 14,936,250 SPAC warrants (the "SPAC Warrants") to purchase common stock in public and private placement offerings, which were consummated on June 23, 2017. As part of the public offering, the Company issued 14,375,000 warrants (the "Public SPAC Warrants") and, as part of the private placement offering, the Company issued 561,250 warrants (the "Private SPAC Warrants"). The SPAC Warrants have a five-year life from the date the Business Combination was consummated, and every four SPAC Warrants entitle the holder to purchase one whole share of common stock at an exercise price of $23.00 per whole share.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private SPAC Warrants are identical to the Public SPAC Warrants, but they (i) are exercisable either for cash or on a cashless basis at the holder’s option, (ii) are not redeemable by the Company as long as such warrants are held by the initial purchasers or their affiliates and permitted transferees, and (iii) may be subject to the limitations on exercise as specified in the warrant agreement. As a result of these difference in features between the Public SPAC Warrants and Private SPAC Warrants, the Company concluded that the Private SPAC Warrants should be classified as a liability, if still held by the original Private SPAC Warrant holder, and marked to market each financial reporting period in the Company’s statement of operations.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, a total of 12,120,397 SPAC Warrants were exercised, resulting in the Company’s issuance of 3,030,092 shares of common stock and the receipt of $69.7 million in gross proceeds. Outstanding SPAC Warrants totaled 2,815,853 as of June 30, 2023 and December 31, 2022. Private SPAC Warrants that were still owned by the original holder totaled 80,350 as of June 30, 2023 and December 31, 2022.</span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placement Agent Warrants</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with several of DermTech Operations’ financings that took place between 2015 and 2018, DermTech Operations engaged a registered placement agent to assist in marketing and selling common and preferred units. From 2015 to 2016, DermTech Operations issued 168,522 seven-year warrants to purchase one share of common stock each at an exercise price of $8.68 per share. From 2016 to 2018, DermTech Operations issued 72,658 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share. In 2020, the Company issued 15,724 seven-year warrants to purchase one share of common stock at an exercise price of $9.54 per share in connection with the Company’s 2018 bridge note financing. Outstanding placement agent warrants totaled 4,510 as of June 30, 2023 and December 31, 2022.</span></div><div style="margin-top:15pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)    Stock-Based Compensation </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the DermTech, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”), and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"><tr><td style="width:1.0%"></td><td style="width:39.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total compensation cost related to non-vested awards not yet recognized as of June 30, 2023 was $31.2 million, which is expected to be recognized over a weighted average term of 2.43 years. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Departure of Former Chief Executive Officer</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the three and six months ended June 30, 2023 includes accelerated expense of $2.9 million and $3.0 million, respectively, in connection with the transition agreement dated March 1, 2023, between the Company and its former Chief Executive Officer, John Dobak, M.D. (the "Transition Agreement"). The accelerated expense is included within general and administrative expenses in the condensed consolidated statement of operations. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Dobak resigned from his position as Chief Executive Officer and member of the board of directors of the Company (the "Board") effective May 8, 2023 and agreed to serve as a consultant to the Company on an as needed basis until January 1, 2024. The terms of the Transition Agreement allow for continuing vesting of Dr. Dobak's equity awards through the end of the consulting period on January 1, 2024. At the termination of the consulting period, consistent with Dr. Dobak's change of control and severance plan, he will immediately receive an additional 10 months vesting of equity awards and the period to exercise his vested stock options will be increased from 90 days to 12 months. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assessed the consulting services under the Transition Agreement as nonsubstantive pursuant to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ASC 718, Compensation – Stock Compensation (ASC 718) </span>and recognized all stock-based compensation expense related to Dr. Dobak's equity awards vesting in connection with the Transition Agreement upon his resignation. 50000000 100000000 50000000 1482343 30.05 1600000 42900000 0 1759210 2.62 4600000 -100000 4500000 1866661 2.68 5000000 -200000 4800000 500000 75000000 0 0 14936250 14375000 561250 P5Y 23.00 12120397 3030092 69700000 2815853 2815853 80350 80350 168522 P7Y 1 8.68 72658 P7Y 1 9.54 15724 P7Y 1 9.54 4510 4510 <div style="margin-bottom:9pt;margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for employee options, RSUs, the purchase rights issued under the DermTech, Inc. 2020 Employee Stock Purchase Plan, as amended (the “2020 ESPP”), and consultant options was recorded in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.515%"><tr><td style="width:1.0%"></td><td style="width:39.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,515 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 435000 298000 847000 633000 1548000 1067000 3056000 2528000 676000 1330000 1237000 1825000 4856000 2142000 7111000 3745000 7515000 4837000 12251000 8731000 31200000 P2Y5M4D 2900000 3000000 P10M P90D P12M Commitments and Contingencies <div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Plan</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 26, 2023, the Board approved a restructuring plan (the “Restructuring Plan”) to prioritize growth opportunities for the DMT, streamline operations, suspend pipeline programs, and significantly reduce overall operating expenses. The Restructuring Plan includes a reduction of the Company’s workforce by approximately 15%. The actions associated with the employee restructuring under the Restructuring Plan are expected to be substantially complete in the third quarter of 2023.</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company incurred approximately $2.1 million in restructuring charges in connection with the Restructuring Plan for the three and six months ended June 30, 2023, which consist of $1.8 million in charges related to severance payments and employee benefits and $0.3 million in charges related to stock-based compensation for the acceleration of share-based awards. Restructuring charges are included in general and administrative expenses in the condensed consolidated statement of operations. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The restructuring liability as of June 30, 2023 is $1.7 million and is included within accrued liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-top:15pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div>From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows. 0.15 2100000 2100000 1800000 1800000 300000 300000 1700000 Related Party Transactions <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2023, the Company engaged EVERSANA Life Science Services, LLC and its subsidiary Intouch Group, LLC (collectively, “EVERSANA”) to provide certain marketing services to the Company. Leana Wood, the spouse of Todd Wood, the Company’s former Chief Commercial Officer, is an employee of EVERSANA. Mr. Wood's last day of employment as Chief Commercial Officer of the Company was July 3, 2023. The Company incurred $0.4 million and $0.9 million in costs for the three months ended June 30, 2023 and 2022, respectively, and $0.9 million and $1.6 million in costs for the six months ended June 30, 2023 and 2022, respectively. Amounts due to EVERSANA were $0.2 million and $0.3 million as of June 30, 2023 and December 31, 2022, respectively. </span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other related party transactions identified during the three and six months ended June 30, 2023 and 2022.</span></div> 400000 900000 900000 1600000 200000 300000 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 219 220 1 false 43 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://dermtech.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://dermtech.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders??? Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical) Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies The Company and a Summary of its Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Balance Sheet Details Sheet http://dermtech.com/role/BalanceSheetDetails Balance Sheet Details Notes 10 false false R11.htm 0000011 - Disclosure - Fair Value Measurements Sheet http://dermtech.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 0000012 - Disclosure - Stockholders' Equity Sheet http://dermtech.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 0000013 - Disclosure - Commitments and Contingencies Sheet http://dermtech.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 0000014 - Disclosure - Related Party Transactions Sheet http://dermtech.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 9954701 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies The Company and a Summary of its Significant Accounting Policies (Policies) Policies http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies 15 false false R16.htm 9954702 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables The Company and a Summary of its Significant Accounting Policies (Tables) Tables http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies 16 false false R17.htm 9954703 - Disclosure - Balance Sheet Details (Tables) Sheet http://dermtech.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://dermtech.com/role/BalanceSheetDetails 17 false false R18.htm 9954704 - Disclosure - Fair Value Measurements (Tables) Sheet http://dermtech.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://dermtech.com/role/FairValueMeasurements 18 false false R19.htm 9954705 - Disclosure - Stockholders' Equity (Tables) Sheet http://dermtech.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://dermtech.com/role/StockholdersEquity 19 false false R20.htm 9954706 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails The Company and a Summary of its Significant Accounting Policies - Additional Information (Details) Details 20 false false R21.htm 9954707 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Details 21 false false R22.htm 9954708 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Sheet http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Details 22 false false R23.htm 9954709 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details) Details 23 false false R24.htm 9954710 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 24 false false R25.htm 9954711 - Disclosure - Balance Sheet Details - Continuous Loss Position (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails Balance Sheet Details - Continuous Loss Position (Details) Details 25 false false R26.htm 9954712 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details) Details 26 false false R27.htm 9954713 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Sheet http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details) Details 27 false false R28.htm 9954714 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 28 false false R29.htm 9954715 - Disclosure - Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details) Sheet http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details) Details 29 false false R30.htm 9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Sheet http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details) Details 30 false false R31.htm 9954717 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://dermtech.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 31 false false R32.htm 9954718 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 32 false false R33.htm 9954719 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details) Sheet http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails Stockholders' Equity - Share-Based Compensation Expense (Details) Details 33 false false R34.htm 9954720 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 34 false false R35.htm 9954721 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 35 false false All Reports Book All Reports [dq-0540-EntitySmallBusiness-Value] In submission type 10-Q, EntitySmallBusiness value true, is not equivalent to header element smallBusinessFlag value, false, in the Required Context. dmtk-20230630.htm 4 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dmtk:NumberOfWarrantsEntitleHolderToPurchaseOneShare, us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - dmtk-20230630.htm 4 dmtk-20230630.htm dmtk-20230630.xsd dmtk-20230630_cal.xml dmtk-20230630_def.xml dmtk-20230630_lab.xml dmtk-20230630_pre.xml dmtk-20230630xex311.htm dmtk-20230630xex312.htm dmtk-20230630xex321.htm dmtkex31amendedandrestated.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-20230630.htm": { "axisCustom": 0, "axisStandard": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 648, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 219, "dts": { "calculationLink": { "local": [ "dmtk-20230630_cal.xml" ] }, "definitionLink": { "local": [ "dmtk-20230630_def.xml" ] }, "inline": { "local": [ "dmtk-20230630.htm" ] }, "labelLink": { "local": [ "dmtk-20230630_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20230630_pre.xml" ] }, "schema": { "local": [ "dmtk-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 360, "entityCount": 1, "hidden": { "http://dermtech.com/20230630": 1, "http://fasb.org/us-gaap/2023": 3, "http://xbrl.sec.gov/dei/2023": 5, "total": 9 }, "keyCustom": 24, "keyStandard": 196, "memberCustom": 16, "memberStandard": 26, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://dermtech.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Balance Sheet Details", "menuCat": "Notes", "order": "10", "role": "http://dermtech.com/role/BalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://dermtech.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "12", "role": "http://dermtech.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "13", "role": "http://dermtech.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "14", "role": "http://dermtech.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "15", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "16", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables", "shortName": "The Company and a Summary of its Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Balance Sheet Details (Tables)", "menuCat": "Tables", "order": "17", "role": "http://dermtech.com/role/BalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "18", "role": "http://dermtech.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "19", "role": "http://dermtech.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "20", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": "INF", "lang": "en-US", "name": "dmtk:NumberOfRevenueStreams", "reportCount": 1, "unique": true, "unitRef": "revenuestream", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "menuCat": "Details", "order": "21", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)", "menuCat": "Details", "order": "22", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "menuCat": "Details", "order": "23", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "shortName": "Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Balance Sheet Details - Additional Information (Details)", "menuCat": "Details", "order": "24", "role": "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Balance Sheet Details - Continuous Loss Position (Details)", "menuCat": "Details", "order": "25", "role": "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "shortName": "Balance Sheet Details - Continuous Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "menuCat": "Details", "order": "26", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "menuCat": "Details", "order": "27", "role": "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "28", "role": "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-107", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-144", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details)", "menuCat": "Details", "order": "29", "role": "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "shortName": "Fair Value Measurements - Assumptions Used to Determine Fair Value of Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-144", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-154", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "menuCat": "Details", "order": "30", "role": "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-152", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-157", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Fair Value Measurements - Narrative (Details)", "menuCat": "Details", "order": "31", "role": "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-157", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Stockholders' Equity - Additional Information (Details)", "menuCat": "Details", "order": "32", "role": "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-160", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)", "menuCat": "Details", "order": "33", "role": "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity - Share-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "34", "role": "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-210", "decimals": "2", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Related Party Transactions - Additional Information (Details)", "menuCat": "Details", "order": "35", "role": "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-214", "decimals": "-5", "lang": "en-US", "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-13", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-38", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity", "menuCat": "Statements", "order": "6", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-43", "decimals": "INF", "lang": "en-US", "name": "dmtk:StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-30", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-30", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - The Company and a Summary of its Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dmtk_AccruedBonusAndDeferredCompensationCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued bonus and deferred compensation, current.", "label": "Accrued Bonus And Deferred Compensation Current", "terseLabel": "Accrued salaries and wages" } } }, "localname": "AccruedBonusAndDeferredCompensationCurrent", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AccruedConsultingServicesCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consulting services, current.", "label": "Accrued Consulting Services Current", "terseLabel": "Accrued consulting services" } } }, "localname": "AccruedConsultingServicesCurrent", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Warrant Issued, Shares", "label": "Adjustments to Additional Paid in Capital, Warrant Issued, Shares", "terseLabel": "Issuance of common stock from warrant exercises (in shares)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedShares", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "dmtk_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At-The Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in unrealized gain loss on available-for-sale marketable securities.", "label": "Change In Unrealized Gain (Loss) On Available For Sale Marketable Securities", "terseLabel": "Change in unrealized net gains/(losses) on available-for-sale marketable securities and cash equivalents" } } }, "localname": "ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ClassOfWarrantOrRightWarrantsOrRightsIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights issued to purchase common stock.", "label": "Class Of Warrant Or Right, Warrants Or Rights Issued To Purchase Common Stock", "terseLabel": "Warrants issued to purchase common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightWarrantsOrRightsIssuedToPurchaseCommonStock", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommonSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares issued upon exercise of warrants.", "label": "Common Shares Issued Upon Exercise Of Warrants", "verboseLabel": "Common shares issued upon exercise of warrants (in shares)" } } }, "localname": "CommonSharesIssuedUponExerciseOfWarrants", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_ComputerEquipmentGross": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Computer equipment gross.", "label": "Computer Equipment Gross", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentGross", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ContractRevenueAdhesivePatchKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, adhesive patch kits.", "label": "Contract Revenue Adhesive Patch Kits [Member]", "terseLabel": "Adhesive patch kits" } } }, "localname": "ContractRevenueAdhesivePatchKitsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueProjectManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue project management fees.", "label": "Contract Revenue Project Management Fees [Member]", "terseLabel": "Project management fees" } } }, "localname": "ContractRevenueProjectManagementFeesMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueRNAExtractionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, RNA extractions.", "label": "Contract Revenue R N A Extractions [Member]", "terseLabel": "RNA extractions" } } }, "localname": "ContractRevenueRNAExtractionsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractualActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract activities.", "label": "Contractual Activities [Member]", "terseLabel": "Contract revenue" } } }, "localname": "ContractualActivitiesMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen Limited Liability Company.", "label": "Cowen Limited Liability Company [Member]", "terseLabel": "Cowen and Company LLC" } } }, "localname": "CowenLimitedLiabilityCompanyMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CreditLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Credit Losses", "label": "Credit Losses", "terseLabel": "Credit losses" } } }, "localname": "CreditLosses", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of debt securities with contractual maturities of less than 12 months.", "label": "Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months", "terseLabel": "Estimated market value of debt securities with contractual maturities of less than 12 months" } } }, "localname": "EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 21 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 21 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 21 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo21Months", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 23 Months", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To 23 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in stock issuance costs.", "label": "Increase (Decrease) In Stock Issuance Costs", "negatedLabel": "Decrease in issuance costs" } } }, "localname": "IncreaseDecreaseInStockIssuanceCosts", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_NatureOfOperationsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature Of Operations Policy", "label": "Nature Of Operations Policy [Policy Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperationsPolicyPolicyTextBlock", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_NumberOfRevenueStreams": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of revenue streams.", "label": "Number Of Revenue Streams", "terseLabel": "Number of revenue streams (in number of streams)" } } }, "localname": "NumberOfRevenueStreams", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfWarrantsEntitleHolderToPurchaseOneShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants entitle holder to purchase one share.", "label": "Number Of Warrants Entitle Holder To Purchase One Share", "terseLabel": "Number of warrants entitle holder to purchase one share" } } }, "localname": "NumberOfWarrantsEntitleHolderToPurchaseOneShare", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private special purpose acquisition companies warrants.", "label": "Private Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Private SPAC Warrants" } } }, "localname": "PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PublicSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public special purpose acquisition companies warrants.", "label": "Public Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Public SPAC Warrants" } } }, "localname": "PublicSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dmtk_RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring Plan", "label": "Restructuring Plan [Member]", "verboseLabel": "Restructuring Plan" } } }, "localname": "RestructuringPlanMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue", "label": "Revenue, Performance Obligation Satisfied, Variable Consideration Update, Increase (Decrease) In Revenue", "terseLabel": "Increase (decrease) in revenue" } } }, "localname": "RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and PP&E.", "label": "Schedule Of Prepaid Expenses And Property And Equipment Table [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and PP&E" } } }, "localname": "ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTableTextBlock", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional Award Vesting Period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional Award Vesting Period", "terseLabel": "Additional award verting period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAwardVestingPeriod", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAdditionalExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Additional Exercise Period", "terseLabel": "Additional exercise period of stock options (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAdditionalExercisePeriod", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_SpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special purpose acquisition companies warrants.", "label": "Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "SPAC Warrants" } } }, "localname": "SpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and RSU release.", "label": "Stock Issued During Period, Shares, Stock Options Exercised And RSU Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and RSU release.", "label": "Stock Issued During Period, Value, Stock Options Exercised And RSU Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "dmtk_TestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Test", "label": "Test [Member]", "terseLabel": "Test" } } }, "localname": "TestMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TestRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Test Revenue", "label": "Test Revenue [Member]", "terseLabel": "Test revenue", "verboseLabel": "DermTech Melanoma Test" } } }, "localname": "TestRevenueMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Line Items]", "terseLabel": "The Company and Summary of its Significant Accounting Policies [Line Items]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Table]", "terseLabel": "Accounting Policies" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_TwoThousandEighteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen convertible bridge notes.", "label": "Two Thousand Eighteen Convertible Bridge Notes [Member]", "terseLabel": "2018 Convertible Bridge Notes" } } }, "localname": "TwoThousandEighteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability fair value disclosure.", "label": "Warrant Liability Fair Value Disclosure", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "dmtk_WeightedAveragePurchasePricePerShareInOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price per share in offering.", "label": "Weighted Average Purchase Price Per Share In Offering", "terseLabel": "Weighted average purchase price per share (in usd per share)" } } }, "localname": "WeightedAveragePurchasePricePerShareInOffering", "nsuri": "http://dermtech.com/20230630", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r146", "r147", "r258", "r275", "r387", "r550", "r552" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r242", "r243", "r244", "r245", "r303", "r419", "r457", "r476", "r477", "r535", "r536", "r537", "r538", "r539", "r542", "r543", "r557", "r565", "r576", "r582", "r659", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r242", "r243", "r244", "r245", "r303", "r419", "r457", "r476", "r477", "r535", "r536", "r537", "r538", "r539", "r542", "r543", "r557", "r565", "r576", "r582", "r659", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r185", "r420", "r451", "r452", "r453", "r454", "r455", "r456", "r545", "r566", "r581", "r604", "r655", "r656", "r660", "r678" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r185", "r420", "r451", "r452", "r453", "r454", "r455", "r456", "r545", "r566", "r581", "r604", "r655", "r656", "r660", "r678" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r242", "r243", "r244", "r245", "r295", "r303", "r330", "r331", "r332", "r395", "r419", "r457", "r476", "r477", "r535", "r536", "r537", "r538", "r539", "r542", "r543", "r557", "r565", "r576", "r582", "r585", "r653", "r659", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r242", "r243", "r244", "r245", "r295", "r303", "r330", "r331", "r332", "r395", "r419", "r457", "r476", "r477", "r535", "r536", "r537", "r538", "r539", "r542", "r543", "r557", "r565", "r576", "r582", "r585", "r653", "r659", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r146", "r147", "r258", "r275", "r387", "r551", "r552" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r304", "r629" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r162", "r304", "r601", "r629" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r162", "r304", "r601", "r602", "r629" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r580" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r117", "r188", "r189", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r188", "r189" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r78" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums, net of accretion of discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r16", "r43" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued bonus and commissions" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r111", "r444" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r122", "r123", "r124", "r126", "r132", "r133", "r617" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r21", "r68", "r118", "r441", "r462", "r463" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r63" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r336", "r337", "r338", "r474", "r626", "r627", "r628", "r662", "r681" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r46", "r47", "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r7", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "verboseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r7", "r35", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of common stock from warrant exercises" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r334", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive equity instruments excluded from diluted net loss per share of common stock" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r90", "r113", "r143", "r174", "r179", "r183", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r344", "r348", "r369", "r439", "r497", "r580", "r593", "r657", "r658", "r666" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r107", "r121", "r143", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r344", "r348", "r369", "r580", "r657", "r658", "r666" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r50" ], "calculation": { "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r194" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r195" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r191", "r229", "r438" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r192", "r229", "r433", "r634" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Total marketable securities, available for sale", "verboseLabel": "Estimated Market Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r25", "r26", "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment recorded in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r24", "r109", "r546" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r24", "r76", "r141" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r24", "r76", "r141" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r76" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r613", "r677" ], "calculation": { "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r114", "r115", "r116", "r173", "r273", "r274", "r275", "r277", "r280", "r285", "r287", "r465", "r466", "r467", "r468", "r565", "r600", "r623" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issued for each warrant (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Total number exercised of public warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r583", "r584", "r585", "r587", "r588", "r589", "r590", "r626", "r627", "r662", "r680", "r681" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r62", "r485" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r62", "r485", "r503", "r681", "r682" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r62", "r440", "r580" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value per share; 100,000,000 and 50,000,000 shares authorized as of June\u00a030, 2023 and December\u00a031, 2022, respectively; 33,408,810 and 30,297,408 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r22", "r128", "r130", "r134", "r434", "r449" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r56", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r290", "r291", "r294" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Short term deferred revenue", "verboseLabel": "Short-term deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r573", "r575", "r679" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r72", "r143", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r369", "r657" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRefundLiabilityCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.", "label": "Customer Refund Liability, Current", "terseLabel": "Customer refund liability" } } }, "localname": "CustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r59", "r60", "r91", "r92", "r148", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r376", "r560", "r561", "r562", "r563", "r564", "r624" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r18", "r148", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r376", "r560", "r561", "r562", "r563", "r564", "r624" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r97", "r233", "r558" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "AFS, Greater than 12 months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r97", "r233" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedTerseLabel": "AFS, Greater than 12 months, Gross Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r97", "r233", "r558" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "AFS, Less than 12 months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r97", "r233" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "AFS, Less than 12 months, Gross Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "verboseLabel": "Debt Securities, Available-for-Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Short-Term Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r95", "r231", "r558" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "totalLabel": "AFS, Total, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r96", "r232" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "AFS, Total, Gross Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r4", "r33" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r293", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r293", "r566", "r567", "r568", "r569", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenues Disaggregated by Revenue Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r6", "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r135", "r154", "r155", "r156", "r157", "r158", "r163", "r165", "r167", "r168", "r169", "r171", "r359", "r360", "r435", "r450", "r554" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share of common stock outstanding, basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r135", "r154", "r155", "r156", "r157", "r158", "r165", "r167", "r168", "r169", "r171", "r359", "r360", "r435", "r450", "r554" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share of common stock outstanding, diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Total accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current [Abstract]", "terseLabel": "Accrued compensation:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Compensation cost related to non-vested awards not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average term expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r105", "r131", "r132", "r133", "r149", "r150", "r151", "r153", "r159", "r161", "r172", "r222", "r223", "r289", "r336", "r337", "r338", "r341", "r342", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r370", "r371", "r372", "r373", "r374", "r375", "r380", "r458", "r459", "r460", "r474", "r527" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r4" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r362", "r363", "r367" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r362", "r363", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r263", "r296", "r297", "r298", "r299", "r300", "r301", "r363", "r392", "r393", "r394", "r561", "r562", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r51", "r89" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r362", "r363", "r364", "r365", "r368" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r263", "r296", "r301", "r363", "r392", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r263", "r296", "r301", "r363", "r393", "r561", "r562", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r263", "r296", "r297", "r298", "r299", "r300", "r301", "r363", "r394", "r561", "r562", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r9", "r51" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r9", "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r263", "r296", "r297", "r298", "r299", "r300", "r301", "r392", "r393", "r394", "r561", "r562", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r361", "r368" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r378" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r378" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease obligations, less current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r224", "r225", "r226", "r227", "r228", "r230", "r234", "r235", "r271", "r285", "r356", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r448", "r558", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r647", "r648", "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r82" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r621" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73", "r507" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r71", "r143", "r174", "r178", "r182", "r184", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r369", "r556", "r657" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit/(loss)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r236", "r238", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r238", "r512" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and deferred revenue" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r603", "r620" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r136", "r139", "r140" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on finance lease obligations" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r119", "r547", "r580" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure [Abstract]", "terseLabel": "Marketable securities, available for sale:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r82" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r143", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r345", "r348", "r349", "r369", "r484", "r555", "r593", "r657", "r666", "r667" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r67", "r93", "r443", "r580", "r625", "r651", "r664" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r108", "r143", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r345", "r348", "r349", "r369", "r580", "r657", "r666", "r667" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r50" ], "calculation": { "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value on a recurring basis" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Letters of credit maintained" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r82" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r615" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Notes [Member]", "terseLabel": "Municipal debt securities" } } }, "localname": "MunicipalNotesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r138" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r138" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r76", "r77", "r78" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r78", "r94", "r106", "r127", "r129", "r133", "r143", "r152", "r154", "r155", "r156", "r157", "r160", "r161", "r166", "r174", "r178", "r182", "r184", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r360", "r369", "r447", "r505", "r525", "r526", "r556", "r591", "r657" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements Issued But Not Yet Effective" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r25", "r26", "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Property and equipment acquired under finance leases" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Nonoperating Income (Expense) [Abstract]" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r174", "r178", "r182", "r184", "r556" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r378" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r378" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r377" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r621" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r79", "r80", "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "The Company and a Summary of its Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r120", "r580" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r112" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r122", "r125", "r220" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized net gain/(loss) on marketable securities and cash equivalents" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r635" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r616" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]", "terseLabel": "Prepaid expenses and other current assets:" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r549", "r559", "r652" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock in connection with at-the-market offering, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r2", "r10" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r2" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from contributions to the Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r619" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of common stock warrants", "verboseLabel": "Total proceeds from exercise of public warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r106", "r127", "r129", "r137", "r143", "r152", "r160", "r161", "r174", "r178", "r182", "r184", "r221", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r343", "r346", "r347", "r360", "r369", "r436", "r446", "r473", "r505", "r525", "r526", "r556", "r577", "r578", "r592", "r618", "r657" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r82", "r110", "r445" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property and equipment, gross:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r437", "r445", "r580" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofPrepaidExpensesandPPEDetails", "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r630", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r302", "r384", "r385", "r479", "r480", "r481", "r482", "r483", "r502", "r504", "r534" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]", "verboseLabel": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r144", "r145", "r384", "r385", "r386", "r387", "r479", "r480", "r481", "r482", "r483", "r502", "r504", "r534" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r508", "r509", "r512" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r302", "r384", "r385", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r479", "r480", "r481", "r482", "r483", "r502", "r504", "r534", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]", "verboseLabel": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r381", "r382", "r383", "r385", "r388", "r470", "r471", "r472", "r510", "r511", "r512", "r531", "r533" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments of Debt and Lease Obligation", "negatedLabel": "Principal repayments of finance lease obligations" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r57", "r340", "r674" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r613", "r622", "r675", "r677" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash, end of period:" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r98", "r614", "r622" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percent of workforce being reduced" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r4", "r239", "r241", "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r237", "r240" ], "calculation": { "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring liability" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsScheduleofAccruedCompensationandAccruedLiabilitiesDetails", "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAcceleratedDepreciation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.", "label": "Restructuring and Related Cost, Accelerated Depreciation", "terseLabel": "Accelerated depreciation" } } }, "localname": "RestructuringReserveAcceleratedDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r64", "r87", "r442", "r461", "r463", "r469", "r486", "r580" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r149", "r150", "r151", "r153", "r159", "r161", "r222", "r223", "r336", "r337", "r338", "r341", "r342", "r350", "r352", "r353", "r355", "r358", "r458", "r460", "r474", "r681" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r175", "r176", "r177", "r180", "r181", "r185", "r186", "r187", "r292", "r293", "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r175", "r176", "r177", "r180", "r181", "r185", "r186", "r187", "r292", "r293", "r420" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r506", "r544", "r553" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation, estimated revenue expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r379", "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Compensation and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "verboseLabel": "Debt Securities, Available-for-Sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r53", "r54", "r508", "r509", "r512" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r36", "r37", "r38", "r39", "r40", "r41", "r42", "r85", "r86", "r87", "r114", "r115", "r116", "r173", "r273", "r274", "r275", "r277", "r280", "r285", "r287", "r465", "r466", "r467", "r468", "r565", "r600", "r623" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/RelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-Based Payment Arrangement, Accelerated Cost", "terseLabel": "Accelerated expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Assumed volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Assumed volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Assumed volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Assumed risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Assumed risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Assumed risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/StockholdersEquityShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Issuance price per share (in usd per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r19", "r105", "r131", "r132", "r133", "r149", "r150", "r151", "r153", "r159", "r161", "r172", "r222", "r223", "r289", "r336", "r337", "r338", "r341", "r342", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r370", "r371", "r372", "r373", "r374", "r375", "r380", "r458", "r459", "r460", "r474", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r149", "r150", "r151", "r172", "r420", "r464", "r475", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r502", "r504", "r506", "r507", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r586" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r149", "r150", "r151", "r172", "r420", "r464", "r475", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r498", "r499", "r500", "r501", "r502", "r504", "r506", "r507", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r527", "r586" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r7", "r61", "r62", "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r61", "r62", "r87", "r465", "r527", "r540" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock, net of issuance costs shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r7", "r61", "r62", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r61", "r62", "r87", "r474", "r527", "r540", "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs shares", "verboseLabel": "Issuance of preferred stock, total offering amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r62", "r65", "r66", "r81", "r487", "r503", "r528", "r529", "r580", "r593", "r625", "r651", "r664", "r681" ], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets", "http://dermtech.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r84", "r142", "r272", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r289", "r357", "r530", "r532", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Conversion ratio of reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r271", "r285", "r356", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r448", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r647", "r648", "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "auth_ref": [ "r587", "r588", "r589", "r590", "r676" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).", "label": "US Government Agencies Short-Term Debt Securities [Member]", "terseLabel": "U.S. government debt securities" } } }, "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/BalanceSheetDetailsContinuousLossPositionDetails", "http://dermtech.com/role/BalanceSheetDetailsScheduleofShortTermMarketableSecuritiesDetails", "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government debt securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r30", "r31", "r32", "r99", "r100", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r583", "r584", "r587", "r588", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/TheCompanyandaSummaryofitsSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://dermtech.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants expiration period" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/StockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantyRightsAndObligationsFairValueOptionMember": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "This element represents the rights and obligations under a warranty that is not a financial instrument (because it requires or permits the warrantor to provide goods or services rather than a cash settlement) but whose terms permit the warrantor to settle by paying a third party to provide those goods or services.", "label": "Warranty, Rights and Obligations, Fair Value Option [Member]", "terseLabel": "Warranty liability" } } }, "localname": "WarrantyRightsAndObligationsFairValueOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/FairValueMeasurementsAssumptionsUsedtoDetermineFairValueofWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r164", "r169" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r163", "r169" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://dermtech.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482834/825-10-15-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r595": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r596": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r597": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r598": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r599": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org//210/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 54 0001651944-23-000077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651944-23-000077-xbrl.zip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�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